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 Urinary tract infections (UTIs) affect 13 million women annually in the United 
States. Uropathogenic Escherichia coli (UPEC) is the predominant etiologic agent of 
UTI; however, several other uropathogens, including Klebsiella pneumoniae, are also 
significant causative agents.  In a murine cystitis model, UPEC utilize a multistep 
pathogenic pathway in which they invade and form intracellular bacterial communities 
(IBCs) within bladder facet cells.  Type 1 pili, adhesive fimbriae, are necessary for UPEC 
binding and invasion of urothelial cells and formation of IBCs.  UPEC ultimately 
disperse from the IBC, many with filamentous morphology, and proceed to infect other 
host urothelial cells.  This work evaluates the conservation of the IBC pathogenic 
pathway across both host and uropathogen. 
 To determine if the IBC pathway occurs in human UTI, urine samples from 
women with acute, uncomplicated cystitis and from asymptomatic women were blindly 
analyzed.  We found evidence of IBCs in 18% and filamentous bacteria in 41% of urines 
 xv
from women with UTI.  None of the urines from the asymptomatic comparative group or 
from Gram-positive UTIs showed evidence of IBCs or filaments.  These findings suggest 
that the IBC pathogenic pathway characterized in the mice also occurs in humans.   
 Numerous non-UPEC, Gram-negative uropathogens were found competent for 
IBC formation in the murine cystitis model.  The uropathogenesis of one of these IBC 
formers, K. pneumoniae, was compared to UPEC.  K. pneumoniae was able to colonize 
the murine bladder and form IBCs, but to a lesser extent than UPEC early in infection.  
Much of this disparity can be attributed to differences in expression and function of type 
1 pili.  Specifically, K. pneumoniae encodes an extra fim operon gene, fimK, which 
inhibits expression of type 1 pili.  Additionally, K. pneumoniae has a defect in the 
mannose-sensitive hemagglutination phenotype of type 1 pili specific to its FimH adhesin 
domain.  These differences in expression and function of K. pneumoniae type 1 pili 
explain, in part, why K. pneumoniae is a less prevalent etiologic agent of UTI than 
UPEC.  To further analyze host factors involved in UTI pathogenesis of K. pneumoniae 
and other uropathogens, we developed a streptozocin-induced diabetic model of UTI.  
Diabetic mice were found to be more susceptible to UTI, especially by non-UPEC 
uropathogens, compared to healthy mice. 
  
 This work revealed that the IBC pathogenic pathway occurs in human UTI and is 
common to several uropathogens, albeit to varying degrees of efficiency.  Further insight 
into this conserved pathway may lead to enhanced UTI treatments and prevention of 
recurrence. 
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Overview 
 Urinary tract infections (UTIs) are one of the most common bacterial infections 
affecting greater than half of all women in their lifetimes.  While these infections can 
often be treated with short-course antibiotic therapy, recurrent infection is a serious and 
menacing problem.  Interestingly, a high proportion of recurrent UTIs are caused by the 
same strain of bacteria as the initial infection.  Uropathogenic Escherichia coli (UPEC) is 
the predominant etiologic agent of UTI, however, many other uropathogens are also 
capable of causing disease.  A murine model of cystitis provides a valuable tool for 
studying  host-pathogen interactions during the infection process.  In this model, it has 
been shown that UPEC utilize adhesive structures known as type 1 pili to bind and invade 
the bladder urothelium.  Within the superficial facet cells of the bladder, UPEC form 
biofilm-like intracellular bacterial communities (IBCs).  This intracellular niche allows 
for bacterial replication in an environment largely protected from host innate immunity 
and possibly antibiotic treatment.  UPEC disperse from IBCs, many in filamentous 
morphology, and progress to infect other urothelial cells.  This IBC pathogenic pathway 
occurs in the murine bladder with multiple UPEC isolates, but has not been studied with 
other uropathogens or in the human host.  Additionally, it has been shown that UPEC can 
form quiescent intracellular reservoirs (QIRs) within the urothelium that may ultimately 
seed recurrent infection.  These findings change the paradigm of UTI pathogenesis and 
provide an additional explanation for recurrent infection.  UTIs are not as simple as once 
thought and further insight into this pathogenic pathway and its conservation may lead to 
better therapies and treatments for this disease.   
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Urinary Tract Infections 
Epidemiology 
 Urinary tract infections (UTIs) are the second most common infection and a 
significant cause of morbidity in the United States (35).  They are responsible for 13 
million office visits annually in the United States and an economic burden of greater than 
2 billion dollars (19, 25).  It has been estimated that there are 175 million cases of UTI 
worldwide each year (77).  UTIs are more common in women than men, largely because 
of anatomical differences, and it is estimated that half of all women will experience at 
least one UTI in their lifetime (76).   
 Risk factors for developing a UTI in sexually active young women include recent 
sexual intercourse, recent use of a diaphragm with spermicide, and a history of recurrent 
urinary tract infections (34).  It is widely known that certain subpopulations, such as 
diabetic or pregnant women, are more prone to UTIs which often result in serious 
sequelae (3, 74).  In addition to community-acquired UTIs, nosocomial infection is 
extremely common, especially amongst elderly or catheterized patients, and can result in 
sepsis with significant morbidity and mortality (15). 
 
Clinical Presentation, Diagnosis and Treatment 
 UTIs are often subdivided into multiple categories including uncomplicated and 
complicated UTIs.  Complicated infections often involve anatomic abnormalities or 
medical instrumentation (97).   Furthermore, infections can be categorized based on site 
of infection.  These classifications include cystitis (infection of the bladder) and 
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pyelonephritis (infection of the kidney).  Pyelonephritis is several-fold less common than 
cystitis but can result in more serious sequelae (19, 21).  Patients with UTI can present 
with a wide range of symptoms including dysuria, frequency, hematuria, cloudy urine, 
suprapubic pain, low back pain, fever, chills, nausea and vomiting (35).   
 Diagnosis of UTI is confirmed by urine culture, however, patients are often 
treated empirically based on history, pyuria or urine reagent test strip analysis.  A positive 
diagnosis requires greater than 102 bacteria/ml of a uropathogen in a symptomatic patient 
or greater than 105 bacteria/ml under any conditions (33, 47).  Occasionally patients are 
found to have asymptomatic bacteriuria which may ultimately progress to symptomatic 
UTI.   
 Community-acquired UTIs are generally treated with oral antibiotics.  Only short 
courses (usually 3 or 7 days) of antibiotics are generally required for acute, 
uncomplicated cystitis (32).   A variety of antibiotics are used including antimetabolites, 
fluoroquinolones, cephalosporins and nitrofurantoin. In the majority of cases, antibiotics 
lead to quick resolution of symptoms, however, in rare cases UTI can progress to sepsis 
and even death (15, 83).  Additionally, many uropathogens are developing resistance to 
multiple classes of antibiotics (26-28) warranting the need for new and effective UTI 
treatments.   
 
Etiologic Agents  
 Uropathogenic Escherichia coli (UPEC) is the leading causative agent of UTI, 
responsible for up to 85% of community-acquired UTIs and 25% of nosocomial UTIs 
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(75).  Staphylococcus saprophyticus, Klebsiella pneumoniae and other 
Enterobacteriaceae are also significant outpatient uropathogens.  Less frequent causes of 
uncomplicated UTI are enterococcus and group B streptococcus.  Complicated UTIs have 
a more diverse etiology; organisms that rarely cause disease in healthy individuals can 
cause significant disease in patients with underlying anatomic, immunologic, or 
metabolic disorders (73).  Diabetics, for example, have a much higher rate of UTI caused 
by Klebsiella pneumoniae (30, 51). 
 
Paradigm of Pathogenesis and Recurrence 
 The majority of UTIs are thought to arise when uropathogens present in the fecal 
flora are able to colonize the vaginal introitus, enter the urethra and ascend into the 
normally sterile urinary bladder (46).  It has been assumed that upon entering the bladder, 
uropathogens adhere to the host epithelium and initiate disease from this extracellular 
niche.  UPEC and other uropathogens have historically been thought to initiate the host 
response from within the bladder lumen manifested by secretion of cytokines, pyuria and 
the development of physical symptoms. 
 Recurrence after an initial episode of UTI is a serious and menacing problem.  It 
has been estimated that within six months of an index UTI, 25% of women experience a 
recurrent episode and 3% have a third (20).  Another study found that within one year of 
an index UTI, 44% of women will have a recurrence (38).  These recurrent episodes 
occur despite appropriate therapy of the initial infection and negative follow-up urine 
cultures.  In addition to the frustration and morbidity associated with these recurrent 
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infections, a history of recurrent cystitis is associated with an increased risk of developing 
pyelonephritis and antibiotic resistant infection (69, 76). 
 The most apparent risk factor for developing recurrent UTI is having had a recent 
initial UTI (38).  An event, or series of events, may occur during the primary UTI that 
predisposes the patient to a subsequent infection.  Interestingly, a high proportion of 
recurrent UTIs are caused by the same strain of bacteria as the initial infection.  One 
study that followed 58 women with an index UTI episode, found that 68% of recurrences 
were caused by the same strain of E. coli as determined by restriction fragment length 
polymorphism (RFLP) analysis (78).  Another long-term prospective study demonstrated 
that the same strain of UPEC can cause a recurrent UTI up to 3 years later (9).   A third 
study involving female college students demonstrated that after first-time UTIs, 50% of 
recurrent strains appeared genotypically identical to the original bacterial strain (22).  In a 
subset of patients from these studies, the causative strain was found in the vaginal and/or 
fecal cultures of these women despite negative urine cultures at the time.  Based on these 
data, researchers have proposed that recurrences occur through reascension and 
reinoculation of the bladder lumen by a uropathogenic strain of bacteria that has persisted 
in the periurethral or fecal flora.  The notion that these strains may be persisting in the 
bladder epithelium and seeding recurrence has not been studied. 
 Women who get frequent recurrent UTIs have been offered a variety of 
prevention strategies.  Often these women are given antibiotics to take upon first 
presentation of symptoms, after sexual intercourse, or daily as UTI prophylaxis (62, 85, 
86).  These courses, however, promote uropathogen antibiotic resistance.  Additional 
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studies have looked at cranberry products (5), Lactobacillus probiotic therapy (90), and 
vaccination against bacterial adhesins (49, 50).  While many of these strategies are 
promising, they have yet to be validated in large-scale clinical trials.   
 
Bladder Histology and Physiology 
 The anatomy of the urinary bladder is important for proper investigation of 
bacterial pathogenesis during cystitis.  The bladder is a sac-like structure designed for the 
storage of urine prior to micturition.  It is typically a sterile organ and the presence of 
microbes indicates an infectious process.  The bladder is composed of four layers: the 
adventitia, muscularis, lamina propria, and urothelium (31) (Figure 1).  The adventitia, or 
serosa, surrounds the bladder and consists of connective tissue and fat (not shown).  The 
muscularis is composed of three layers of smooth muscle which contribute to bladder 
tone.  The lamina propria is made of connective tissue and contains blood vessels, 
fibroblasts, collagen fibers and elastic fibers.  The urothelium is a pseudostratified 
epithelium consisting of intermediate and basal transitional cells and superficial facet 
cells.  This pseudostratified architecture has evolved in order to maintain impermeability 
while allowing for the constant expansion and contraction of the organ.  Superficial facet 
cells are large, highly differentiated, typically binucleate cells composed of a thicker 
luminal leaflet of the apical plasma membrane termed the asymmetric unit membrane 
(AUM).  The AUM is composed of plaques of hexagonal arrays of uroplakin complexes 
important in allowing the bladder to stretch while maintaining the permeability barrier 
(87).  Uroplakin proteins (Ia, Ib, II, and III) are incorporated into fusiform vesicles that  
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Figure 1.  Structure of the Urinary Bladder   
The bladder consists of four distinct layers:  the serosa (not shown), muscularis, lamina 
propria and urothelium.  The tunica muscularis is responsible for the contraction of the 
bladder during micturition.  The lamina propria, or submucosal layer, consists largely of 
connective tissue and contains blood vessels and nerves.  The mucosal layer, or 
urothelium, is a pseudostratified epithelium responsible for maintaining the impermeable 
barrier of the bladder preventing the leakage of toxins back into the body.  The most 
superficial umbrella cells of the bladder, or facet cells, are often binucleate, very large, 
and form the asymmetric unit membrane containing hexameric uroplakin plaques.   
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are retracted from and fused into the facet cell membrane allowing for changes in surface 
area during bladder distention (57, 95).  The bladder also produces a mucinous 
glycosaminoglycan (GAG) layer.  GAGs are long anionic polysaccharides and include 
hyaluronic acid, chondroitin, and heparin.  Their negative charge creates a stable water 
layer creating a shielding effect which also aids in prevention of toxin and solute leakage 
(68).   
 The transitional epithelium creates an impermeable barrier and prevents the 
leakage of toxins, solutes and other waste materials into tissue.  The urothelium 
responsible for maintaining this barrier has a very slow rate of turnover.  Under normal 
circumstances, the bladder epithelium has a slow but continuous turnover rate; a year or 
more is required in humans and approximately 40 weeks in mice for the bladder to fully 
turnover (40, 41).    While epithelial regeneration signaling pathways are generally under 
tight inhibition, sloughing of the terminally-differentiated superficial umbrella cells, or 
facet cells, leads to activation of bladder progenitor cells and fusion of bladder 
intermediate cells to form new facet cells (60).  The bladder has evolved numerous 
mechanisms to maintain impermeability and disruption of this barrier likely leads to host 
symptoms associated with UTI and other bladder diseases.   
 
Type 1 Pili 
 UPEC employ a wide array of virulence factors to successfully colonize and 
survive within the urinary tract, including adhesive organelles such as P, F1C, and S pili 
(4, 39, 65, 66), iron acquisition/transport systems (84), hemolysin (63), and flagella (48, 
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94).  Among them, the best characterized and arguably most important virulence factor is 
type 1 pili.  Type 1 pili are adhesive hair-like fibers that enable bacteria to bind numerous 
moieties including the bladder surface (36), Tamm-Horsfall protein (67), collagens (71), 
and laminin (45).  They are critical in causing cystitis in several models of UTI (49, 50, 
64).  Specifically, type 1 pili are required for the binding to and the invasion of bladder 
urothelial cells.  The proteins involved in biogenesis and composition of type 1 pili are 
encoded by fimA-H of the fim operon (Figure 2), the expression of which is regulated by 
an invertible promoter switch element (often termed fimS).  This phase-varying switch is 
controlled by neighboring recombinases fimB and fimE, along with other recombinases in 
the genome including fimX (10, 29).   
 Type 1 pili consist of a thicker pilus rod, composed of FimA, and a thinner tip 
fibrillum, composed of FimF, FimG and the adhesin, FimH.  Type 1 pili are assembled 
via the chaperone-usher pathway (37) (Figure 3).  Subunits, such as FimA, the major 
subunit, contain an incomplete immunoglobulin fold and an N-terminal extension.  
Donor-strand complementation takes place in which the N-terminal extension of an 
adjacent pilus subunit complements and completes the immunoglobulin fold of its 
neighbor (8, 81).  FimC is a periplasmic chaperone required to stabilize pilus subunits 
and escort them to FimD, the outer membrane usher (80).  The type 1 pilus adhesin, 
FimH, contains a pilin domain and an adhesin domain which confers receptor specificity 
and tissue tropism (36).  Atomic force microscopy studies have demonstrated that, once 
assembled, type 1 pili are able to reversibly unravel.  This unraveling may be an essential 
mechanism for absorbing physiological shear forces in the urinary tract (56). 
 11
 
 
Figure 2.  UPEC Type 1 Pili Encoded by the fim Operon  
This schematic representation shows the UPEC fim operon.  FimB and FimE are 
regulatory recombinases controlling the expression of fimA-H.  FimA is the major subunit 
of type 1 pili and forms the helical rod.  FimC acts as a chaperone, stabilizing subunits 
prior to secretion through FimD, the outer membrane usher.  FimF, FimG, and FimH 
form the distal tip fibrillum.  The adhesin FimH is composed of a pilin domain and an 
adhesin or receptor binding domain.  Figure adapted from (92). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 12
 
 
Figure 3.  Donor Strand Exchange and Biogenesis of Type 1 Pili 
(A) Schematic diagram showing donor strand complementation in which the N-terminal 
extension of one pilus subunit completes the immunoglobulin fold of its neighbor.  (B)  
Ribbon diagram of FimH pilin domain stabilized by the chaperone, FimC, G1 strand.  (C)  
Chaperone-Usher pathway of pilus biogenesis.  FimC stabilizes subunits prior to 
incorporation into the pilus at the FimD usher.  Excess or misfolded proteins are 
degraded by proteases such as DegP.  (Inset) High resolution electron micrograph of type 
1 pilus.  Figure adapted from (92).    
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Intracellular Bacterial Community Pathogenic Pathway 
 A murine cystitis model has been established to better study the interplay between 
host and pathogen during a UTI.  In this system, bacteria are inoculated directly into the 
bladder of the mouse via a small transurethral catheter.  Using this murine model, it was 
demonstrated that UPEC utilize a multi-step pathogenic cascade during infection in 
which they invade bladder facet cells and replicate intracellularly (Figure 4) (2, 42, 58).  
Virtually all UPEC strains express type 1 pili (11).  The FimH adhesin of type 1 pili 
recognizes mannosylated uroplakins on the luminal surface of facet cells (96).  Recently, 
it was shown that UPEC type 1 pili are also able to bind β-1 and α-3 integrins on host 
urothelial cells (16). 
 Binding of UPEC to host urothelial cells induces a cascade of signaling events 
that ultimately leads to bacterial internalization (53).  Within the superficial umbrella 
cells of the bladder, UPEC replicate to form early intracellular bacterial communities 
(IBCs) of loosely-packed bacteria (42).  The bacteria then progress to form large, mid-
stage IBCs of morphologically coccoid bacteria.  This large IBC has biofilm-like 
characteristics including positive periodic acid-Schiff (PAS) staining (2).  Type 1 pili also 
have an intracellular role and are required for UPEC to form tightly packed biofilms (93).  
As the IBC matures, the bacteria begin to flux out of the epithelial cell, some in 
filamentous morphology.  These long filaments subvert engulfment by neutrophils, 
permitting survival of the bacteria and allowing them to re-enter the IBC developmental 
cascade.  The transient SulA-mediated inhibition of cell division leading to bacterial 
filamentation is essential for UPEC persistence in the murine model of cystitis (43). 
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Figure 4.  UPEC Intracellular Bacterial Community Pathogenic Pathway 
UPEC utilize a multi-step pathogenic pathway in a murine cystitis model.  Upon 
introduction into the bladder, UPEC bind to the host urothelium via type 1 pili and an 
invasion event ensues.  UPEC escape into the facet cell cytoplasm and replicate to form 
loosely-packed early IBCs and ultimately tightly packed mid and late IBCs.  Bacteria 
disperse from the IBC, many in filamentous morphology, bind to another host cell and 
can ultimately reenter this developmental pathway.  In addition, UPEC are able to form 
intracellular reservoirs within different layers of the urothelium that may lead to recurrent 
bacteriuria.   
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 UPEC also form quiescent intracellular reservoirs (QIRs).  QIRs are small 
membrane bound collections of bacteria within host urothelial cells.  This reservoir can 
persist for several weeks in a quiescent state, protected from antibiotics and seemingly 
undetected by the host immune system (58, 82).  External stresses and other cues may 
trigger bacterial replication and the reemergence of the reservoir, which may reside as 
bacterial rosettes within Lamp-1 positive vesicles, leading to recurrent bacteriuria (59).  
The presence of QIRs, if confirmed in humans, may explain recurrent UTI in a subset of 
women.   
 The host has evolved a variety of defense mechanisms in the event of bacterial 
colonization of the bladder.  The utilization of the IBC pathogenic pathway by UPEC 
largely subverts many of these host responses allowing for bacterial persistence.  
Micturition represents a powerful force that bacteria must withstand in order to colonize 
the bladder.  UPEC are able to do so via their strong interactions with facet cells using 
type 1 pili.  The host recruits neutrophils to the bladder in the event of infection.  UPEC 
are able to resist phagocytosis while hiding within urothelial cells or while in the 
filamentous morphology.  Finally, infected host facet cells undergo apoptosis and are 
exfoliated and expelled in the urine.  UPEC are able to form QIRs deep in the bladder 
tissue and remain dormant for weeks prior to causing recurrent bacteriuria.   
 The IBC pathogenic pathway has been characterized using the cystitis isolate, 
UTI89, in primarily C3H/HeN or C57BL/6 mice.  Recently, however, numerous UPEC 
isolates from various clinical syndromes of UTI were shown to be competent for IBC 
formation in the murine cystitis model (23).  Additionally, UPEC are able to form IBCs 
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in the urothelium of a variety of murine backgrounds (23).  It would seem advantageous 
for other uropathogenic bacteria to progress through a similar pathogenic cascade in order 
to efficiently infect the host.  Many other Gram-negative uropathogens also produce type 
1 pili highly homologous to that of UPEC.  However, with few exceptions, it is unknown 
whether other uropathogens are able to progress through an IBC-like pathway and/or 
establish an intracellular reservoir in the murine cystitis model. 
 
K. pneumoniae and Other Non-UPEC Uropathogens 
UTIs Caused by Non-UPEC Uropathogens.    
 While UPEC are the most common causative agent of UTI, there are several other 
important Gram-negative and Gram-positive uropathogens (73).  Little is known about 
the pathogenesis of these organisms in vivo, however, many share common features with 
UPEC.  For example, K. pneumoniae and Proteus mirabilis both express type 1 pili 
highly homologous to that of UPEC.  Enterococcus faecalis, a Gram-positive bacterium 
responsible for many nosocomial UTIs, has been tested in the mouse model and no 
evidence of progression through the IBC pathogenic cascade similar to that of UPEC has 
been found (44).  Instead, E. faecalis displayed a kidney tropism in the murine model.  
Additional studies need to be done to evaluate other non-UPEC uropathogens including 
K. pneumoniae, P. mirabilis, S. saprophyticus, Group B streptococci, Enterobacter 
aerogenes, Citrobacter diversus and Pseudomonas aeruginosa in the murine model of 
UTI. 
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K. pneumoniae Epidemiology   
 K. pneumoniae is a Gram-negative, non-motile, encapsulated, rod-shaped 
bacterium of the family Enterobacteriaceae.  Klebsiella species are ubiquitous in both the 
environment and on mammalian mucosal surfaces.  The detection rate for these bacteria 
in normal human stool samples ranges from 5 to 38% although they are identified in 77% 
of stool samples of hospitalized patients (89).  The urinary tract is the most common site 
of Klebsiella infection, however it also causes pneumonia in compromised hosts (12).  
Klebsiella accounts for up to 17-29% of all nosocomial UTI and even shows higher 
incidence among specific groups of patients (51, 70).  Among diabetic women, 
asymptomatic bacteriuria is several-fold more prevalent and acute pyelonephritis is ten 
times more common (61).  A significant proportion of UTIs in diabetics are caused by K. 
pneumoniae.  In one study, Klebsiella caused 26.7% of community-acquired diabetic UTI 
compared to 10.1% of non-diabetic community-acquired UTI (51).  Klebsiella also 
caused greater than double nosocomial diabetic UTIs as compared to E. coli (37.7% 
versus 18.3%, respectively).  Over the past twenty years, there has been a substantial 
increase in the spread of drug resistant strains of Klebsiella, particularly those producing 
extended-spectrum β-lactamases (55). 
 
Fimbrial Expression in K. pneumoniae 
K. pneumoniae encodes type 1 pili highly homologous to that of E. coli with 
greater than 80% amino acid sequence identity between both the adhesin, FimH, and the 
major pilus subunit, FimA, of the two species (24).  However, in addition to the common 
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components, Klebsiella appears to contain an additional gene, termed fimK (formerly 
fimI), downstream of the adhesin gene fimH (24).  The function of the fimK gene, or 
whether it is co-transcribed as part of the Klebsiella fim operon, is unknown.  Like the E. 
coli system, expression of Klebsiella type 1 pili appears to be controlled by phase 
variation in which an invertible promoter element is flipped. However, the details of this 
switch in Klebsiella are still unclear.  It is known that Klebsiella encodes the regulatory 
genes fimB and fimE, the recombinases involved in turning this promoter switch on and 
off.  It has been difficult to stimulate natural expression of these pili in Klebsiella species 
in the laboratory setting.  While some researchers have used serial passages through 
various broth media over the course of weeks to stimulate the expression of type 1 pili, 
most have utilized inducible plasmid expression systems or even recovered piliated 
bacteria directly from the urine of patients (17, 52).  K. pneumoniae’s type 1 pili have 
been shown to mediate attachment to rat bladder epithelial cells in vitro and the urothelial 
surface of the rat bladder in vivo (17, 18). 
 K. pneumoniae also possesses a type 3 pilus system that, unlike type 1 pili, 
mediate a mannose-resistant, Klebsiella-like hemagglutination (MR/K-HA) of 
erythrocytes that have been treated with tannin.  These pili mediate attachment to the 
basolateral surface of tracheal epithelial cells and basement membrane components (88).  
Type 3 pili are encoded by the mrk operon with mrkA encoding the major subunit and 
mrkD encoding the adhesin (1).  Additionally, MrkF appears to be an anchoring protein 
responsible for attachment of the pilus to the bacterial membrane and MrkE appears to be 
a regulatory protein encoded upstream of mrkA.  The regulation of type 3 pili is not clear 
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and subclones lacking the mrkE gene have no evident change in the level of pilus 
expression (1). 
 
Additional Adhesins and Virulence Factors Expressed by K. pneumoniae 
 In addition to type 1 and type 3 pili, K. pneumoniae encodes at least two other 
non-pilus adhesins.  The CF29K adhesin mediates attachment to Intestine-407 and CaCo-
2 cell lines and is thought to be important in mediating attachment within the mammalian 
intestine (13).  Another adhesin, KPF-28, has been observed in the majority of Klebsiella 
strains producing extended spectrum β-lactamases (14).  In addition, it has recently been 
discovered that K. pneumoniae encodes a luxS homologue that produces functional type 2 
quorum sensing signaling molecules (7).  Analysis of a luxS mutant strain revealed that 
the LuxS-dependent signal plays a role in the early stages of K. pneumoniae biofilm 
formation in vitro.   
 K. pneumoniae generates massive layers of complex acid polysaccharides 
covering the bacterial surface.  This capsule, which can be classified into 77 serological 
types, is essential for Klebsiella virulence (6).  It is thought to aid in pathogenesis by 
protecting the bacterium from phagocytosis by polymorphonuclear leukocytes and 
prevent killing of the bacterium by bactericidal serum factors (91).  Strains expressing the 
capsule antigens K1 and K2 are the most ubiquitous serotypes isolated from UTI and 
pneumonia patients and are thought to be especially virulent (72).  Interestingly, this 
thick capsule has been shown to impede the in vitro adhesion to and invasion of ileocecal 
and bladder epithelial cells by K. pneumoniae (79).  A separate study looking at K. 
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pneumoniae clinical isolates found that all 22 blood isolates were encapsulated and did 
not express type 1 pili while 10 of 11 UTI isolates expressed type 1 fimbriae but were 
unencapsulated (54).  Studies of the contributions of these and other Klebsiella virulence 
factors to pathogenesis in the urinary tract are still needed. 
 
Summary 
 UTIs are one of the most common forms of bacterial infection and new aspects of 
pathogenesis are being elucidated using a murine model of infection.  The discovery of 
an IBC pathogenic pathway challenges the current dogma of UPEC pathogenesis.  
Moreover, the ability of UPEC to utilize an intracellular niche also has dramatic 
implications for UTI recurrence.  The research presented in this dissertation examines the 
conservation of this IBC pathogenic pathway across both host and uropathogen. 
 While it is clear that UPEC progresses through an IBC pathway in the murine 
bladder, this pathogenic pathway has yet to be investigated in humans.  It is imperative to 
determine whether UPEC possesses this ability in human infection.  This finding would 
change the way the scientific and medical community think about UTI.  Extrapolation to 
the human host is absolutely required before new treatment and therapeutic modalities 
can be employed to conquer this disease or prevent recurrence.   
 The IBC pathway has been discovered and characterized exclusively with the 
most prominent UTI etiologic agent, E. coli.  Perhaps this pathway represents a virulence 
property that sets UPEC apart from other uropathogens.  It is unclear whether other non-
UPEC uropathogens are able to utilize an intracellular niche during infection.  If so, 
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elucidating differences in aspects of the pathogenic cycle may help explain differences 
observed in the clinical course of non-UPEC UTIs. 
 K. pneumoniae is a prime uropathogen with which to initiate these studies 
because it is closely related to UPEC and may employ many of the same virulence factors 
in uropathogenesis.  Despite its similarities to UPEC, K. pneumoniae causes significantly 
fewer UTIs in healthy individuals.  By studying this uropathogen in the murine cystitis 
model, not only can we learn about K. pneumoniae uropathogenesis, but we can also 
begin to distinguish the factors and characteristics that make UPEC the predominant 
uropathogen. 
 Type 1 pili are extremely important virulence factors in UPEC infection, as they 
are required for multiple steps of the IBC pathogenic pathway.  K. pneumoniae also 
encodes type 1 pili similar to those of UPEC.  However, small differences in expression 
or structure of type 1 pili can have significant effects on uropathogenesis.  Examining the 
extra gene, fimK, of K. pneumoniae and small differences in the FimH adhesin compared 
to UPEC may provide insights into pathogenesis and the role of type 1 pili.   
 Finally, while UTI has been extensively studied in healthy mouse models, UTI 
has seldom been studied in the diabetic setting.  Diabetics are significantly more 
susceptible to UTI and are infected with a wider range of uropathogens.  Development 
and characterization of a murine model of diabetic UTI could aid in our understanding of 
why diabetics are more prone to UTI and why specific uropathogens, such as K. 
pneumoniae, are more apt to infect diabetic individuals. 
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 In summary, UTIs are one of the most common bacterial infections in the United 
States and the entire world.  These infections are not simple extracellular infections as 
once thought.  UPEC are able to invade the bladder and form IBCs during acute UTI.  
This research examines the IBC pathogenic pathway in different host settings and 
investigates the ability of different uropathogens to undergo these events.  This work has 
revealed that the IBC pathogenic pathway occurs during human UTI and is common to 
several uropathogens, albeit to varying degrees of efficiency.  Further insight into this 
conserved pathway may lead to enhanced UTI treatments and prevention of recurrent 
infections. 
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Abstract 
Background. 
Urinary tract infections (UTIs) are one of the most common bacterial infections and are 
predominantly caused by uropathogenic Escherichia coli (UPEC). While UTIs are 
typically considered extracellular infections, it has been recently demonstrated that UPEC 
bind to, invade, and replicate within the murine bladder urothelium to form intracellular 
bacterial communities (IBCs).  These IBCs dissociate and bacteria flux out of bladder 
facet cells, some with filamentous morphology, and ultimately establish quiescent 
intracellular reservoirs that can seed recurrent infection.  This IBC pathogenic cycle has 
not yet been investigated in humans.     
 
Methods and Findings.   
We collected midstream, clean-catch urine specimens from 80 young healthy women 
with acute uncomplicated cystitis and 20 asymptomatic women with a history of UTI.  
Investigators were blinded to culture results and clinical history.  Samples were analyzed 
by light microscopy, immunofluorescence and electron microscopy for evidence of 
exfoliated IBCs and filamentous bacteria.  Evidence of IBCs was found in 14 of 80 (18%) 
urines from women with UTI.  Filamentous bacteria were found in 33 of 80 (41%) urines 
from women with UTI.  None of the twenty urines from the asymptomatic comparative 
group showed evidence of IBCs or filaments.  Filamentous bacteria were present in all 14 
urines with IBCs compared to 29% (19/66) of samples with no evidence of IBCs 
(P<0.001).  14 of 65 (22%) urines from patients with E. coli infections had evidence of 
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IBCs and 29 of 65 (45%) had filamentous bacteria, while none of the Gram-positive 
infections had IBCs or filamentous bacteria. 
 
Conclusions.   
The presence of exfoliated IBCs and filamentous bacteria in the urines of women with 
acute cystitis suggests that the IBC pathogenic pathway characterized in the murine 
model may occur in humans.  The findings support the occurrence of an intracellular 
bacterial niche in some women with cystitis that may have important implications for 
UTI recurrence and treatment. 
 
Introduction 
 Urinary tract infections (UTIs) affect nearly 13 million women annually in the 
United States alone and can result in significant costs and morbidity (7, 11, 13, 14, 25).  
Uropathogenic Escherichia coli (UPEC) is the predominant causative agent, responsible 
for up to 85% of community-acquired infections (23, 24).  The majority of UTIs are 
thought to arise when uropathogens present in the fecal flora colonize the vaginal 
introitus, ascend into the bladder, and initiate a host response manifested by secretion of 
cytokines, pyuria and the onset of symptoms (18). 
 Women have a 25% chance of experiencing a recurrent UTI within six months (8) 
of an index episode and a 44% chance of recurrence within one year (15) despite 
appropriate therapy of the initial infection and negative follow-up urine cultures.  Over 
one-half of all recurrent episodes of acute uncomplicated cystitis are caused by the same 
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bacterial strain as the initial infection (9, 26).  As with initial UTIs, it is widely thought 
that recurrences occur through re-ascension and re-inoculation of the bladder lumen by a 
UPEC strain that has persisted in the periurethral or fecal flora following the previous 
UTI. 
 Recently, it has been demonstrated in a murine model of cystitis that UPEC utilize 
a multi-step pathogenic cycle during infection in which they progress through an 
intracellular niche within the bladder (Figure 1) (1, 16, 21).  UPEC express adhesive 
fibers known as type 1 pili that mediate binding and invasion into luminal facet cells of 
the bladder (19, 20, 30).  This intracellular niche is conducive for UPEC replication and 
formation of intracellular bacterial communities (IBCs) with biofilm-like properties (1).  
IBCs exist only transiently before the bacteria dissociate and flux out of the facet cell, 
many adopting a filamentous morphology (16).  The filamentous UPEC avoid 
engulfment by neutrophils, thus allowing them to reinvade the urothelium (16).  Upon 
infection, the host exfoliates and expels bladder epithelial cells into the urine.  Ultimately, 
UPEC are able to form quiescent intracellular reservoirs comprised of small rosettes of 
bacteria within Lamp-1 positive endocytic vesicles that can persist for several weeks 
protected from antibiotics and presumably undetected by the host immune system (21, 
22, 27).  Epithelial turnover may cause the quiescent bacteria to revert into an actively 
replicative form leading to recurrent bacteriuria (22). 
 To date, this phenomenon has not been investigated in humans.  In this study, 
with the knowledge that superficial bladder cells exfoliate in response to infection, we 
analyzed urine samples from women with acute, uncomplicated cystitis and from  
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Figure 1.  UPEC IBC Pathogenic Pathway Observed in the Murine Cystitis Model 
The bladder urothelium (A) is a pseudostratified transitional epithelium lined by large 
facet cells.  These cells have an apical asymmetric unit membrane containing uroplakins 
that help form the impermeable bladder barrier and also serve as receptors for UPEC.  
Bacteria introduced into the bladder adhere to the bladder surface via type 1 pili (B).  
Upon attachment, bacteria are able to invade (C) and replicate (D) within the facet cell 
cytoplasm.  UPEC form large biofilm-like IBCs within these cells (E).  Ultimately the 
bacteria flux out of their intracellular niche (G), some adopting a filamentous 
morphology, adhere to other host cells and re-enter the infectious cycle.  During this 
process, infected urothelial cells are sloughed into the urine (F) and neutrophils are 
recruited to the site of infection. 
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asymptomatic women to investigate whether the IBC and/or filamentous ex vivo 
hallmarks of the IBC cycle were present.   
 
Materials and Methods 
Specimen Collection. 
Specimens were collected from women between the ages of 18 and 49 who were enrolled 
in various studies of acute cystitis at the Student Health Center of the University of 
Washington in Seattle, Washington between January 2005 and January 2007.  Urine 
samples were collected from 80 women with acute cystitis prior to treatment and a 
comparative group of 20 different asymptomatic women seen for follow-up at least one 
week after successful cystitis treatment.  Exclusion criteria for both groups included 
antibiotic use in the prior week, phenazopyridine use in the prior two days, symptoms or 
signs of pyelonephritis, pregnancy, chronic illness such as diabetes, recent 
catheterization, or known anatomic or functional abnormalities of the urinary tract.  
Subjects provided midstream, clean-catch urine specimens for culture and analysis and 
questionnaire data which included information about their general health, current UTI 
episode, and UTI and sexual histories.  All studies were approved by the Human Subjects 
Review Committee at the University of Washington and all participants provided written 
informed consent.  A small number of urine samples from women with acute cystitis at 
the Medical Campus Student Health Clinic at Washington University in St. Louis, 
Missouri were also collected for optimization of microscopy and staining methods.  The 
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collection and analysis of all specimens was approved by the Washington University 
Human Research Protection Office.   
 Urines were cultured by standard methods and acute cystitis isolates were banked 
at the University of Washington.  A woman was considered to have a UTI if she had 
urinary symptoms and a urine culture of ≥102 CFU/ml of a uropathogen(29).  
Asymptomatic bacteriuria was defined as the presence of ≥105 CFU/ml of a uropathogen 
in a woman with no urinary symptoms.  Urine hemocytometer white blood cell (WBC) 
counts were determined using Kova Glasstic Slide 10s with Grids (Hycor Biomedical 
Inc.).  Within one hour of micturition, urines were separated into three aliquots that were 
fixed with 1% final concentration of formalin, 2.5% final concentration of glutaraldehyde 
or left unfixed and sent overnight on ice to Washington University in St. Louis, Missouri.  
To reduce potential bias, no clinical information was sent to investigators at Washington 
University prior to examination of the urine specimens for IBCs and filamentous bacteria. 
  
Light microscopy.   
Fixed and unfixed urine samples were cytocentrifuged for 6 min at 1,000 rpm onto poly-
L-lysine-coated glass slides using a CytoPro 7620 cytocentrifuge (Wescor).  Samples 
were then briefly heat fixed and stained with filter sterilized Protocol Hema 3 stains 
(Wright-Giemsa method, Fisher Scientific).  Between 800 μl and 5 ml of each sample 
were screened by light microscopy using an Olympus BX51 light microscope (Olympus 
America). 
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Immunofluorescence.   
Slides of unfixed and formalin-fixed urine specimens were prepared as described above, 
washed in filter-sterilized PBS, blocked in 1% BSA/0.3% Triton X-100 for 1 hr at room 
temperature, and subsequently incubated for 1 hr with rabbit anti-E. coli (1:1000, cross 
reacts with other Enterobacteriaceae, U.S. Biological) and goat anti-uroplakin III (1:100, 
Santa Cruz Biotechnology) primary antibodies.  After three washes in PBS for 5 min and 
staining with Alexa Fluor 488-, 594- or 546-conjugated donkey secondary antibodies 
(1:1000, Molecular Probes) for 30 min, slides were washed, stained with Hoescht or 
TOPRO-3, coverslipped with Fluoromount G (Southern Biotechnology Assoc.) and 
examined using an epifluorescent Zeiss Axioskop or Zeiss LSM410 confocal laser 
scanning microscope (Carl Zeiss). 
 
Electron microscopy.   
Electron microscopy was utilized to gain higher resolution images of IBCs in human 
urines.  For transmission electron microscopy (TEM) and immunostaining, 
glutaraldehyde-fixed urine specimens were gently pelleted and embedded in 1% agarose. 
Samples were processed and immunostained as previously described using rabbit anti-E. 
coli antibody (1:200) followed by 18nm colloidal gold-conjugated anti-rabbit IgG (1:30, 
Jackson ImmunoResearch Laboratories) (19).  All labeling experiments were conducted 
in parallel with controls in which primary antibodies were omitted.  Sections were viewed 
on a JEOL 1200 EX transmission electron microscope (JEOL USA) at 80 kV 
accelerating voltage.   
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 For scanning electron microscopy (SEM), glutaraldehyde-fixed urine specimens 
were cytocentrifuged as described above onto 1% polyethylenimine-coated, 12 mm, 
round, glass cover slips.  Processing of samples and SEM was done as previously 
described(19) and viewed with a Hitachi S-450 scanning electron microscope (Hitachi) at 
20 kV accelerating voltage.   
 
IBC and filament criteria.   
The presence of IBCs and filamentous bacteria in urine was screened for by light 
microscopy and, if detected, verified by immunofluorescence.  Specimens were 
considered positive for IBCs if large, dark-staining epithelial cells were observed 
containing collections of what appeared to be intracellular bacteria.  Positive staining 
with anti-uroplakin antibodies detected by immunofluorescence and fluorescent intensity 
profiles were used as confirmation that bacteria were located within facet cells.  
Filamentation was confirmed using immunofluorescent staining and measurements were 
made to determine whether bacteria greater than 20 μm in length were present. 
 
Mouse infection studies.   
An E. coli isolate from a cystitis patient with findings of urine IBCs and filamentous 
bacteria was inoculated by transurethral catheterization into the bladders of eight-week-
old female C3H/HeN mice (Harlan-Sprague Dawley) as previously described (20) in 
order to compare human and mouse urine cytology.  Mouse urine samples were collected 
30 hours post inoculation by bladder massage over a sterile 1.5 ml Eppendorf tube, 
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cytocentrifuged and stained as described above.  Bladders were aseptically removed, 
fixed in neutral buffer formalin, paraffin embedded and sections were stained with 
hematoxylin and eosin (H&E). 
 
Statistical analysis.   
Categorical variables were compared using Pearson chi square and Fisher’s exact tests as 
appropriate.  Continuous variables were compared using the Mann-Whitney U test since 
these variables were not normally distributed.  All tests were two-tailed and a P value less 
than 0.05 was considered significant.  Analyses were performed using SPSS (version 
14.0) and SAS (version 9.0). 
 
 
Results 
Study population. 
The urines of 100 women at the University of Washington were analyzed in this 
study, 80 with acute uncomplicated cystitis and 20 asymptomatic women with a history 
of recent UTI.  The median age of these 100 women was 22 (range 18-41) and the 
majority were white (75%) and never married (77%).  This population reported a median 
of 3 (range 0-30) previous UTIs and 53% reported having had sexual intercourse in the 
24-48 hours prior to sample collection. 
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Urine cultures. 
 The pathogens cultured from the 80 urines obtained from women with UTI 
included 65 (81%) E. coli, 4 (5%) Staphylococcus saprophyticus, 3 (4%) Enterococcus, 2 
(3%) each of Enterobacter aerogenes, Klebsiella pneumoniae, and Proteus mirabilis, and 
1 (1%) Citrobacter diversus.   There was also 1 (1%) UTI with high levels of both E. coli 
and S. saprophyticus.  None of the 20 comparative asymptomatic women had significant 
bacteriuria. 
 
Light microscopy, immunofluorescence, and electron microscopy. 
 Light microscopic analysis of some urine samples revealed large biofilm-like 
collections of morphologically coccoid bacteria, often in association with cell nuclei or 
debris (Figure 2A).  Analysis also revealed large, dark-staining cells containing what 
appeared to be intracellular bacteria in several samples (Figure 2B-D).  Bacteria were 
sometimes observed seemingly protruding or exiting from these often binucleate cells – a 
common characteristic of facet cells.  Additionally, long filamentous bacteria were seen 
in many of the urine samples (Figure 2E-H).  Neutrophils, epithelial cells and 
morphologically normal bacteria were also observed in the majority of specimens. 
 Immunofluorescence verified the presence of urine IBCs and filaments (Figure 3).  
Cells were stained with antibodies to E. coli (Figure 3A) and uroplakin III, a marker that 
stains facet cell membrane and cytoplasmic vesicles (Figure 3B).  Merged images (Figure 
3C) revealed communities of bacteria within exfoliated urine facet cells.  The distribution 
of fluorescent staining was defined quantitatively by generating profiles of fluorescent  
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Figure 2.  Light Microscopy Findings of Potential IBCs and Filaments in Urines 
from Women with Cystitis 
Light microscopy screening of urines from cystitis patients revealed biofilm-like 
collections of bacteria (A), potential intracellular bacterial communities (B-D) and 
filamentous bacteria (E-H).  Many large biofilm-like collections of small, 
morphologically coccoid bacteria were found in cystitis urine samples.  Dark-staining 
epithelial cells with potential IBCs were observed often with bacteria that appear to be 
protruding from within (arrows).  Tangled collections and individual long filamentous 
bacteria were also found in several of the samples.  Scale bar, 20 μm, applies to all 
panels.   
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Figure 3.  Immunofluorescence Confirmation of IBCs and Filaments in Urines from 
Women with Cystitis 
Urines from women with cystitis were stained with antibodies against E. coli (green) and 
uroplakin III (red).  Confocal microscopy analysis revealed large collections of bacteria 
(A) and cells with partial membrane and cytoplasmic uroplakin staining (B).  Merged 
images (C) show these bacteria to be intracellular.  Filaments of the uropathogen greater 
than 20 μm in length were also observed in many of the urine samples (D-E).  To 
quantify fluorescence, a slice was taken through the middle of an IBC (F) and fluorescent 
intensity was analyzed along a traversing line (arrow).  A representative fluorescent 
intensity distribution profile (G) shows peaks of uroplakin (red) staining corresponding to 
the facet membrane and E. coli (green) staining localized intracellularly.  Scale bars, 20 
μm. 
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intensity along lines traversing the middle of IBCs (Figure 3F-G).  IBCs generally had 
higher peaks of uroplakin staining (red) for the cellular membrane while the uropathogen 
staining (green) was primary localized within the cell itself between the membrane peaks.  
In addition, filamentous bacteria were stained (Figure 3D-E) and measured to verify 
multiple bacterial filaments greater than 20 μm in a given positive sample. 
 SEM and TEM were used to generate higher resolution images of IBCs and 
filaments (Figure 4).  Large collections of bacteria were often observed associated with 
nuclei, lipid membrane or other cellular debris (Figure 4A).  The size, morphology and 
spacing of the bacteria in these large collections in human urines (Figure 4B) were 
similar to what has been observed in murine urine samples (Figure 4C).  Intracellular 
bacterial filaments were also found within an exfoliated epithelial cell from an E. coli 
urine specimen (Figure 4D).  By SEM, large spherical biofilm-like collections of bacteria 
(Figure 4E-F) were observed in fixed urine positive for IBCs and filaments.  Higher 
magnification revealed that these bacteria adopted a smaller, more coccoid morphology 
as typically seen in mouse IBCs.  Long filamentous bacteria were also found in these 
samples (Figure 4G).  Immunoelectron microscopy of these E. coli urine specimens with 
anti-E. coli antibody demonstrated positive staining of the large collections of bacteria 
and filaments. 
 
Comparison of cystitis and asymptomatic subjects. 
 Women with cystitis had higher urine WBC counts, more frequently reported 
recent sexual intercourse, and were slightly older than comparative subjects.  The two  
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Figure 4.  Electron Microscopy Findings in Urines from Women with Cystitis 
TEM analysis of human cystitis urine specimens (A) revealed large collections of 
bacteria associated with nuclei and other cellular debris.  These collections of bacteria 
from human urines (B) have similar morphology and organization as those recovered 
from intact murine intracellular bacterial communities (C).  Bacteria and filaments were 
also observed intracellularly within exfoliated epithelial cells in a urine sample quickly 
fixed and analyzed from an E. coli cystitis patient (D).  SEM analysis of cystitis urines 
deemed positive for IBCs and filaments captured large bacterial biofilm-like collections 
(E-F) composed of bacteria with a smaller, more coccoid morphology than typical E. coli.  
Long filaments were also captured by SEM (G).   Scale bars, 2 μm (A, D), 1 μm (B, C), 
and 5 μm (E-G). 
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groups were similar in race, education, marital status, and number of previous UTIs.  
IBCs were detected in 14 (18%) and filamentous bacteria in 33 (41%) of the 80 urine 
specimens from women with acute cystitis.  None of the 20 urines from the comparative 
group showed evidence of IBCs or filaments (Table 1). 
 
Characteristics of urines from women with cystitis. 
 All 14 (100%) of the urines with IBCs had filamentous bacteria compared with 19 
of 66 (29%) urines without IBCs (P<0.001).  IBCs and filaments were observed only in 
urines with Gram-negative uropathogens, with none of the Gram-positive urines showing 
such evidence (P=0.038).  Every specimen that contained IBCs and the majority of 
specimens positive for filamentous bacteria (30 of 33, 88%) were from UTIs caused by E. 
coli.  Filamentous bacteria were also observed in urine samples from cases of cystitis 
caused by E. aerogenes, K. pneumoniae, and P. mirabilis.   
 
Comparison of cystitis patients with and without urine IBCs and filaments. 
 To determine if evidence of IBCs and filaments was associated with any patient 
or UTI characteristics, cystitis patients with and without IBCs or filaments were 
compared.  IBCs and filaments were associated with higher bacterial burdens (P=0.014) 
and a longer duration of symptoms (P=0.007) (Table 2).  In addition, patients with urine 
IBCs or filaments were significantly younger than those without these findings (P=0.032) 
(Table 2).  There were no statistically significant differences in other demographic or 
behavioral factors (Table 2).   
 52
 
 
* P values refer to grouped categorical data, not all groups shown.  Unknowns are excluded from analysis. 
† Reported having had sexual intercourse 24-48 hours prior to sample collection. 
‡ WBC values too numerous to count (≥2400/μl) were considered 2400 WBC/μl in analyses. 
 
 
 
 
 
 
 
 
 
 
 
Table 1.  Comparisons of Women with Acute Cystitis versus Asymptomatic Women 
Characteristic Units 
Cystitis 
Subjects 
(N=80) 
Comparative 
Subjects 
(N=20) 
P Value 
Demographics 
Age –  median (min-max) years 23 (18-41) 20.5 (18-37) 0.031 
Race – no. (%) * white 62 (77.5) 13 (65.0) 0.309 
Education – no. (%) * 13-15 years 38 (47.5) 16 (80.0) 0.079 
Marital Status – no. (%) * never married 59 (73.8) 18 (90.0) 0.557 
Previous UTIs – median (min-max) no. episodes 3 (0-30) 2 (1-20) 0.574 
Recent Intercourse – no. (%) † yes 49 (61.3) 4 (20.0) <0.001 
Urine Findings     
IBCs – no. (%) positive 14 (17.5) 0 (0.0) 0.066 
Filaments – no. (%) positive 33 (41.3) 0 (0.0) <0.001 
WBCs – median (min-max) ‡  WBCs/μl 137.5 (0-2400) 0 (0-10) <0.001 
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* P values refer to grouped categorical data, not all groups shown.  Unknowns are excluded from analysis. 
† Reported having had sexual intercourse 24-48 hours prior to sample collection. 
‡ Number of symptomatic days prior to and including the day of sample collection. 
§ WBC values too numerous to count (≥2400/μl) were considered 2400 WBC/μl in analyses. 
α Sample containing both E. coli and S. saprophyticus was considered Gram-negative in analysis. 
β E. coli accounted for 30/33 of these Gram-negative infections. 
 
 
 
 
 
 
 
 
 
Table 2.  Comparisons of Cystitis Subjects With and Without Urine IBCs or Filaments 
Characteristic Units 
IBC or 
Filament 
Positive 
(N=33) 
IBC and 
Filament 
Negative 
(N=47) 
P Value 
Demographics 
Age – median (min-max) years 21 (18-33) 23 (19-41) 0.032 
Race – no. (%) * white 25 (75.8) 37 (78.7) 0.915 
Education – no. (%) * 13-15 years 19 (57.6) 19 (40.4) 0.483 
Marital status – no. (%) * never married 24 (72.7) 35 (74.5) 0.963 
Previous UTIs – median (min-max) no. episodes 2 (0-30) 3 (0-20) 0.664 
Recent Intercourse – no. (%) *† yes 18 (54.5) 31 (66.0) 0.333 
Characteristics of Cystitis Episode 
First or Recurrent UTI – no. (%) * recurrent 26 (78.8) 39 (83.0) 0.491 
Uropathogen – no. (%) Gram-negativeα 33β (100.0) 40 (85.1) 0.038 
 Gram-positive 0 (0.0) 7 (14.9)  
Quantity of Uropathogen – no. (%) <105 CFU/ml 6 (18.2) 21 (44.7) 0.014 
 ≥105 CFU/ml 27 (81.8) 26 (55.3)  
Symptom Duration – med. (min-max)‡ days 3 (1-9) 2 (1-7) 0.007 
WBCs – median (min-max) § WBCs/μl 200 (10-2400) 75 (0-2400) 0.856 
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Comparison of urine cytology in human and murine UTIs. 
 Histologic examination of mouse bladders infected with an E. coli strain isolated 
from a woman with acute cystitis revealed IBCs in superficial facet cells present in the 
tissue (Figure 5A), and sloughed into the lumen (Figure 5B).  Filamentous bacteria and a 
robust inflammatory response were also observed.  The urines of these mice contained 
several large, dark-staining IBCs (Figure 5C) that appeared morphologically 
indistinguishable from those of the original human urine specimen (Figure 5D). 
 
 
Discussion 
 Our study provides evidence that episodes of E. coli cystitis in humans may 
involve an IBC pathogenic pathway similar to that observed in mice.  Evidence of 
filamentous bacteria and exfoliated bladder facet cells containing large collections of E. 
coli were observed by light microscopy and confirmed by immunofluorescence.  High 
resolution electron microscopy showed large biofilm-like IBCs and long filamentous 
bacteria.  The expected variety of uropathogens (23) was cultured from infected women 
in the study, yet IBCs and filaments were not observed in urines from women infected 
with Gram-positive pathogens or in urines from asymptomatic women.  Additionally, the 
urine cytologies observed in human and murine UTIs were indistinguishable. 
 Previous studies support our findings of an intracellular bacterial niche during 
UTI.  In one study, human bladder biopsies from 33 women with recurrent urinary tract 
symptoms were analyzed after antibiotic therapy (5).  Sixteen of these patients had sterile  
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Figure 5.  Mouse Trial and Comparison of Human and Mouse Urine 
The E. coli isolate from a urine specimen positive for IBCs and filaments was inoculated 
into mice where it progressed through the IBC pathogenic cycle.  Several IBCs were 
observed by H&E in the mouse bladder at 30 hours post infection (A, arrow).  IBCs could 
also be seen exfoliated into the bladder lumen (B, arrowhead).  Urine collected from mice 
at this time point were positive for IBCs (C).  These IBCs were similar in morphology 
and size to those formed by the same E. coli isolate in the original human urine specimen 
(D).  Scale bar, 50 μm, applies to all panels. 
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urine cultures; however, bacteria were cultured from eight patients’ biopsies.  These 
findings suggest that urine culture results may not necessarily reflect the bacteriologic 
status of the bladder epithelium and that there may be a persistent niche for uropathogens 
associated with bladder tissue.  In addition, multiple studies have shown that UPEC 
strains are able to invade and replicate within human urothelial cell lines (6, 19, 21).  
More recently, it has been demonstrated that the majority of UPEC isolates from patients 
with various clinical syndromes of UTI are competent for IBC formation in the murine 
cystitis model (10). 
 The ability to form filaments is an important virulence property that facilitates 
persistence in the murine cystitis model (17).  Filamentation can be the result of the 
Gram-negative bacterial SOS response which is induced by a variety of stressful stimuli, 
including antibiotics (28).  In this study, however, patients had no recent history of 
antibiotic usage.  Also, filamentation did not correlate with WBC counts in the urines of 
these patients as one might expect if this were a non-specific stress response.  Thus, the 
filaments likely represented bacteria that had emerged from an intracellular niche as seen 
in the murine model.  The filamentation event has been shown to be triggered by TLR-4-
dependent inflammatory responses in the murine model of cystitis (17), however, 
whether this is also true in the human remains to be determined.  We were able to capture 
electron microscope images of these filamentous bacteria within the intracellular niche of 
sloughed urothelial cells. In addition, the urine finding of filamentous bacteria 
significantly correlated with the presence of IBCs in these samples.  This correlation 
could be explained by the association of these two entities in the same pathogenic 
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pathway or may be due to the higher bacterial burden in these samples and an enhanced 
ability to detect these endpoints by microscopy. 
 Interestingly, the presence of IBCs or filaments was associated with patients who 
had significantly longer self-reported durations of symptoms.  This may relate to the 
kinetics of the IBC cycle and the time point at which IBCs are exfoliated into the urine, 
or it may be related to the higher burden of bacteria in the urines at these time points.  
Each urine analyzed represents a single point in what may be a temporally regulated 
pathogenic pathway.  IBCs and filaments are likely transient (16) and, thus, could be 
missed if the sampling interval is not appropriate.  In addition, the volume of urine 
analyzed represents a small proportion of the total sample micturated.  Thus, the findings 
in this study may underestimate the prevalence of the IBC pathway.   
 Exfoliated cells found in the urine, while a useful reflection of the bladder tissue, 
have generally lost considerable structural integrity.  Bacterial invasion into these 
damaged cells after they have been shed from the urothelium, while possible, seems 
unlikely.  Mistaking such rare events for IBCs is implausible because samples were fixed 
upon micturition and bacteria would have needed significant time to multiply into large 
biofilm-like communities.  While bladder biopsies are usually contraindicated in actively 
infected patients, future studies could assess biopsies from selected women with a history 
of recurrent UTI for the presence of an intracellular reservoir.  As is observed in the 
murine model (21, 22, 27), a quiescent intracellular bacterial reservoir forms within the 
transitional epithelium.  In this model, epithelial turnover and differentiation induce the 
bacteria within this reservoir to emerge and initiate the formation of new IBCs and 
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recurrent bacteriuria.  Reservoir formation, not explored in this study, could possibly 
serve as a seed for recurrence in same-strain UTIs in some women. 
 This study involved a large number of well-characterized young healthy women 
with acute cystitis and provides strong evidence that IBCs and filamentous bacteria can 
be found in this group of women. However, there are also several limitations to this 
study.  We cannot extrapolate our results to women with different demographic 
characteristics or with different clinical syndromes, such as asymptomatic bacteriuria, 
pyelonephritis, or catheter-associated infections. We were not able, because of treatment 
considerations, to collect serial specimens from these women with acute cystitis, and thus 
we could not optimize collection time points when IBCs and filaments might be most 
abundant.  The patients were not followed prospectively and thus we cannot evaluate 
important temporal associations between presence of IBCs or filaments and response to 
treatment and patterns of recurrence. It is possible that the sensitivity of our assays might 
have been better if we had been able to analyze urines quickly without the agitation of 
shipping. The low number of non-E.coli infections makes it difficult to assess the ability 
of other uropathogens to form filaments and IBCs during human infection.  Lastly, it was 
outside the scope of this study to perform genetic analyses of bacteria collected as has 
been done in previous studies (4, 10).  Thus, potential genetic differences and other 
characteristics of bacteria collected in this study are not known at this time. 
 Despite these limitations, our data provide compelling evidence that there is an 
association between IBCs, filaments and acute uncomplicated cystitis in young women 
and are suggestive of an IBC pathway in a subset of these women.  In this pathway in 
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mice, bacteria are able to invade and replicate within the urothelium where they are 
largely protected from host innate immunity, which may explain how the relatively few 
bacteria introduced into the bladder with urethral milking or sexual intercourse (2, 3, 12) 
are able to survive and multiply to numbers high enough to elicit symptoms in the host.  
The implications of these observations with regard to clinical management remain 
unclear.  Urine IBCs and filaments may be prognostic indicators of specific clinical 
outcomes or women with these findings may benefit from different management or 
prevention strategies such as longer treatment or use of antimicrobials with better 
intracellular penetration.  It is imperative that additional studies with appropriate patient 
follow-up be conducted to address these specific questions.  Further understanding of the 
IBC pathogenic pathway in human infection may provide new potential targets and 
approaches to the treatment and prevention of UTI.   
 
Acknowledgements 
 We are indebted to Ellen Cassen, ARNP and Niki DeShaw for subject enrollment 
in Seattle, WA, Marsha Cox and Sheila Manuguid for sample preparation, urine cultures 
and isolate collection, Karen Winters, MD for Washington University patient referral and 
specimen collection, Melissa Krauss, MPH for statistical analysis, Wandy Beatty, PhD 
and Darcy Gill, PhD for transmission electron microscopy preparation and analysis and 
immunofluorescence technical assistance, and G. Michael Veith for scanning electron 
microscopy support.   
 60
 This work was supported by National Institutes of Health Office of Research on 
Women’s Health:  Specialized Center of Research on Sex and Gender Factors Affecting 
Women’s Health, grant R01 DK64540 and National Institute of Diabetes and Digestive 
and Kidney Diseases, grants R01 DK051406 and P01 DK53369.  Funding organizations 
had no role in study design, data collection and analysis, decision to publish, or 
preparation of this manuscript. 
 
 
References 
1. Anderson, G. G., J. J. Palermo, J. D. Schilling, R. Roth, J. Heuser, and S. J. 
Hultgren. 2003. Intracellular bacterial biofilm-like pods in urinary tract infections. 
Science 301:105-107. 
2. Bran, J. L., M. E. Levison, and D. Kaye. 1972. Entrance of bacteria into the 
female urinary bladder. N Engl J Med 286:626-629. 
3. Buckley, R. M., Jr., M. McGuckin, and R. R. MacGregor. 1978. Urine bacterial 
counts after sexual intercourse. N Engl J Med 298:321-324. 
4. Chen, S. L., C. S. Hung, J. Xu, C. S. Reigstad, V. Magrini, A. Sabo, D. Blasiar, T. 
Bieri, R. R. Meyer, P. Ozersky, J. R. Armstrong, R. S. Fulton, J. P. Latreille, J. 
Spieth, T. M. Hooton, E. R. Mardis, S. J. Hultgren, and J. I. Gordon. 2006. 
Identification of genes subject to positive selection in uropathogenic strains of 
Escherichia coli: a comparative genomics approach. Proc Natl Acad Sci U S A 
103:5977-5982. 
 61
5. Elliott, T. S., L. Reed, R. C. Slack, and M. C. Bishop. 1985. Bacteriology and 
ultrastructure of the bladder in patients with urinary tract infections. J Infect 
11:191-199. 
6. Feldmann, F., L. J. Sorsa, K. Hildinger, and S. Schubert. 2007. The Salmochelin 
siderophore receptor IroN contributes to invasion of urothelial cells by 
extraintestinal pathogenic Escherichia coli in vitro. Infect Immun 75:3183-3187. 
7. Foxman, B. 2002. Epidemiology of urinary tract infections: incidence, morbidity, 
and economic costs. Am J Med 113 Suppl 1A:5S-13S. 
8. Foxman, B. 1990. Recurring urinary tract infection: incidence and risk factors. 
Am J Public Health 80:331-333. 
9. Foxman, B., L. Zhang, P. Tallman, K. Palin, C. Rode, C. Bloch, B. Gillespie, and 
C. F. Marrs. 1995. Virulence characteristics of Escherichia coli causing first 
urinary tract infection predict risk of second infection. J Infect Dis 172:1536-
1541. 
10. Garofalo, C. K., T. M. Hooton, S. M. Martin, W. E. Stamm, J. J. Palermo, J. I. 
Gordon, and S. J. Hultgren. 2007. Escherichia coli from Urine of Female Patients 
with Urinary Tract Infections Is Competent for Intracellular Bacterial Community 
Formation. Infect Immun 75:52-60. 
11. Griebling, T. L. 2007. Urinary Tract Infections in Women, p 587-620.  In M. S. 
Litwin and C. S. Saigal (ed.), Urologic Diseases in America. US Department of 
Health and Human Services, Public Health Service, National Institutes of Health, 
 62
National Institute of Diabetes and Digestive and Kidney Diseases. NIH 
Publication No. 07–5512. US Government Printing Office, Washington, DC. 
12. Hooton, T. M., S. Hillier, C. Johnson, P. L. Roberts, and W. E. Stamm. 1991. 
Escherichia coli bacteriuria and contraceptive method. Jama 265:64-69. 
13. Hooton, T. M., D. Scholes, J. P. Hughes, C. Winter, P. L. Roberts, A. E. 
Stapleton, A. Stergachis, and W. E. Stamm. 1996. A prospective study of risk 
factors for symptomatic urinary tract infection in young women. N Engl J Med 
335:468-474. 
14. Hooton, T. M., and W. E. Stamm. 1997. Diagnosis and treatment of 
uncomplicated urinary tract infection. Infect Dis Clin North Am 11:551-581. 
15. Ikaheimo, R., A. Siitonen, T. Heiskanen, U. Karkkainen, P. Kuosmanen, P. 
Lipponen, and P. H. Makela. 1996. Recurrence of urinary tract infection in a 
primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis 
22:91-99. 
16. Justice, S. S., C. Hung, J. A. Theriot, D. A. Fletcher, G. G. Anderson, M. J. 
Footer, and S. J. Hultgren. 2004. Differentiation and developmental pathways of 
uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci 
U S A 101:1333-1338. 
17. Justice, S. S., D. A. Hunstad, P. C. Seed, and S. J. Hultgren. 2006. Filamentation 
by Escherichia coli subverts innate defenses during urinary tract infection. Proc 
Natl Acad Sci U S A 103:19884-19889. 
 63
18. Kunin, C. M., F. Polyak, and E. Postel. 1980. Periurethral bacterial flora in 
women. Prolonged intermittent colonization with Escherichia coli. JAMA 
243:134-139. 
19. Martinez, J. J., M. A. Mulvey, J. D. Schilling, J. S. Pinkner, and S. J. Hultgren. 
2000. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO 
J 19:2803-2812. 
20. Mulvey, M. A., Y. S. Lopez-Boado, C. L. Wilson, R. Roth, W. C. Parks, J. 
Heuser, and S. J. Hultgren. 1998. Induction and evasion of host defenses by type 
1-piliated uropathogenic Escherichia coli. Science 282:1494-1497. 
21. Mulvey, M. A., J. D. Schilling, and S. J. Hultgren. 2001. Establishment of a 
Persistent Escherichia coli Reservoir during the Acute Phase of a Bladder 
Infection. Infect Immun 69:4572-4579. 
22. Mysorekar, I. U., and S. J. Hultgren. 2006. Mechanisms of uropathogenic 
Escherichia coli persistence and eradication from the urinary tract. Proc Natl 
Acad Sci U S A 103:14170-14175. 
23. Ronald, A. 2003. The etiology of urinary tract infection: traditional and emerging 
pathogens. Dis Mon 49:71-82. 
24. Ronald, A. R., L. E. Nicolle, E. Stamm, J. Krieger, J. Warren, A. Schaeffer, K. G. 
Naber, T. M. Hooton, J. Johnson, S. Chambers, and V. Andriole. 2001. Urinary 
tract infection in adults: research priorities and strategies. Int J Antimicrob Agents 
17:343-348. 
 64
25. Ronald, A. R., and A. L. Pattullo. 1991. The natural history of urinary infection in 
adults. Medical Clinics Of North America 75:299-312. 
26. Russo, T. A., A. Stapleton, S. Wenderoth, T. M. Hooton, and W. E. Stamm. 1995. 
Chromosomal restriction fragment length polymorphism analysis of Escherichia 
coli strains causing recurrent urinary tract infections in young women. J Infect Dis 
172:440-445. 
27. Schilling, J. D., R. G. Lorenz, and S. J. Hultgren. 2002. Effect of trimethoprim-
sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice 
infected with uropathogenic Escherichia coli. Infect Immun 70:7042-7049. 
28. Schoemaker, J. M., R. C. Gayda, and A. Markovitz. 1984. Regulation of cell 
division in Escherichia coli: SOS induction and cellular location of the sulA 
protein, a key to lon-associated filamentation and death. J Bacteriol 158:551-561. 
29. Stamm, W. E., G. W. Counts, K. R. Running, S. Fihn, M. Turck, and K. K. 
Holmes. 1982. Diagnosis of coliform infection in acutely dysuric women. N Engl 
J Med 307:463-468. 
30. Wright, K. J., P. C. Seed, and S. J. Hultgren. 2007. Development of intracellular 
bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. 
Cell Microbiol 9:2230-2241. 
 
 
 
 
 
 
 
 65
 
 
 
 
Chapter 3 
 
 
Utilization of an IBC Pathway in Klebsiella pneumoniae Urinary Tract 
Infection and the Effects of FimK on Type 1 Pilus Expression 
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Abstract 
 Klebsiella pneumoniae is an important cause of urinary tract infection (UTI), but 
little is known about its pathogenesis in vivo.  The pathogenesis of the K. pneumoniae 
cystitis isolate, TOP52 1721, was compared to the uropathogenic Escherichia coli 
(UPEC) isolate, UTI89, in a murine cystitis model.  Bladder and kidney titers of TOP52 
1721 were lower than UTI89 at early timepoints, but similar at later timepoints. TOP52 
1721, like UTI89, formed biofilm-like intracellular bacterial communities (IBCs) within 
the murine bladder, albeit at significantly lower levels than UTI89.  Additionally, 
filamentation of TOP52 1721 was observed, a process critical for UTI89 evasion of 
neutrophil phagocytosis and persistence in the bladder.  Thus, the IBC pathway is not 
specific to UPEC alone.  We investigated if differences in type 1 pilus expression may 
explain TOP52 1721’s early defect in vivo.  The type 1 pilus operon is controlled by 
recombinase-mediated (fimE, fimB, and fimX) phase variation of an invertible promoter 
element.  We found that K. pneumoniae encodes an extra gene of unknown function at 
the 3’ end of its type 1 operon, fimK, and the genome lacks the recombinase fimX.  A 
deletion of fimK was constructed and TOP52ΔfimK had higher titers and formed more 
IBCs in the murine cystitis model than wildtype.  The loss of fimK or expression of E. 
coli fimX from a plasmid in TOP52 1721 resulted in a larger phase ON population, higher 
expression of type 1 pili, and gave TOP52 1721 the ability to form type 1-dependent 
biofilms.   Complementation with pfimK decreased type 1 pilus expression and biofilm 
formation of TOP52ΔfimK and decreased UTI89 biofilm formation. Thus, K. pneumoniae 
appears programmed for minimal expression of type 1 pili which may explain, in part, 
why K. pneumoniae is a less prevalent etiologic agent of UTI than UPEC. 
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Introduction 
 Nearly 13 million women get urinary tract infections (UTIs) per year in the 
United States alone and greater than half of all women will experience a UTI during their 
lifetime (16, 23, 28, 29, 52).  These infections often recur and over half of all recurrent 
episodes are caused by the same bacterial strain as the initial infection (17, 54).  
Uropathogenic Escherichia coli (UPEC) is the most common etiologic agent, responsible 
for 80-85% of community acquired UTIs (51). However, there are several other 
significant uropathogens including Staphylococcus saprophyticus, Klebsiella pneumoniae 
and Proteus mirabilis (49). 
 K. pneumoniae causes up to 5% of community acquired UTI and is significantly 
more common in diabetic patients and in the nosocomial setting (26, 36, 50).  The urinary 
tract is the most common site of Klebsiella infection, although it may be better 
recognized as a cause of pneumonia in compromised hosts (7). Over the past twenty five 
years, there has been a substantial increase in the spread of drug resistant strains of 
Klebsiella, particularly those producing extended-spectrum β-lactamases (42).  K. 
pneumoniae encodes type 1 pili and its corresponding fim operon is highly homologous 
to that of E. coli (14, 22).  Like E. coli, expression of the fim operon is phase variable 
controlled by an invertible promoter element, fimS.  FimE and fimB, are recombinases 
encoded in the type 1 pilus gene cluster that mediate the phase switching of fimS (33).  
FimX is not part of the fim gene cluster but encodes a recombinase that is also important 
in fimS phase switching in vivo (4, 25).  ON-phase K. pneumoniae display superior in 
vitro binding to ciliated hamster tracheal epithelial cells and rat bladder epithelial cells 
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(12, 15) and in vivo infection of the rat urinary tract (13) compared to OFF-phase 
organisms.  It has also been shown that infection of the mouse urinary tract leads to a 
population shift favoring organisms expressing type 1 pili (37).   
 UPEC utilize a multi-step pathogenic pathway during human and murine infection 
in which they invade bladder facet cells and replicate intracellularly (1, 19, 30, 44, 53).  
Almost all UPEC strains express type 1 pili which consist of a thin tip fibrillum attached 
to a thicker pilus rod (5).  Genes essential for UPEC type 1 pilus biogenesis are organized 
in the fim operon with fimH encoding the adhesin that recognizes mannosylated 
uroplakins on the luminal surface of facet cells (63).  Binding of UPEC to the host cell, 
possibly through beta1 and alpha3 integrins, induces a cascade of signaling events that 
leads to bacterial internalization (11, 38, 39).  Within the superficial facet cells of the 
bladder, piliated UPEC replicate to form intracellular bacterial communities (IBCs) with 
biofilm-like properties (1, 62).  IBCs are transient and the bacteria ultimately flux out of 
epithelial cells, some adopting a filamentous morphology.  These long filaments evade 
engulfment by neutrophils and are necessary for persistence in the murine cystitis model 
(31).  UPEC are also able to form quiescent intracellular reservoirs (QIRs) that can 
persist for several weeks protected from antibiotics and seemingly undetected by the host 
immune system (44, 46, 57).  It has not yet been determined whether non-UPEC 
uropathogens, such as K. pneumoniae, utilize an intracellular bladder niche during 
infection.  In this study we investigated the pathogenesis of K. pneumoniae in the murine 
cystitis model compared to UPEC.  We discovered interesting differences in the 
pathogenic pathway of K. pneumoniae that were related to expression of type 1 pili. 
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Materials and Methods 
Bacterial strains and culture conditions.   
A complete list of bacterial strains and plasmids used in this study can be found in Table 
1.  Clinical strains used include UTI89, a UPEC cystitis isolate (44), and TOP52 1721, a 
K. pneumoniae cystitis isolate.  TOP52 1721 (abbreviated TOP52) was isolated from the 
urine of a 26 year old woman with acute cystitis in a previous UTI study (53).  After 
successful completion of antibiotic therapy and negative follow-up urine cultures, this 
patient developed recurrent cystitis with the same strain of K. pneumoniae, as determined 
by restriction fragment length polymorphism analysis.  Bacteria were cultured at 37°C in 
Luria-Bertani (LB) broth containing, as appropriate, 20 μg/ml chloramphenicol, 50 μg/ml 
kanamycin and arabinose as indicated. 
 
TOP52 1721 and UTI89 mutant construction and complementation.   
Targeted deletions of fimK and fimA-H in the K. pneumoniae isolate TOP52 were 
constructed with the pKOV vector as described previously (35). Flanking sequences of 
approximately 1000 bp on each side of the targeted gene were amplified with the 
indicated primers (Table 2) and cloned into pKOV.  Potential knockouts were screened 
by PCR and the knockout region was sequenced.  Growth curves were done for all 
mutant strains and showed no differences in growth compared to wildtype.  
 UTI89ΔfimA-H was constructed using the red recombinase method as previously 
described (9, 45), with pKD4 as a template and the primers indicated (Table 2).  PCR 
using flanking primers was used to confirm the deletion.    
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Table 1.  Bacterial Strains and Plasmids 
Strain Description Reference 
UTI89 UPEC cystitis isolate (44) 
UTI89ΔfimA-H Knockout of fimA-H in UTI89 This study 
TOP52 1721 Klebsiella pneumoniae cystitis isolate (53) and this study 
TOP52ΔfimK Knockout of fimK in TOP52 This study 
TOP52ΔfimA-H Knockout of fimA-H in TOP52 This study 
Plasmid Description Reference 
pBAD33 Empty expression vector, Para, CmR (24) 
pfimK fimKTOP52 expression vector, Para, CmR This study 
pfimX fimXUTI89 expression vector, Para, CmR (25) 
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Table 2.  Primer Sequences 
Primer Name Primer Use Primer Sequence 
NotIFimKF1 Amplify 1kb fimK 5’ 
Flanking Region 
5’-CGGTAACGCGGCCGCGACTATCC 
GGAAACGATCACC-3’ 
HindIIIFimKR2 Amplify 1kb fimK 5’ 
Flanking Region 
5’-AACAAGCTTAGACGATCCGGATG 
ACTCAC-3’ 
HindIIIFimKF3 Amplify 1kb fimK 3’ 
Flanking Region 
5’-CATAAGCTTAGAAAAGCGCACCG 
GTTA-3’ 
SalIFimKR4 Amplify 1kb fimK 3’ 
Flanking Region 
5’-AACGTCGACAAAACAGAAACCAC 
AGCAACG-3’ 
3FimKCheckF Check TOP52ΔfimK 5’-GTCGATTATCGGCATCACCT-3’ 
3FimKCheckR Check TOP52ΔfimK 5’-GTGGCGAAGGTAGTGGAAAA-3’ 
NotIFimF1 Amplify 1kb fimA 5’ 
Flanking Region 
5’-CGGTAACGCGGCCGCGCATTAGC 
GAACTGCTGGAT-3’ 
BamHIFimR2 Amplify 1kb fimA 5’ 
Flanking Region 
5’-AACGGATCCCAGGGCTGACACAA 
CAATCA-3’ 
BamHIFimF3 Amplify 1kb fimH 3’ 
Flanking Region 
5’-TACGGATCCGTCAATCTCGGCCTG 
ACG-3’ 
SalIFimR4 Amplify 1kb fimH 3’ 
Flanking Region 
5’-AACGTCGACGGAGGGTATGTTGAC 
CGAAA-3’ 
3FimCheckF Check TOP52ΔfimA-H 5’-CCAACGCCATCGCTATTC-3’ 
3FimCheckR Check TOP52ΔfimA-H 5’-GATACACCACGATCCGCTTC-3’ 
3FimKcompF Amplify TOP52 fimK 
for cloning into pBAD 
5’-AATTCCATGGGGCATCACCTTTGT 
CTATCAATGATG-3’ 
3FimKcompR Amplify TOP52 fimK 
for cloning into pBAD 
5’-AATTGGTACCCGGTGCGCTTTTCT 
CGCACCCTCAACG-3’ 
pBADF Check pBAD33 Clones 5’-TATCGCAACTCTCTACTGTTTCTC 
CA-3’ 
pBADR Check pBAD33 Clones 5’-CTGTATCAGGCTGAAAATCTTCTC 
TCA-3’ 
UTI89fimA-H KO F Knockout fimA-H in 
UTI89 
5’-ATGAAAATTAAAACTCTGGCAATTG 
TTGTTCTGTCGGCTCTGTCCCTGAGCAT 
ATGAATATCCTCCTTAG-3’ 
UTI89fimA-H KO R Knockout fimA-H in 
UTI89 
5’-TTATTGATAAACAAAAGTCACGCCAA 
TAATCGATTGCACATTCCCTGCAGGTGT 
AGGCTGGAGCTGCTTC-3’ 
UTI89fimA-
HcheckF 
Check UTI89ΔfimA-H 5’-GTTTGTGCGCGATGCTTTCC-3’ 
UTI89fimA-
HcheckR 
Check UTI89ΔfimA-H 5’-GAGCACCTGAGCCTGCCATT-3’ 
2KlebphaseF Amplify fimS Region 
for Phase Assay 
5’-GGGACAGATACGCGTTTGAT-3’ 
2KlebphaseR Amplify fimS Region 
for Phase Assay 
5’-GGGACAGATACGCGTTTGAT-3’ 
 72
 For complementation studies, fimK was amplified and cloned into the arabinose-
inducible pBAD33 vector (abbreviated pBAD) to make pfimK.  TOP52 fimK was 
sequenced using both amplification primers and pBAD plasmid primers.  This fimK 
nucleotide sequence has been deposited in the GenBank database under the accession 
number EU315065.  Homology searches were conducted using BLASTN and BLASTP 
to look for homologous genes, proteins and domains.  For expression of fimX, the pfimX 
vector, which contains fimX of UTI89 cloned into pBAD, was used as previously 
described (25).  
 
Mouse infections.   
Bacterial strains were used to inoculate eight-week-old female C3H/HeN mice (National 
Cancer Institute) by transurethral catheterization as previously described (43).  25 ml 
static cultures were started from freezer stocks and grown at 37°C for 18 h and then 
subcultured 1:250 into 25 ml fresh media.  These cultures were then grown statically at 
37°C for 18 h, centrifuged for 5 min at 5800 rpm, and the resultant pellet was 
resuspended in PBS and diluted to approximately 2 x 108 CFU/ml.  50 μl of this 
suspension was used to infect each mouse with an inoculum of 1-2 x 107 CFU.  All 
studies were approved by the Animal Studies Committee at Washington University 
School of Medicine. 
  
Urine collection.   
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For mouse urine studies, samples were collected 24 h post inoculation by bladder 
massage over a sterile 1.5 ml Eppendorf tube and cytocentrifuged for 6 min at 1,000 rpm 
onto poly-L-lysine-coated glass slides using a CytoPro 7620 cytocentrifuge (Wescor).   
Slides were stained with filter sterilized Protocol Hema 3 stains (Wright-Giemsa method, 
Fisher Scientific) and analyzed by light microscopy using an Olympus BX51 light 
microscope (Olympus America). 
 
Organ titers, gentamicin protection assays, and IBC enumeration.  
To quantify bacteria present in mouse organs, bladders and kidneys were aseptically 
harvested at the indicated times post infection, homogenized in PBS, serially diluted, and 
plated onto LB agar plates.  Luminal and intracellular bacteria were quantified using an 
ex vivo gentamicin protection assay as previously described (32).  For ex vivo 
enumeration of IBCs, infected bladders were harvested at the indicated times, bisected, 
splayed, washed with PBS, fixed with 3% paraformaldehyde for 60 min at room 
temperature and lacZ stained as previously described (32).  IBCs were visualized and 
counted using an Olympus SZX12 dissecting microscope (Olympus America). 
 
Histology and immunohistochemistry.   
Infected mouse bladders were aseptically removed, fixed in neutral buffer formalin, 
paraffin embedded and sections were stained with hematoxylin and eosin (H&E).  For 
immunohistochemistry, unstained slides were deparaffinized, washed in filter-sterilized 
PBS, blocked in 1% BSA/0.3% Triton X-100 for 1 h at room temperature, and 
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subsequently incubated for 1 h with rabbit anti-E. coli (1:1000, U.S. Biological), rabbit 
anti-K. pneumoniae (1:100, Virostat) or rabbit anti-gel-purified type 1 pili (1:500) (48) 
and goat anti-uroplakin III (1:100, Santa Cruz Biotechnology) primary antibodies.  After 
three washes in PBS for 5 min and staining with Alexa Fluor 488- and 594-conjugated 
donkey secondary antibodies (1:1000, Molecular Probes) for 30 min, slides were washed, 
stained with Hoescht, coverslipped with Fluoromount G (Southern Biotechnology 
Assoc.) and examined using an epifluorescent Zeiss Axioskop (Carl Zeiss). 
 
FimA immunoblots, phase assays of the fim operon switch, and antigenic titration assays.   
For immunoblot analysis bacterial strains were grown statically as described above for 
mouse infections with 0.01% arabinose, as appropriate.  Acid-treated whole cell 
immunoblotting was performed as previously described (19) using 1:2000 rabbit anti-
type 1 pili primary antibody (48).  Bacteria were normalized by OD600 and Coomassie 
staining was performed to verify similar levels of protein in each lane.  Intensity of each 
band was analyzed using ImageJ software (http://rsb.info.nih.gov/ij/). 
 To determine the orientation of the fimS phase switch in TOP52, a phase assay 
was adapted from the E. coli assay previously described (59).  PCR primers were used to 
amplify an 815 bp DNA region including fimS.   The PCR product was then digested with 
the restriction endonuclease Hinf1 (New England Biolabs) was run on a 2.5% agarose 
gel.  A phase ON switch results in products of approximately 495 and 320 bp and a phase 
OFF switch results in products of approximately 600 and 215 bp. 
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 For antigenic titration assays, all strains were grown statically at 37°C in LB with 
appropriate antibiotics and 0.1% arabinose, as indicated.  Serological titers using anti-
type 1 pili monospecific serum or anti-type 3 pili monospecific serum (20, 21) were 
determined as previously described (10). 
 
Negative stain electron microscopy.   
Strains were cultured as described above for mouse infections and were prepared for 
electron microscopy (EM) as follows. Bacteria were absorbed onto Formvar-
carboncoated copper grids for 1 min. Grids were washed in distilled water and stained 
with 1% aqueous uranyl acetate (Ted Pella Inc.) for 1 min. Excess liquid was gently 
wicked off, and grids were allowed to air dry. Samples were viewed on a JEOL 1200EX 
transmission electron microscope (JEOL USA) at an accelerating voltage of 80 kV and 
representative images are shown. 
 
Biofilm assays.   
Bacteria were grown in LB broth in wells of microtiter plates in the presence of 0.1% 
arabinose (for complementation in UTI89) or 0.01% arabinose (for complementation in 
TOP52), as appropriate.  After 48 h of growth at room temperature, wells were rinsed, 
stained with crystal violet, and biofilms were quantified as previously described (47).  
Resulting graphs compare means +/- SEM of two independent experiments, each with 
duplicate plates.   
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Statistical analysis.   
Continuous variables were compared using the Mann-Whitney U test since these 
variables were not normally distributed.  For biofilm data, means of multiple plates from 
two independent experiments were compared and t tests were performed.  All tests were 
two-tailed and a P value less than 0.05 was considered significant.  Analyses were 
performed using GraphPad Prism (GraphPad Software, version 4.03). 
 
 
Results 
TOP52 1721 compared to UTI89 in a murine cystitis model. 
 To contrast urinary tract infection of K. pneumoniae and E. coli, C3H/HeN female 
mice were inoculated by transurethral catheterization with 107 TOP52 1721 (abbreviated 
TOP52), a K. pneumoniae cystitis isolate, or 107 UTI89, an E. coli cystitis isolate.  
Inoculations with less than 107 TOP52 did not result in consistent infection in the mouse 
model (data not shown).  Bladders and kidneys were harvested at various timepoints post 
inoculation and bacterial titers were determined.  In the bladder (Figure 1A), TOP52 had 
significantly lower titers than UTI89 at both 6 h (P<0.0001) and 24 h (P=0.0487) 
timepoints. At later timepoints, TOP52 and UTI89 had similar bladder titers.  At 2 weeks 
post inoculation, TOP52 and UTI89 had similar distributions of bladder titers.  In the 
kidney (Figure 1B), TOP52 had slightly lower titers than UTI89 at 6 h (P=0.0304), 
however, it had similar or higher titers than UTI89 in the kidney at all other timepoints 
tested. 
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Figure 1.  Timecourse of TOP52 and UTI89 bladder and kidney infections and 
gentamicin protection assays.  Female C3H/HeN mice were inoculated with 107 TOP52 
(●) or UTI89 (Δ) by transurethral inoculation.  For organ titers, bladders (A) and kidneys 
(B) were harvested at various timepoints post infection and CFU were calculated.  Titer 
data are combined from N=3 independent experiments.  For ex vivo gentamicin 
protection assays, bladders were harvested at 6 h (C) and 24 h (D) post infection and 
luminal and intracellular populations of bacteria were quantified.  Short bars represent 
geometric means of each group and full dotted lines represent limits of detection.  
Significant P-values, as calculated using the Mann-Whitney U test, are displayed.   
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 It has been shown that UPEC invade into bladder epithelial cells during infection. 
The ability of K. pneumoniae to invade into bladder epithelial cells during UTI was 
investigated using gentamicin protection assays of the bladder performed at 6 h and 24 h 
post inoculation.  At each timepoint, luminal bacteria were collected by successive 
bladder washes, prior to gentamicin treatment.  TOP52, like UTI89, had substantial 
intracellular populations of bacteria at both 6 and 24 h post inoculation. At 6 h (Figure 
1C), TOP52 had significantly more intracellular bacteria than luminal bacteria 
(P=0.0087) as did UTI89 (P=0.0022).  By 24 h (Figure 1D), the number of intracellular 
bacteria was similar to the number of extracellular bacteria for both TOP52 and UTI89.  
However, the number of both luminal and intracellular TOP52 bacteria was significantly 
less than respective UTI89 levels at 6 h (P=0.0022). Thus, TOP52 may be defective in 
adherence and/or invasion of the bladder urothelium early in infection relative to UTI89. 
 These data demonstrate that the K. pneumoniae cystitis isolate, TOP52, is able to 
infect the bladder and kidneys of mice in the murine cystitis model.  However, TOP52 
has significantly reduced titers early in infection compared to the E. coli cystitis isolate, 
UTI89.  Similar to UTI89, there also appears to be a significant intracellular population 
of TOP52 early in infection.  
 
TOP52 progresses through an IBC pathway. 
 Histology was performed on TOP52 bladders at 6 h post inoculation and 
numerous sections were analyzed in order to further characterize the intracellular 
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population of TOP52.  Large intracellular bacterial communities (IBCs) were found in 
TOP52-infected bladders (Figure 2A).  These biofilm-like communities, found within 
superficial bladder facet cells, appeared morphologically identical to those found in 
UTI89-infected bladders (Figure 2B).  Immunohistochemistry staining with Klesbsiella-
specific antibodies confirmed that these IBCs were composed of K. pneumoniae (data not 
shown).  Staining with antibodies against type 1 pili (green) confirmed that type 1 pili are 
expressed within TOP52 IBCs (Figure 2C) and UTI89 IBCs (Figure 2D), similar to what 
has been reported previously for UTI89 (62).  At 24 h post inoculation, filamentous 
bacteria, another hallmark of the IBC pathway, were found in urines from both TOP52-
infected (Figure 2E) and UTI89-infected (Figure 2F) mice. 
 IBCs were visualized and quantified by lacZ staining of whole mounted, fixed 
bladders at 6 and 24 h post inoculation of TOP52 or UTI89 (Figure 2G).  TOP52 had 
significantly fewer IBCs than UTI89 at both 6 h (P=0.0012) and 24 h (P=0.0221) 
timepoints.  Taken together, these data demonstrate that TOP52 progresses through an 
IBC pathogenic pathway.  TOP52, however, forms fewer IBCs than UTI89 early in 
infection. 
 
The fim operon of TOP52 contains fimK and TOP52ΔfimK has higher bacterial titers in 
vivo. 
 We investigated whether the differences in bacterial burden and IBC formation 
between TOP52 and UTI89 observed at early timepoints in infection may, in part, relate  
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Figure 2.  TOP52 progresses through an IBC pathogenic pathway.  Histologic 
analysis of murine bladders after 6 h infection with TOP52 (A) or UTI89 (B) revealed 
morphologically identical IBCs within superficial urothelial cells.  
Immunohistochemistry demonstrated that bacteria express type 1 pili within IBCs of both 
TOP52 (C) and UTI89 (D) infections.  Staining was done with antibodies against type 1 
pili (green), the facet cell marker, uroplakin III (red), and nuclei were visualized with 
Hoescht staining (blue).  Urine samples from mice at 24 h post infection with TOP52 (E) 
or UTI89 (F) contained long bacterial filaments.  IBCs were quantified (G) after 
visualization by LacZ staining and revealed that TOP52 forms significantly fewer IBCs 
than UTI89 at both 6 and 24 h post inoculation.  Short bars represent geometric means 
and significant P-values, as calculated using the Mann-Whitney U test, are displayed.  
Scale bar, 10 μm, applies to panels A-F.   
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to expression of type 1 pili.  We found that while K. pneumoniae encodes intact fimB and 
fimE recombinases important in mediating phase variation of the invertible promoter 
element, it lacks fimX.   Compared to UTI89, the fim operon of TOP52 also contains an 
extra gene of unknown function, fimK (Figure 3A).  FimK was also found to be present 
immediately downstream of fimH in both other strains of K. pneumoniae in which 
sequence of this region was available (22, 41).  Sequence of the 1410 bp open reading 
frame of fimK (GenBank accession number EU315065) showed no homology to 
sequenced bacterial genes.  However, the carboxy-terminus contained an EAL domain, a 
domain which has previously been implicated in cleavage of the second messenger cyclic 
di-GMP (8, 58, 60). 
 A deletion of fimK was constructed and the ability of TOP52ΔfimK to colonize 
and form IBCs was investigated in the murine cystitis model.  At 6 h post inoculation, 
TOP52ΔfimK had significantly higher bladder (Figure 3B) and kidney (Figure 3C) titers 
than wildtype TOP52 (P=0.0112 and P=0.0240, respectively). The fimK gene was cloned 
downstream of an arabinose-inducible promoter to make pfimK for complementation 
studies.  TOP52ΔfimK/pfimK had significantly lower bladder and kidney titers than the 
empty vector control, TOP52ΔfimK/pBAD (P=0.0006 and P=0.0091, respectively). 
 LacZ staining of whole mounted, fixed bladders was performed to determine if 
the deletion of fimK had a quantitative effect on IBC formation (Figure 3D).  While 
wildtype TOP52 formed a mean of 1.8 IBCs per bladder, TOP52ΔfimK formed 4.6 
(P=0.0312).  TOP52ΔfimK/pBAD vector control formed a mean of 5.7 IBCs per bladder 
while TOP52ΔfimK/pfimK formed 3.3 IBCs per bladder (P=0.0939).  These data suggest  
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Figure 3.  TOP52ΔfimK has higher organ titers and forms more IBCs in the murine 
cystitis model than wildtype.  (A)  The fim operons of E. coli and K. pneumoniae, which 
encode type 1 pili, have similar composition and organization, but K. pneumoniae 
contains an extra gene of unknown function, fimK.  (B)  TOP52ΔfimK had higher 6 h 
titers in the bladder than wildtype and this phenotype was complemented with pfimK.  
(C)  TOP52ΔfimK, compared to wildtype, also had consistently higher kidney titers at 6 h 
and this difference could be complemented back to wildtype levels.  (D)  Enumeration of 
IBCs at 6 h post infection revealed that TOP52ΔfimK forms more IBCs than TOP52.  
Titer and IBC data are combined from N=3 independent experiments.  Short bars 
represent geometric means of each group and full dotted lines represent limits of 
detection.  Significant P-values, as calculated using the Mann-Whitney U test, are 
displayed. 
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that loss of fimK results in higher bacterial titers, greater number of IBCs, and overall 
more efficient bladder infection. 
 
TOP52ΔfimK and TOP52/pfimX have higher expression of type 1 pili. 
 We hypothesized that the lower bladder colonization and IBC formation of 
TOP52 compared to UTI89 may be related to type 1 pilus expression.  Possible 
differences in type 1 pilus expression could potentially result from the lack of the fimX 
recombinase or the presence of the fimK gene in TOP52.  The higher bladder titers and 
increased abundance of IBCs observed with the loss of fimK could potentially be 
explained by higher expression of type 1 pili.  Thus, the effects of fimK loss or fimX 
addition on type 1 pilus expression were investigated.  Levels of the major type 1 pilus 
subunit, FimA, were monitored by whole cell immunoblots using anti-FimA antibodies.  
Cells were normalized by OD600 and Coomassie staining was used to verify similar levels 
of protein in each lane.  In addition, the orientation of the fimS promoter was analyzed in 
phase assays to test if the loss of fimK or the addition of fimX affects type 1 pilus 
expression (Figure 4).  TOP52ΔfimK produced a larger FimA band compared to TOP52 
as determined by immunoblot.  Complementation of TOP52ΔfimK with pfimK reduced 
the size of the FimA band close to wildtype levels.  Moreover, the addition of fimX in 
TOP52 also led to the production of a larger FimA band compared to vector control.  As 
a control, fimA-H was deleted in TOP52.  This negative control strain, TOP52ΔfimA-H, 
did not produce a FimA band.   
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Figure 4.  TOP52ΔfimK and TOP52/pfimX have higher expression of type 1 pili than 
wildtype and vector controls.  FimA immunoblots showed that TOP52ΔfimK makes 
more type 1 pili than wildtype TOP52.  Expression of FimA was complemented down to 
wildtype levels with pfimK.  TOP52/pfimX also produced a much larger FimA band than 
vector control.  Bacteria were normalized by OD600 and Coomassie staining was used to 
verify similar levels of protein in each lane.  Relative densitometry was calculated using 
ImageJ software.  Phase assays, showing the orientation of the fimS promoter region of 
the fim operon, revealed that wildtype TOP52 and TOP52/pBAD vector control were 
largely phase OFF while TOP52ΔfimK and TOP52/pfimX had significant phase ON 
populations. 
 
 
 
 
 
 85
 Phase assays were performed in which the fimS invertible region was amplified by 
PCR and digested using a restriction endonuclease to determine the orientation of the fim 
operon promoter.  TOP52ΔfimK had a larger proportion of phase ON cells compared to 
TOP52 which was primarily phase OFF.  This phenotype could be partially 
complemented using pfimK. TOP52ΔfimK/pfimK had a slightly larger phase OFF 
population than TOP52ΔfimK/pBAD vector control.  Expression of fimX in TOP52 
resulted in a significant shift in the population to the phase ON position compared to 
TOP52/pBAD vector control which was primarily phase OFF.  The negative control, 
TOP52ΔfimA-H, did not yield a PCR product because a portion of the corresponding 
DNA had been deleted. 
 For semi-quantitative measures of type 1 pilus expression in these K. pneumoniae 
strains, we performed antigenic titration assays (Table 3).  This assay tests the ability of 
various dilutions of type 1 pili monospecific antisera to agglutinate bacteria.  For 
wildtype TOP52, only dilutions of antibody up to 1:160 caused agglutination, while 
TOP52ΔfimK agglutinated at levels up to 1:2560, indicating much higher expression of 
type 1 pili in TOP52ΔfimK.  While vector control resulted in similar antibody titers, 
complementation of TOP52ΔfimK with pfimK resulted in a titer of 1:80 with arabinose 
induction, thus fully decreasing type 1 piliation down to levels similar to wildtype.  The 
negative control TOP52ΔfimA-H, as expected, did not agglutinate even with the highest 
concentration of type 1 antisera.  It should also be noted that all strains had similar titers 
using antisera to type 3 pili (data not shown) indicating that fimK does not affect 
expression of type 3 pili. 
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aTiters are the reciprocal of the highest dilution of serum causing visable agglutination 
after 5 minutes. 
bTiters represent the median of three independent experiments. 
cThe lowest dilution of antibody used in this assay was 1:20. 
 
 
 
 
 
 
 
 
Table 3.  Serological titers of K. pneumoniae strains 
using anti-type 1 pili monospecific serum. 
Strain Arabinose Titerab 
TOP52 - 160 
TOP52ΔfimK - 2560 
TOP52ΔfimK/pBAD - 1280 
TOP52ΔfimK/pBAD + 2560 
TOP52ΔfimK/pfimK - 1280 
TOP52ΔfimK/pfimK + 80 
TOP52ΔfimA-H - <20c 
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 Additionally, negative stain EM was performed to visualize type 1 pili in the 
different strains (Figure 5).  Wildtype TOP52 showed low to moderate levels of type 1 
piliation while TOP52ΔfimA-H was exclusively bald.  TOP52ΔfimK and 
TOP52ΔfimK/pBAD had a dramatic shift in the proportion of heavily type 1 piliated 
bacteria.  This hyperpiliation phenotype was reduced in TOP52ΔfimK/pfimK.  
TOP52/pfimX also displayed higher levels of piliation compared to TOP52/pBAD vector 
control.   
 These data suggest that fimK inhibits type 1 piliation in TOP52 and addition of 
fimX can increase piliation.  This was demonstrated at the transcriptional level in which 
loss of fimK or addition of fimX resulted in an increased population of phase ON bacteria 
and increased amounts of FimA.  Wildtype TOP52 was primarily phase OFF with 
inherently low production of type 1 pili possibly hindering its ability to cause infection in 
the urinary tract.  The presence of fimK and lack of fimX in TOP52 may, in part, account 
for the significantly reduced bacterial titers early in infection compared to UTI89.   
 
fimK and fimX affect in vitro biofilm formation. 
 To determine if the loss of fimK or the gain of fimX have effects on type 1-
dependent biofilm formation which may be important in vivo, TOP52 biofilm assays 
were performed (Figure 6A).  Crystal violet was used to stain biofilms and the amount of 
biofilm was quantified by absorbance at OD600.  Wildtype TOP52 failed to make biofilm  
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Figure 5.  TOP52ΔfimK and TOP52/pfimX appear hyperpiliated by negative stain 
electron microscopy.   Negative stain EM was performed on TOP52 cultures are 
representative images are displayed.  TOP52 had low to moderate piliation and the 
negative control TOP52ΔfimA-H appeared bald.  TOP52ΔfimK was hyperpiliated 
compared to wildtype and this phenotype could be partially complemented with pfimK.  
TOP52/pfimX also displayed higher levels of piliation compared to vector control. 
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Figure 6.  The presence of fimK and fimX affect biofilm formation of TOP52 and 
UTI89.  A 48 h biofilm assay was used to quantify biofilms produced by TOP52 (A) 
strains and UTI89 strains (B).  TOP52 and the negative control TOP52ΔfimA-H failed to 
form biofilms.  However, TOP52ΔfimK and TOP52/pfimX were able to form biofilm.  
TOP52ΔfimK/pfimK formed significantly less biofilm than vector control.  Wildtype 
UTI89 formed robust biofilm and the negative control UTI89ΔfimA-H was unable to 
form biofilm.  Complementation of UTI89 with TOP52 fimK resulted in significantly less 
biofilm formation than UTI89/pBAD vector control.  Data combine means of 2 
independent experiments, each with duplicate plates.  Error bars represent standard error 
of the mean.   
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in this assay after 48 hours as did the negative control, TOP52ΔfimA-H.  TOP52ΔfimK, 
however, formed biofilm under the same conditions.  TOP52ΔfimK/pfimK made 
significantly less biofilm than TOP52ΔfimK/pBAD vector control (P=0.0128).   Thus, 
complementation of TOP52ΔfimK with pfimK significantly reduced its ability to form 
biofilm. Expression of the recombinase fimX on a plasmid also conferred TOP52 with the 
ability to form biofilm.  TOP52/pfimX made significantly more biofilm than 
TOP52/pBAD vector control which was unable to form biofilm (P=0.0002).    
TOP52ΔfimA-H/pfimX did not form biofilm (data not shown) verifying that biofilm 
formation required type 1 pilus expression. 
 UTI89 was transformed with pfimK in order to determine if fimK expression 
would also reduce UTI89 biofilm formation (Figure 6B).  Wildtype UTI89 formed a 
robust biofilm after 48 hours.  The negative control, UTI89ΔfimA-H, was unable to form 
biofilm.  Expression of pfimK in UTI89 decreased biofilm formation compared to 
UTI89/pBAD vector control (P=0.0022). 
 While wildtype TOP52 is unable to form type 1 pili-dependent biofilms, loss of 
fimK or addition of fimX transforms a non-biofilm former into a biofilm producer.  
Interestingly, these data suggest that fimK acts as an inhibitory factor for biofilm 
formation in both TOP52 and UTI89, likely through affecting changes in expression of 
type 1 pili.  Thus, fimK is likely affecting type 1 pili or biofilm regulatory pathways that 
are conserved in both K. pneumoniae and E. coli. 
 
 91
Discussion 
 Despite being the second most common cause of Gram-negative UTI, few studies 
have analyzed the pathogenesis of K. pneumoniae in a UTI model.  In this study, we 
infected mice with TOP52 1721, a K. pneumoniae cystitis isolate, and found that, early in 
infection, it had lower bladder and kidney titers than UTI89, a UPEC strain.  The reason 
for this early deficiency is likely related, in part, to the type 1 piliation state of TOP52.   
 TOP52 encodes the gene fimK which acts to reduce type 1 piliation.  Additionally, 
TOP52 lacks fimX, a recombinase able to increase type 1 piliation.  These factors may 
predispose K. pneumoniae to be a less effective uropathogen compared to UPEC.  The 
few bacteria that get introduced into the host bladder (3, 6, 27) are less likely to adhere to 
or invade the bladder surface because of less type 1 piliation.  A less piliated organism is 
presumably at a significant disadvantage upon entrance into the bladder and is less likely 
to survive to initiate significant infection in the host.  In addition, it should be noted that 
while we analyzed the expression of K. pneumoniae type 1 pili, it is not clear that their 
function is the same as those of E. coli.  More work needs to be done to determine if there 
are structural or functional differences of K. pneumoniae and UPEC type 1 pili that may 
also affect UTI pathogenesis.   
 TOP52 was able to form biofilm-like IBCs in the bladder, however it made 
significantly fewer compared to UTI89.  Interestingly, despite this defect, TOP52 titers 
are similar to those of UTI89 at later timepoints in infection.  TOP52 may be able to 
persist at a relatively constant level throughout the course of infection, while UTI89 
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infection levels decrease to that of TOP52.  This could be due to the influence of the host 
inflammatory responses to each uropathogen.  Alternatively there may be a lag in K. 
pneumoniae infection due to type 1 pilus expression or other factors.  Bacterial 
filamentation has been shown to be important for UPEC persistence in the murine cystitis 
model (31).  It should be noted that no obvious differences in the levels of bacterial 
filamentation were observed in 24 h urine samples of UTI89-infected and TOP52-
infected mice, however, quantitative measurements of filamentation were not performed.  
Ultimately, both UTI89 and TOP52 were able to effectively persist in similar fashion in 
the murine cystitis model with a 107 inoculum.  In humans, relatively few bacteria are 
introduced into the bladder and if K. pneumoniae has a lower probability of forming IBCs 
relative to UPEC, than K. pneumoniae may be cleared more efficiently. 
 This is the first account of a non-UPEC uropathogen forming IBCs in the bladder.  
Thus, the ability to form IBCs is not specific to UPEC. The IBC pathway may be a 
conserved mechanism by which many uropathogens evade the host innate immune 
response.  Uropathogens may form these intracellular biofilms to multiply unhindered 
within the protected niche of the urothelial cell and even escape antibiotic penetration. 
Further studies need to be done to determine which uropathogens, including other K. 
pneumoniae isolates, are able to utilize an intracellular niche during acute bladder 
infection.   
 UPEC IBCs are transient in nature, however, UPEC has the ability to form long-
lasting quiescent intracellular reservoirs (QIRs) that can seed recurrent infection (46). 
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These QIRs consist of bacterial rosettes within Lamp-1 positive endocytic vesicles.  This 
study did not analyze long term reservoir formation by K. pneumoniae.  Future studies 
are needed to determine if K. pneumoniae can form QIRs and if these reservoirs can seed 
recurrent infection.   
 While it is clear that the presence of FimK inhibits type 1 piliation in K. 
pneumoniae, the mechanism of this inhibition is not known.  FimK does contain an EAL 
domain, named after conserved residues, which has been implicated in the cleavage of 
the second messenger molecule, cyclic di-GMP (8, 58, 60).  Loss of FimK may lead to 
higher levels of cyclic di-GMP which has been implicated in biofilm formation, 
production of adhesive surface structures, and inhibition of motility (18, 34, 61).  Further 
studies are needed to determine if FimK is an active phosphodiesterase with the ability to 
cleave cyclic di-GMP and how this second messenger may influence expression of type 1 
pili in K. pneumoniae.  FimK may be exclusively acting on expression of type 1 pili or 
FimK may also affect the expression of other adhesins or virulence factors in K. 
pneumoniae which may play a role in UTI.  The ability of FimK to decrease type 1-
dependent biofilm formation in UTI89 implies that it acts on a regulatory network 
affecting type 1 piliation that is conserved between K. pneumoniae and E. coli. 
 It is not clear why K. pneumoniae is programmed to keep type 1 pili primarily in 
the phase OFF orientation.  While type 1 pili have been shown to be important in cystitis, 
perhaps the presence of type 1 pili is detrimental for Klebsiella in other environments or 
conditions.  UPEC type 1 pili have been shown to switch to a phase-OFF state in the 
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kidney (56).  Klebsiella may have evolved to be primarily a kidney pathogen without the 
need for high levels of type 1 pili in this niche.  Type 1 pili may be antigenic in the lung 
or gut and may lead to K. pneumoniae clearance.  Additionally, while capsule is an 
essential virulence factor for K. pneumoniae in many environments (2), it has also been 
shown to impede adhesion to and invasion of bladder epithelial cells (55).  It has been 
noted that type 1 pili and capsule may be inversely expressed or regulated in K. 
pneumoniae (40) and this may explain the predisposition towards a less piliated state. 
 Our studies have demonstrated that the ability to utilize an intracellular niche 
during UTI is not specific to UPEC alone.  Despite being able to progress through an IBC 
pathway, K. pneumoniae forms fewer IBCs and has lower bladder titers than UPEC early 
in infection.  These differences are related, in part, to type 1 pilus expression.  This work 
begins to explain the difference in prevalence of E. coli and K. pneumoniae UTI and 
emphasizes the importance of type 1 pili regulatory elements in the ability of 
uropathogens to infect the urinary tract.  Specifically, we have identified a novel 
regulatory gene in K. pneumoniae, fimK, capable of suppressing IBC and biofilm 
formation and impeding UTI pathogenesis. 
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FimH Affect Function and Pathogenesis in the Urinary Tract  
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Abstract 
 Type 1 pili mediate binding, invasion and biofilm formation of uropathogenic 
Escherichia coli (UPEC) in the host urothelium during urinary tract infection (UTI) via 
the adhesin FimH.  In this study, we characterized the molecular basis of functional 
differences between FimH of the UPEC isolate, UTI89, and the Klebsiella pneumoniae 
cystitis isolate, TOP52 1721.  Type 1 pili characteristically mediate mannose-sensitive 
hemagglutination (MSHA) of guinea pig erythrocytes.  Although the adhesin domain of 
K. pneumoniae TOP52 1721 FimH (FimH52) is highly homologous to that of E. coli, with 
an identical mannose binding pocket and surrounding hydrophobic ridge, it lacks the 
ability to mediate MSHA.  In addition, FimH-dependent biofilm formation in K. 
pneumoniae is inhibited by heptyl mannose, but not methyl mannose, suggesting the need 
for contacts outside of the mannose binding pocket.  The binding specificity differences 
observed for FimH52 resulted in significant functional differences seen in K. pneumoniae 
UTI pathogenesis compared to E. coli.  Infections in a murine model of UTI 
demonstrated that although the K. pneumoniae strain TOP52 1721 required FimH52 for 
invasion and IBC formation in the bladder, FimH52 was not essential for early 
colonization.  This work reveals that a limited amount of sequence variation between the 
FimH of E. coli and K. pneumoniae results in significant differences in function and 
ability to colonize the urinary tract.  
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Introduction 
 Bacterial adherence to host mucosal surfaces is often an important first step in the 
infection process.  This is especially true in the case of urinary tract infections (UTIs) 
(59).  It is estimated that half of all women will experience at least one UTI in their 
lifetime (49), the vast majority of which are caused by uropathogenic Escherichia coli 
(UPEC) and other Enterobacteriaceae (48).  An essential step in UPEC infection of the 
bladder is adherence to the host urothelial surface via type 1 pili (2, 27, 29).  Type 1 pili 
are assembled via the chaperone/usher pathway (3, 30, 53).  They are adhesive hair-like 
fibers consisting of cylindrical pilus rods composed of FimA pilin subunits and small tip 
fibrillae composed of FimF, FimG and the adhesin, FimH (6, 31).  The FimH adhesin 
recognizes mannosylated uroplakins and β-1 and α-3 integrin receptors on the luminal 
surface of bladder urothelial cells (17, 29, 63).  Binding of UPEC to host cells induces a 
cascade of signaling events that ultimately leads to bacterial internalization and the 
formation of biofilm-like intracellular bacterial communities (IBCs) (1, 17, 22, 32, 39, 
43, 51). IBC formation is also dependent on type 1 pili (62).  Ultimately bacteria disperse 
from this intracellular niche and progress to infect other urothelial cells. 
 Type 1 piliated bacteria have historically been characterized by their ability to 
agglutinate guinea pig red blood cells (RBCs) in a mannose-sensitive manner (14, 15, 
52).  This mannose-sensitive hemagglutination (MSHA) phenotype of E.coli expressing 
type 1 pili requires the FimH adhesin.  FimH consists of two domains: an amino-terminal 
adhesin domain (receptor binding domain) and a carboxy-terminal pilin domain (8, 29, 
31).  FimH recognizes mannosylated glycoproteins including those present on the host 
urothelium through its adhesin domain. FimH-mediated adhesion can be inhibited by D-
mannose or oligosaccharides containing terminal mannose residues (5, 19-21).  
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Additionally, it has been demonstrated that the FimH adhesin domain binds more tightly 
to α-D-mannosides with longer alkyl chains.  Heptyl mannose was found to have the 
highest affinity for FimH (5).  In animal models, neutralization of the adhesin by FimH-
specific antibodies protects from UPEC cystitis (35, 36).  X-ray crystal structures of 
FimH reveal a highly-conserved mannose-binding pocket at the tip of the FimH adhesin 
domain surrounded by a distal hydrophobic ridge (8, 29).  Minor sequence differences in 
E. coli FimH, many of which are not located in close proximity to the mannose binding 
pocket, have been found to correlate with differential binding phenotypes (54-56).   
 Klebsiella pneumoniae is the second leading cause of Gram-negative UTI and 
encodes numerous chaperone/usher pili including type 1 pili and type 3 pili (23).  While 
type 1 pili have historically been defined by their MSHA phenotype, type 3 pili display a 
mannose-resistant hemagglutination (MRHA) with tannin-treated RBCs (47).  Type 1 pili 
of K. pneumoniae are highly homologous to those of UPEC (23) and have been 
previously implicated in UTI pathogenesis (18, 40).  The fim operon of K. pneumoniae, 
encoding type 1 pili, contains a terminal fimK gene, not present in UPEC, which plays a 
role in suppressing the expression of type 1 pili (50).  K. pneumoniae binds, invades and 
forms IBCs within host urothelial cells, albeit less efficiently than UPEC in the murine 
cystitis model.  Similar to UPEC, K. pneumoniae also expresses type 1 pili within these 
IBCs (50).    In this study, we discovered that type 1 piliated K. pneumoniae are unable to 
mediate MSHA despite the presence of wild type FimH containing an identical mannose 
binding pocket as E. coli FimH.  We analyzed functional and structural differences in 
FimH of the K. pneumoniae strain, TOP52 1721, and the effects of these differences on 
UTI pathogenesis.   
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Materials and Methods 
Bacterial strains and culture conditions.   
A complete list of bacterial strains and plasmids used in this study can be found in Table 
1.  Clinical strains used include UTI89, a UPEC cystitis isolate (43), and TOP52 1721 
(abbreviated TOP52), a K. pneumoniae cystitis isolate (50).  Bacteria were cultured at 
37°C in Luria-Bertani (LB) broth containing, as appropriate, 20 μg/ml chloramphenicol 
and 0.4% arabinose as indicated. 
 
TOP52 and UTI89 mutant construction and complementation.   
A targeted deletion of fimH in the K. pneumoniae isolate, TOP52, was constructed with 
the pKOV vector as described previously (37). Flanking sequences of approximately 
1000 bp on each side of the targeted gene were amplified with the indicated primers 
(Table 2) and cloned into pKOV.  Potential knockouts were screened by PCR and the 
knockout region was sequenced.  Growth curves were performed for mutant strains and 
showed no differences in growth compared to wildtype.  
 UTI89ΔfimH was constructed using the red recombinase method as previously 
described (10, 44), with pKD4 as a template and the primers indicated (Table 2) followed 
by expression of the FLP recombinase to eliminate the kanamycin cassette.  PCR using 
flanking primers was used to confirm the deletion.    
 For complementation studies, the adhesin domains (ADs) and pilin domains 
(PDs) of both UTI89 fimH and TOP52 fimH were amplified using the primers indicated 
(Table 2).  Subscripts 89 and 52 were used to indicate a given domain was from UTI89 or  
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Table 1.  Bacterial Strains and Plasmids 
Strain Description Reference 
UTI89 UPEC cystitis isolate (43) 
UTI89ΔfimH Knockout of fimH in UTI89 This study 
TOP52 1721 Klebsiella pneumoniae cystitis isolate (50) 
TOP52ΔfimH Knockout of fimH in TOP52 This study 
TOP52ΔfimK Knockout of fimK in TOP52 (50) 
Plasmid Description Reference 
pBAD33 Empty expression vector, Para, CmR (24) 
pfimX fimXUTI89 expression vector, Para, CmR (25) 
pfimH89  
(pfimH-AD89PD89) 
fimHUTI89 expression vector, Para, CmR This study 
pfimH-AD89PD52 fimH chimera expression vector, Para, 
CmR 
This study 
pfimH-AD52PD89 fimH chimera expression vector, Para, 
CmR 
This study 
pfimH52  
(pfimH-AD52PD52) 
fimHTOP52 expression vector, Para, CmR This study 
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Table 2.  Primer Sequences 
Primer Name Primer Use Primer Sequence 
NotIFimHF1 Amplify 1kb fimH 5’ 
Flanking Region 
5’-CGGTAACGCGGCCGCGGCGAATC 
GAAGGATTTTACT-3’ 
BamHIFimHR2 Amplify 1kb fimH 5’ 
Flanking Region 
5’-AACGGATCCAAAGGACCAGGCGT 
TCATC-3’ 
BamHIFimHF3 
 
Amplify 1kb fimH 3’ 
Flanking Region 
5’-AACGGATCCACGCGATCTTCACCA 
ATACC-3’ 
SalIFimHR4 
 
Amplify 1kb fimH 3’ 
Flanking Region 
5’-AACGTCGACGTCTGGGGGTGAAGT 
ACCTG-3’ 
FimHCheckF1 Check TOP52ΔfimH 5’-GGACAGCACCGGCTATTACA-3’ 
FimHCheckR2 Check TOP52ΔfimH 5’-GGGATCGTCAGGGAGATACA-3’ 
UTI89fimH KO F Knockout fimH in 
UTI89 
5’-ATGAAACGAGTTATTACCCTGTTTGCT 
GTACTGCTGATGGGCTGGTCGGTAGTGTA
GGCTGGAGCTGCTTC-3’ 
UTI89fimH KO R Knockout fimH in 
UTI89 
5’-TTATTGATAAACAAAAGTCACGCCAA 
TAATCGATTGCACATTCCCTGCAGTCATAT
GAATATCCTCCTTAG -3’ 
UTI89fimHcheckF Check UTI89ΔfimH 5’-CAATCAGCGCACTTCCCGTTACAGG-3’ 
UTI89fimHcheckR Check UTI89ΔfimH 5’-CTCGAATTATAAACAACCCGCGGCG -3’ 
2KlebphaseF Amplify fimS Region 
for Phase Assay 
5’-GGGACAGATACGCGTTTGAT-3’ 
2KlebphaseR Amplify fimS Region 
for Phase Assay 
5’-GGGACAGATACGCGTTTGAT-3’ 
ADecoliF Amplify E. coli fimH 
Adhesin Domain 
5’-AATTCCATGGGATGAAACGAGTTATT 
ACCCTGTTTGCTG-3’ 
ADecoliR Amplify E. coli fimH 
Adhesin Domain 
5’-TCGCAGCCGCCAGTGGGCACCACCAC-3’ 
 
PDecoliF Amplify E. coli fimH 
Pilin Domain 
5’-GTGGTGGTGCCCACTGGCGGCTGCGA-3’ 
 
PDecoliR Amplify E. coli fimH 
Pilin Domain 
5’-AATTGGTACCATTGATAAACAAAAGTC 
ACGCCAATAATCG-3’ 
ADklebF Amplify Kleb. fimH 
Adhesin Domain 
5’-AATTCCATGGGATGATGAAAAAAATAA 
TCCCCCTGTTCACC-3’ 
ADklebR Amplify Kleb. fimH 
Adhesin Domain 
5’-TCGCAGCCGCCGGTGGGGACCACC 
AC-3’ 
PDklebF Amplify Klebsiella 
fimH Pilin Domain 
5’-GTGGTGGTCCCCACCGGCGGCTGCGA-3’ 
 
PDklebR Amplify Klebsiella 
fimH Pilin Domain 
5’-AATTGGTACCCATTGATAGACAAAGGT 
GATGCCGATG-3’ 
pBADF Check pBAD33 
Clones 
5’-TATCGCAACTCTCTACTGTTTCTCCA-3’ 
pBADR Check pBAD33 
Clones 
5’-CTGTATCAGGCTGAAAATCTTCTCT 
CA-3’ 
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TOP52, respectively.  Single ADs and PDs were added together as templates in a PCR 
reaction to create a full length fimH gene that was subsequently cloned into the arabinose-
inducible pBAD33 vector (abbreviated pBAD).  The four permutations of the ADs and 
PDs yielded fimH complementation vectors pAD89PD89 (pfimH89), pAD89PD52, 
pAD52PD89, and pAD52PD52 (pfimH52).  All constructs were verified and sequenced using 
pBAD plasmid primers.  The TOP52 fimH nucleotide sequence has been deposited in the 
GenBank database under the accession number EU327536. 
 
Hemagglutination assays.   
Hemagglutination assays (HAs) were performed with guinea pig red blood cells (OD640 = 
2.0, Colorado Serum Company) as previously described using serial dilutions in 
microtiter plates with and without the addition of 100 mM methyl α-D-mannopyranoside 
(28).   
 
Biofilm assays.   
Bacteria were grown in LB broth in wells of microtiter plates in the presence of 0.01% 
arabinose and either no mannose, 1 mM methyl mannose, 100 mM methyl mannose or 1 
mM heptyl mannose.  After 48 hours of growth at room temperature, wells were rinsed, 
stained with crystal violet, and biofilms were quantified as previously described (46).  
 
Modeling of K. pneumoniae FimH.  
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K. pneumoniae TOP52 FimH was modeled onto the X-ray crystal structure of E.coli 
FimH from the J96 isolate FimC-H complex structure (PDB ID: 1KLF) (29) using the 
protein structure threading program Phyre (4).  The resulting model was compared to the 
J96 structure and UTI89 amino acid sequence (a structure for UTI89 FimH has not been 
solved to date and J96 FimH only differs by 4 amino acids from UTI89 FimH).  Figures 
were rendered in the molecular modeling program Pymol (11). 
 
Mouse infections.   
Bacterial strains were used to inoculate eight-week-old female C3H/HeN mice (National 
Cancer Institute) by transurethral catheterization as previously described (42).  25 ml 
static cultures were inoculated from freezer stocks and grown at 37°C for 18 hours and 
then subcultured 1:250 into 25 ml fresh media.  These cultures were then grown statically 
at 37°C for 18 hours, centrifuged for 5 min at 5800 rpm, and the resultant pellet was 
resuspended in PBS and diluted to approximately 2 x 108 CFU/ml.  50 μl of this 
suspension was used to infect each mouse with an inoculum of 1-2 x 107 CFU.  All 
studies were approved by the Animal Studies Committee at Washington University 
School of Medicine. 
 
Organ titers, gentamicin protection assays, and IBC enumeration.   
To quantify bacteria present in mouse organs, bladders and kidneys were aseptically 
harvested at the indicated times post infection, homogenized in PBS, serially diluted, and 
plated onto LB agar plates.  Luminal and intracellular bacteria were quantified using an 
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ex vivo gentamicin protection assay as previously described (33).  For ex vivo 
enumeration of IBCs, infected bladders were harvested at 1 hour post infection, bisected, 
splayed, washed with PBS, fixed with 3% paraformaldehyde for 1 hour at room 
temperature and lacZ stained as previously described (33).  IBCs were visualized and 
counted using an Olympus SZX12 dissecting microscope (Olympus America). 
 
Fim operon phase assay.   
To determine the orientation of the type 1 pili phase-variable promoter switch (fimS) in 
UTI89ΔfimH, a phase assay was performed as previously described (58).  Briefly, PCR 
primers were used to amplify a 589 bp DNA region including fimS.   The PCR product 
was then digested with the restriction endonuclease Hinf1 (New England Biolabs) and 
was separated on a 2.5% agarose gel.  A phase ON switch results in products of 489 and 
70 bp and a phase OFF switch results in products of 359 and 200 bp. 
 
Immunoelectron microscopy.   
Bacteria were prepared as described above for mouse infection, fixed with 1% 
paraformaldehyde for 10 min, and absorbed onto formvar/carbon-coated copper grids for 
2 min.  Grids were washed two times with PBS, blocked with 1% FBS for 5 min, and 
incubated with rabbit anti-FimH antibody (1:100) for 30 min at room temperature.  The 
rabbit anti-FimH antibody was raised against the FimH adhesin domain (1-159, T2) of E. 
coli J96 (26) (SigmaGenesis).  Grids were subsequently washed two times with PBS, 
blocked with 1% FBS for 5 min, and incubated with 18nm colloidal gold-conjugated anti-
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rabbit IgG (Jackson ImmunoResearch Laboratories) for 30 min at room temperature.  
Following two PBS washes, grids were rinsed in dH2O, and stained with 1% aqueous 
uranyl acetate (Ted Pella Inc.) for 1 min.  Excess liquid was gently wicked off and grids 
were air dried.  Samples were viewed on a JEOL 1200EX transmission electron 
microscope (JEOL USA) at 80 kV accelerating voltage. 
 
Statistical analysis.   
Continuous variables were compared using the Mann-Whitney U test since these 
variables were not normally distributed.  All tests were two-tailed and a P value less than 
0.05 was considered significant.  Analyses were performed using GraphPad Prism 
(version 4.03) and SAS (version 9.0). 
 
 
Results 
Type 1 piliated TOP52 is MSHA negative. 
 In contrast to UPEC, statically passaged K. pneumoniae TOP52 1721 (abbreviated 
TOP52) produced no detectable hemagglutination of guinea pig RBCs despite expression 
of type 1 pili (Table 3).  The MSHA titer of the UPEC strain UTI89 was 1:512.  Deletion 
of fimH abolished the ability of UTI89ΔfimH to produce MSHA.  UTI89ΔfimH produced 
a low MRHA titer of 1:4, unlike UTI89.  Wildtype TOP52 was MSHA negative.  
Deletion of fimH to create TOP52ΔfimH thus had no effect and this strain was also 
MSHA negative.  Recently, we discovered that deletion of fimK, a gene  
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Table 3.  FimH52 is Unable to Produce a Mannose-Sensitive 
Hemagglutination of Guinea Pig Red Blood Cells. 
Strain Guinea Pig RBC 
 
HA Titer (1:2x)* 
Guinea Pig RBC  
+ Mann. 
HA Titer (1:2x)* 
UTI89 9 2 
UTI89ΔfimH 2 2 
TOP52 0 0 
TOP52ΔfimH 0 0 
TOP52ΔfimK 0 0 
TOP52/pBAD 0 0 
TOP52/pfimX 0 0 
TOP52ΔfimH/pBAD 0 0 
TOP52ΔfimH/pfimH52 0 0 
TOP52ΔfimH/pfimH89 4 0 
     *HA titer data are representative of 3 independent experiments. 
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unique to Klebsiella fim gene clusters, resulted in a hyper-type 1 piliated phenotype (50).  
The hyperpiliated TOP52ΔfimK was also MSHA negative.  The fimX recombinase has 
been shown to have fimB-like properties (7, 25) and it’s overexpression results in 
increased expression of type 1 pili in both E. coli (25) and K. pneumoniae (50). The 
hyperpiliated TOP52/pfimX was also MSHA negative.  Thus, the type 1 piliated 
Klebsiella TOP52 strain is unable to mediate MSHA. 
 
FimH52 and FimH89 are highly similar in amino acid sequence and structure. 
 To further investigate the functional differences of TOP52 type 1 pili, we 
sequenced fimH52 (GenBank accession number EU327536) and compared it to other 
known K. pneumoniae FimH sequences and the sequence of E. coli UTI89 FimH 
(FimH89).  The FimH52 amino acid (aa) sequence shares 100% identity to the FimH 
adhesin domain of K. pneumoniae strain IA565 (23),  99.6% aa identity with the FimH of 
K. pneumoniae ATCC 700721 strain (41), 85.3% aa identity with K. pneumoniae strain 
IA551 (16).  FimH52 has 86.4% aa identity to FimH of E. coli UTI89 (FimH89) (Fig. 1A) 
and maintains the general bi-domain composition of E. coli FimH with an amino-terminal 
adhesin domain (aa 1-157) and a carboxy-terminal pilin domain (aa 161-279) separated 
by a short linker region. 
We threaded the K. pneumoniae FimH onto the X-ray crystal structure of FimH 
from the complex structure of FimC-H from the J96 E. coli isolate (29).  We then  
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Figure 1.  FimH52 and FimH89 are highly conserved in sequence and structure.   
(A) The FimH amino acid sequences of UTI89 and TOP52 are shown.  Residues known 
to interact with mannose (orange) and form the hydrophobic ridge (green) are fully 
conserved.  The purple line denotes sequence of the adhesin domain, the green line 
denotes sequence of the pilin domain, and the yellow line denotes the short linker region.  
Amino acid numbers refer to the mature protein without signal sequence.  (B)  Structure 
of E. coli FimH (yellow) (from the J96 strain FimC-H complex, PDB ID: 1KLF) bound 
to mannose (red) overlayed with a threaded model of K. pneumoniae TOP52 FimH.  Side 
chains of TOP52 amino acids that vary from the UTI89 sequence are shown as blue 
sticks.  (Inset) Space filling model of a view into the mannose-binding pocket (same 
colors as above). This shows that all residues in direct contact with the mannose moiety 
and those that form the hydrophobic ridge are fully conserved between UTI89 and 
TOP52.   
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overlayed J96 FimH and TOP52 FimH and compared the positions and identities of 
amino acid (aa) differences in FimH89 and FimH52 (Fig. 1B).  This comparison assumes 
that residues conserved between J96 FimH and UTI89 FimH have the same conformation 
as shown in the three-dimensional J96 FimH structure.  There are only 4 amino acid 
differences between FimH of these two strains. 17 adhesin domain aa differences and 21 
pilin domain aa differences exist between FimH89 and FimH52.  Interestingly, despite its 
MSHA deficit, FimH52 displays full conservation of the residues known to interact with 
mannose in the mannose binding pocket (orange) and those that form the surrounding 
hydrophobic ridge (green) (Fig 1).  Residue differences exist in areas adjacent to the 
receptor binding site and the hydrophobic ridge and in other more distal part of the 
molecule and may together slightly alter the molecular details of the interaction with 
mannose; these differences may help to explain the lack of MSHA in the case of TOP52 
FimH.  
 
The loss of MSHA in TOP52 is specific to the adhesin domain of FimH52. 
 Although all residues involved in direct interactions with the mannose moiety and 
all those in the surrounding hydrophobic ridge are identical between FimH52 and FimH89, 
nearly 14% of amino acids differ between the two proteins.  We hypothesized that if this 
variation in FimH sequence accounts for the lack of the MSHA phenotype, then 
complementation of TOP52ΔfimH with fimH cloned from UTI89 (fimH89), should restore 
the MSHA phenotype.  Thus, TOP52ΔfimH was complemented with the fimH gene of 
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TOP52 (fimH52) or the fimH gene of UTI89 (fimH89) on inducible plasmids.  While 
TOP52ΔfimH/pBAD vector control and TOP52ΔfimH/pfimH52 did not produce a positive 
MSHA titer, TOP52ΔfimH/pfimH89 had an MSHA titer of 1:16 (Table 3).  Thus, the 
complementation indicated that FimH89 is able to participate in type 1 pilus biogenesis 
with the Fim proteins of TOP52 and confers a gain of MSHA function to the TOP52 K. 
pneumoniae strain. 
To test the expression of exogenous fimH in the UTI89ΔfimH background, phase 
assays were conducted analyzing the phase-variable promoter switch of type 1 pili (Fig. 
2).  The fim operon of wildtype UTI89 was primarily phase ON after static growth, 
however, loss of fimH in UTI89ΔfimH and UTI89ΔfimH/pBAD vector control resulted in 
bacterial populations that were primarily in the phase OFF orientation.  Complementation 
with either pfimH89 or pfimH52 did not result in a robust OFF to ON switch as the 
populations remained primarily phase OFF.  However, enough ON phase switching 
occurred to detect MSHA in bacteria complemented with pfimH89 (Table 3). 
 FimH52 and FimH89 function was investigated further by constructing FimH 
chimeras.  We used the chimeras to complement fimH knockout strains and then 
examined the final pilus assembly on each strain by immunoelectron microscopy. The 
adhesin domains (ADs) and pilin domains (PDs) of each strain were amplified and 
expressed in different combinations on the arabinose inducible pBAD33 vector.  This 
resulted in 4 different fimH construct-expressing plasmids:  pAD89PD89 (pfimH89), 
pAD89PD52, pAD52PD89, and pAD52PD52 (pfimH52).   
 121
 
 
Figure 2.  The fim operon of UTI89ΔfimH is primarily in the phase OFF orientation.  
Phase assays of the fimS invertible promoter region of the fim operon were done for 
UTI89, UTI89ΔfimH, UTI89ΔfimH/pBAD, UTI89ΔfimH/pfimH89 and 
UTI89ΔfimH/pfimH52.  UTI89 was largely phase ON while the UTI89ΔfimH strains were 
all primarily phase OFF despite complementation. 
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 The incorporation of pfimH89, pAD89PD52, pAD52PD89, and pfimH52, into pili was 
confirmed by immunoelectron microscopy using anti-FimH antibodies. Consistent with 
the phase switch being primarily OFF in these complementations, the majority of bacteria 
were bald without noticeable pili. However, a subpopulation of bacteria existed in each 
sample that were moderately piliated and immunolabeling at the tips of pili was observed 
for UTI89ΔfimH complemented with each construct (Fig. 3). The low level of type 1 
pilus expression explains the inability to fully complement UTI89ΔfimH to wildtype 
UTI89 levels of MSHA.  
 TOP52ΔfimH was also complemented with each FimH chimera and the MSHA 
titers for all strains were analyzed (Table 4).  Wildtype UTI89 produced an MSHA titer 
of 1:512 while wildtype TOP52 did not have a MSHA titer.  UTI89ΔfimH, 
UTI89ΔfimH/pBAD, TOP52ΔfimH, and TOP52ΔfimH/pBAD all lacked MSHA titers.  
UTI89ΔfimH/pfimH89 and UTI89ΔfimH/pAD89PD52 both produced an MSHA titer of 
1:32 while UTI89ΔfimH/pAD52PD89 and UTI89ΔfimH/pfimH52 did not produce a MSHA 
titer.  This trend was recapitulated in the TOP52ΔfimH background.  While 
TOP52ΔfimH/pfimH52 and TOP52ΔfimH/pAD52PD89 both lacked MSHA titers, 
TOP52ΔfimH/pfimH89 and TOP52ΔfimH/pAD89PD52 both produced MSHA titers of 
1:16. 
 These results demonstrate that the K. pneumoniae TOP52 FimH MSHA defect is 
specific to its adhesin domain.  The adhesin domain of UTI89 FimH is capable of 
agglutinating guinea pig RBCs with the native UTI89 pilin domain or with the pilin  
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Figure 3.  FimH constructs in UTI89ΔfimH are expressed in some bacteria and 
localized at the tips of pili.   
Immunoelectron microscopy using an anti-FimH antibody was performed against A) 
UTI89ΔfimH/pfimH89, B) UTI89ΔfimH/pAD89PD52, C) UTI89ΔfimH/pAD52PD89 and D) 
UTI89ΔfimH/pfimH52.  While the majority of bacteria did not appear to be expressing 
type 1 pili, piliated bacteria could be found in all four samples.  Piliated bacteria 
displayed FimH immmunostaining at the distal tips of pili.   
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Table 4.  Mannose-Sensitive Hemagglutination Deficiency is 
Specific to the Adhesin Domain of FimH52. 
Strain Guinea Pig RBC 
 
HA Titer (1:2x)* 
Guinea Pig 
RBC + Mann. 
HA Titer (1:2x)* 
UTI89 9 3 
UTI89ΔfimH 2 2 
UTI89ΔfimH/pBAD 0 0 
UTI89ΔfimH/pfimH89 5 0 
UTI89ΔfimH/pAD89PD52 5 0 
UTI89ΔfimH/pAD52PD89 0 0 
UTI89ΔfimH/pfimH52 0 0 
TOP52 0 0 
TOP52ΔfimH 0 0 
TOP52ΔfimH/pBAD 0 0 
TOP52ΔfimH/pfimH89 4 0 
TOP52ΔfimH/pAD89PD52 4 0 
TOP52ΔfimH/pAD52PD89 0 0 
TOP52ΔfimH/pfimH52 0 0 
      *HA titer data are representative of 3 independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 125
domain of TOP52.  Thus, variation between the FimH adhesin domains of UTI89 and 
TOP52 are likely responsible for their differences in function.   
 
TOP52 FimH-dependent biofilms are inhibited by heptyl mannose but not methyl 
mannose. 
 TOP52 is able to form biofilm at room temperature when the production of type 1 
pili is induced via the E. coli recombinase, fimX (50).  Thus, we investigated whether this 
biofilm was FimH-dependent.  Biofilms were stained with crystal violet and quantified 
after 48 h of incubation.  Wildtype TOP52 and TOP52/pBAD vector control did not form 
biofilm, however TOP52/pfimX formed biofilm.  TOP52ΔfimH, TOP52ΔfimH/pBAD, 
and TOP52ΔfimH/pfimX did not form biofilm suggesting that the TOP52/pfimX biofilm 
is FimH-dependent.  Thus, although FimH52 is unable to mediate MSHA, it is capable of 
mediating biofilm formation. UTI89 formed a robust biofilm while UTI89ΔfimH did not. 
The formation of UTI89 biofilm was fully inhibited by 100 mM methyl mannose or 1 
mM heptyl mannose (Fig 4). In contrast, TOP52/pfimX biofilm formation was not 
affected by the presence of 100 mM methyl mannose, but was fully inhibited by 1 mM 
heptyl mannose.   
 Therefore, TOP52/pfimX forms a FimH-dependent biofilm that is inhibited by 
heptyl mannose but not methyl mannose. This phenotype is distinct from UTI89 FimH- 
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Figure 4.  Heptyl mannose, but not methyl mannose, inhibits FimH-dependent 
biofilm formation of TOP52/pfimX.  
 A 48 h biofilm assay was used to quantify biofilms produced by UTI89 and TOP52 
strains in the presence of no mannose, 1mM methyl mannose, 100 mM methyl mannose 
or 1 mM heptyl mannose.  TOP52 forms a FimH-dependent biofilm with induced 
expression of type 1 pili via the E. coli recombinase, fimX.  This biofilm formation is 
inhibited by heptyl mannose but not high concentrations of methyl mannose.  UTI89 
forms robust biofilm without mannose but is inhibited by heptyl mannose or high 
concentrations of methyl mannose.  Error bars represent standard deviations.   
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dependent biofilms, which are fully inhibited by the presence of 100 mM methyl 
mannose.  
 
UTI89 and TOP52 both require fimH for effective persistence in the urinary tract. 
 To analyze the respective roles of FimH52 and FimH89 in urinary tract infection, 
107 CFU of UTI89, UTI89ΔfimH, TOP52 or TOP52ΔfimH were inoculated into the 
bladders of C3H/HeN mice by transurethral catheterization.  Bladders and kidneys were 
harvested at various timepoints post inoculation and bacterial titers were determined.  In 
the bladder (Fig. 5A), UTI89 had significantly higher titers than UTI89ΔfimH at 6 
(P<0.0001), 24 (P<0.0001) and 336 hours (P=0.0007) post infection.  UTI89ΔfimH was 
cleared from the bladder as time progressed.   TOP52 had slightly but significantly higher 
titers (P=0.0244) than TOP52ΔfimH in the bladders of mice at 6 hours post inoculation.  
By 24 hours there was no significant difference between TOP52 and TOP52ΔfimH 
bladder titers.  However, by 336 hours post infection, TOP52ΔfimH had significantly 
lower titers than wildtype TOP52 (P=0.0012).  In the kidney (Fig. 5B), UTI89 had 
significantly higher titers than UTI89ΔfimH at 6 hours post infection (P<0.0001), 
however the two strains had similar titers at both 24 and 336 hours post infection.  
TOP52 and TOP52ΔfimH had similar levels of bacterial burden in the kidney at all 
timepoints tested. Thus, FimH-containing type 1 pili in the K. pneumoniae isolate, 
TOP52, does not play a critical role early in bladder infection as is the case with UTI89; 
however, it is required for effective persistence in the bladder in both strains.  
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Figure 5. FimH of TOP52 is required for invasion, IBC formation, and persistence 
but not colonization in the murine model of UTI.   
Female C3H/HeN mice were inoculated with 107 UTI89 (▲), UTI89ΔfimH (Δ), TOP52 
(●), or TOP52ΔfimH (○) by transurethral inoculation.  For organ titers, bladders (A) and 
kidneys (B) were harvested at various timepoints post infection and CFU were calculated.  
Titer data are combined from N=3 independent experiments.  For ex vivo gentamicin 
protection assays, bladders were harvested at 1 h post infection and luminal (C) and 
intracellular (D) populations of bacteria were quantified.  IBCs were quantified (E) after 
visualization by LacZ staining at 6 h post inoculation.  Short bars represent geometric 
means of each group and horizontal dotted lines represent limits of detection.  Significant 
P-values, as calculated using the Mann-Whitney U test, are displayed.   
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FimH52 is required for TOP52 bladder invasion and IBC formation. 
  In order to further assess the role of FimH52 in acute TOP52 cystitis, bladder 
invasion assays were performed at 1 hour post infection with UTI89, UTI89ΔfimH, 
TOP52 or TOP52ΔfimH.  In these assays, luminal bacteria were collected by successive 
bladder washes (Fig. 5C), prior to gentamicin treatment of the bladder to kill extracellular 
bacteria, as previously described (33).  After 1.5 hour incubation in gentamicin, bladders 
were homogenized and titered to reveal the intracellular bacterial burden (Fig. 5D).  
UTI89 had 100-fold higher luminal bacterial counts compared to UTI89ΔfimH at 1 hour 
post infection (P=0.0043).  However, TOP52 and TOP52ΔfimH had similar levels of 
luminal colonization.  At this 1 hour timepoint, UTI89 had significantly higher levels of 
intracellular bacteria than UTI89ΔfimH (P=0.0055), which did not have any intracellular 
titers above the limit of detection (5 CFU).  TOP52 also invaded into the bladder tissue 
and had intracellular bacterial titers that were significantly higher than TOP52ΔfimH 
(P=0.0095), which did not have titers above the limit of detection. 
 To determine if the presence of FimH52 affects the ability of TOP52 to form IBCs, 
we  visualized and quantified IBCs by lacZ staining of whole mounted, fixed bladders as 
described previously (33) at 6 hours post inoculation of UTI89, UTI89ΔfimH, TOP52 or 
TOP52ΔfimH (Fig. 5E).  UTI89 formed a wide range of IBCs with a median of 25.5 per 
bladder while UTI89ΔfimH formed no detectable IBCs.  TOP52 had a median of 2.0 
IBCs per bladder, while TOP52ΔfimH was unable to produce detectable IBCs 
(P=0.0009). 
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 These data suggest that K. pneumoniae TOP52 FimH52, in contrast to E. coli 
UTI89 FimH89, does not play a significant role in early bladder colonization.  However, 
FimH52 is required for TOP52 invasion and IBC formation in the murine bladder as is the 
case for UTI89. 
 
FimH52 does not restore the ability of UTI89ΔfimH to effectively infect the bladder. 
 UTI89 relies on FimH to successfully cause UTI in the murine model.  The ability 
of fimH52 to restore the ability of UTI89ΔfimH to bind, invade, and infect murine 
bladders, was investigated by using UTI89ΔfimH complemented with pBAD vector 
control, pfimH89, and pfimH52. In 1 hour gentamicin protection assays (Fig. 6A-B) 
UTI89ΔfimH complemented with pfimH89 had significantly higher luminal titers than the 
same strain complemented with vector control (Fig. 6A, P=0.0001) despite the known 
expression deficiencies observed above.  Additionally, UTI89ΔfimH/pfimH89 had 
significantly higher 1 hour luminal titers than UTI89ΔfimH/pfimH52, which had 
colonization levels similar to vector control.  Examination of the intracellular population 
at 1 hour (Fig. 6B) revealed that UTI89ΔfimH/pBAD vector control did not have titers 
above the limit of detection, whereas, UTI89ΔfimH/pfimH89 did produce significantly 
higher burdens of intracellular bacteria (P=0.0028).  UTI89ΔfimH/pfimH52 was able to 
invade into the bladder tissue, but at significantly lower levels compared to 
UTI89ΔfimH/pfimH89 (P=0.0106). At 6 hours post inoculation, UTI89ΔfimH/pfimH89 had 
significantly higher burdens of bacteria in the bladder than both UTI89ΔfimH/pBad  
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Figure 6.  Complementation of UTI89ΔfimH with pfimH89 but not pfimH52 leads to 
increased bacterial burden in the murine model of UTI.   
Female C3H/HeN mice were inoculated with 107 UTI89ΔfimH/pBAD vector control, 
UTI89ΔfimH/pfimH89 or UTI89ΔfimH/pfimH52 by transurethral inoculation.  Ex vivo 
gentamicin protection assays were performed in which bladders were harvested at 1 h 
post infection and luminal (A) and intracellular (B) populations of bacteria were 
quantified.  For organ titers, bladders (C) and kidneys (D) were harvested at 6 h post 
infection and CFU were enumerated.  Short bars represent geometric means of each 
group and horizontal dotted lines represent limits of detection.  Significant P-values, as 
calculated using the Mann-Whitney U test, are displayed.   
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(P=0.0043) and UTI89ΔfimH/pfimH52 (P=0.0032).  Complementation of UTI89ΔfimH 
with fimH from either UTI89 or TOP52 did not significantly affect 6 h kidney titers 
compared to vector control.   
 The fimH52 gene was not able to restore UTI89ΔfimH to levels above vector 
control while complementation with fimH89 yielded higher bacterial burdens at 1 and 6 
hours.  This suggests a potential defect in the function of FimH52 in the bladder compared 
to FimH89.   
 
 
 Discussion 
FimH of the K. pneumoniae strain TOP52 1721 (FimH52) has an amino acid 
sequence highly homologous to the sequence encoded by dozens of fimH genes that have 
been sequenced from E. coli (34, 54, 56).  The residues that form the mannose-binding 
pocket (Asn46, Asp47, Asp54, Gln133, Asn135, Asp140) and hydrophobic ridge  (Phe1, 
Ile13, Try48, Ile52, Tyr137, Phe142) surrounding the pocket are completely identical 
between FimH52 and all known FimH adhesins of E. coli.   Despite this identity, FimH52 
has a receptor specificity unique from that of UPEC FimH.  FimH52 is unable to mediate 
MSHA of guinea pig erythrocytes whereas all known UPEC FimH’s are defined by their 
ability to mediate MSHA.  Different E. coli FimH variants have been classified as high 
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affinity monomannose binders or lower affinity trimannose binders (45, 54).  However, 
both trimannose and monomannose variants display MSHA of guinea pig erythrocytes.  
E. coli FimH recognizes mannose and has been shown to be able to interact with 
Manα1,3Manβ1,4GlcNAcβ1,4GlcNAc in an extended binding site (61). These additional 
interactions between FimH and extended oligomannose moieties are mimicked by butyl 
α-D mannose (61). Extended alkyl-α-mannosides have higher affinities for E. coli FimH 
compared to methyl-α-D-mannopyranoside (methyl mannose), with heptyl α-D-
mannopyranoside (heptyl mannose) having the lowest Kd of 5 nM (5).  K. pneumoniae 
FimH-dependent biofilms could only be inhibited by heptyl mannose and not methyl 
mannose arguing that K. pneumoniae FimH requires additional contacts of the alkyl chain 
outside of the mannose binding pocket.   
FimH52 differs at 17 positions from E. coli FimH and was threaded onto the three 
dimensional structure of E. coli FimH.  In the DE loop, adjacent to the hydrophobic 
ridge, Val94 and Asn96 of UTI89 FimH (FimH89) are changed to Ile and Asp, 
respectively, in FimH52.  In the G strand, immediately C-terminal to key residues in the 
hydrophobic ridge, Val145 in FimH89 is changed to Ile in FimH52.  Combined, these 
differences may alter the structural stability of the hydrophobic ridge of FimH52 through 
changes in hydrophobic and hydrogen bond contacts.  Thus, although FimH52 is unable to 
bind methyl mannose, these amino acid changes may facilitate interactions with longer 
oligomannose substrates (61). 
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The inability of FimH52 to mediate MSHA may be due to amino acid changes in 
proximity to the mannose binding pocket.  Gln133 and Asp140 E. coli FimH residues are 
required for HA titers and mannose binding (29).  Two differences in TOP52 primary 
sequence exist in residues adjacent to these mannose-binding residues (His132 and 
Ser141, changed from Arg and Asp, respectively, in FimH89).  The threaded model 
FimH52 suggests that these residues would lie ~8.5 Å away from the bound mannose 
moiety (Fig 1B). Arg132 and Asp141 form a salt bridge in J96 FimH that helps stabilize 
the structure of the FG loop that contains mannose binding residues Gln133, Asn135, and 
Asp140 and forms part of the hydrophobic ridge.  Arg132 NH1 also makes two hydrogen 
bonds to Gln59 OE1 and Glu 89 OE1.  In FimH52, His132 is only able to make a 
hydrogen bond with Glu89 OE2.  Thus, in FimH52 this salt bridge as well as the hydrogen 
bond to Gln59 would be lost.  Thus, at least two hydrogen bonds are lost in the combined 
differences in residues 132 and 141, which may have a destabilizing effect on interactions 
at the mannose site around the Asp140 and Gln133 mannose binding residues.  
Sequence variation in regions of FimH not in close proximity to the mannose-
binding pocket can also significantly affect FimH function (56, 57).  Differences in areas 
both adjacent to the receptor binding site and hydrophobic ridge or other more distal 
differences may together alter the molecular details of the interaction with mannose and 
help explain the loss of affinity for methyl mannose and the differences in MSHA. 
Studies have suggested that fimbrial shafts can influence binding specificities of 
type 1 pili (16, 38).  These effects do not account for the binding specificity differences 
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observed for FimH52.  FimH52 assembled into UTI89 type 1 pili was also MSHA negative 
and FimH89 assembled into TOP52 type 1 pili was MSHA positive.  Thus, the major 
functional disparities between E. coli and K. pneumoniae type 1 pili were specific to the 
adhesin domain of FimH, not the strain background or fimbrial shaft.   However, fimbrial 
shafts may influence FimH binding in more subtle ways that could have been missed in 
this study due to the lower expression of type 1 pili in fimH knockout backgrounds.  
 The binding specificity differences observed for FimH52 result in dramatic 
functional differences seen in K. pneumoniae UTI pathogenesis compared to E. coli.  
Although the K. pneumoniae strain TOP52 requires FimH for invasion and IBC 
formation in the murine bladder, FimH is not essential for early colonization. TOP52 and 
TOP52ΔfimH have similar 1 hour luminal bladder titers, 24 hour whole bladder titers and 
only modest titer differences at 6 hours post infection.  The small but significant 
differences at 6 hours likely represent the intracellular population of bacteria in IBCs 
within TOP52-infected bladders that are absent in TOP52ΔfimH-infected bladders.  K. 
pneumoniae may use a different, non-type 1 pilus adhesin for initial binding to the 
bladder surface that E. coli lacks.  This would explain why TOP52ΔfimH had higher 1 
hour luminal titers and 6 hour whole bladder titers compared to UTI89ΔfimH.  K. 
pneumoniae encodes type 3 pili, however, these pili have not been implicated in binding 
to the bladder surface and are thought to be to mediate attachment to the basolateral 
surface of tracheal epithelial cells and basement membrane components (60).  In addition 
to type 1 and type 3 pili, K. pneumoniae encodes at least two other non-pilus adhesins.  
The CF29K and KPF-28 adhesins may play important roles in mediating attachment 
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within the mammalian intestine, but a role for them in UTI has not been investigated (9, 
12). 
 For many years, the glycoprotein uroplakin Ia has been considered the main 
receptor mediating FimH-dependent adhesion in the bladder (42, 63).  Recently, it has 
been shown that host cell integrins also can mediate type 1 pilus-dependent invasion of 
urothelial cells (17).  We currently do not know if K. pneumoniae FimH52 is capable of 
binding these receptors.  It is possible that FimH52 may only be capable of binding 
integrin receptors (and not uroplakin Ia) for invasion of urothelial cells but not 
necessarily mediating significant adhesion to the uroplakin-coated bladder surface.  
 This work focused on a single uropathogenic isolate of K. pneumoniae and it is 
important to extend this work to other strains.   The sequence of TOP52 FimH was 
almost identical to other sequenced K. pneumoniae FimH proteins and thus may be 
representative.  The inability of TOP52 to produce an MSHA titer is not an isolated 
finding.  The ATCC 700721 strain also lacks an MSHA titer.  The first studies of 
fimbriae and adhesive properties of 154 K. pneumoniae isolates found that 57.6% of 
strains produced little or no MSHA titer (13).  Many considered this to be due to poor 
type 1 expression in K. pneumoniae.  However, K. pneumoniae remained MSHA 
negative when expression of type 1 pili was increased by deletion of fimK or 
overexpression of fimX.  And when E. coli type 1 pili were expressed at similar levels as 
TOP52 type 1 pili, it resulted in a positive MSHA.  
 This study suggests that limited sequence variation between the FimH of E. coli 
and K. pneumoniae results in differences in function and ability to colonize the urinary 
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tract.  Despite its poor adhesive properties in the urinary tract, FimH of K. pneumoniae 
remains an important virulence factor despite its poor adhesive properties in the urinary 
tract.   It enables K. pneumoniae to progress through an IBC pathway during UTI and 
ultimately persist in the host.  K. pneumoniae FimH likely requires ligand/receptor 
contacts outside of the mannose binding pocket for efficient binding.  Further insight into 
these structural determinants will aid in our understanding of the altered host-pathogen 
interactions of K. pneumoniae UTI. 
 
 
Acknowledgments 
 We would like to thank Stefan Oscarson for the heptyl mannose.  We would also 
like to thank Wandy Beatty for assistance with electron microscopy experiments, Chia 
Hung for help with mouse experiments, and Melissa Kraus for statistical support.  
 This work was supported by the National Institutes of Health, Office of Research 
on Women’s Health:  Specialized Center of Research on Sex and Gender Factors 
Affecting Women’s Health, grant DK64540, National Institute of Diabetes and Digestive 
and Kidney Diseases, grant R01 DK051406 and National Institute of Allergy and 
Infectious Diseases, grants R01 AI29549, and R01 AI48689. 
 
 138
References 
1. Anderson, G. G., J. J. Palermo, J. D. Schilling, R. Roth, J. Heuser, and S. J. 
Hultgren. 2003. Intracellular bacterial biofilm-like pods in urinary tract infections. 
Science 301:105-107. 
2. Bahrani-Mougeot, F. K., E. L. Buckles, C. V. Lockatell, J. R. Hebel, D. E. 
Johnson, C. M. Tang, and M. S. Donnenberg. 2002. Type 1 fimbriae and 
extracellular polysaccharides are preeminent uropathogenic Escherichia coli 
virulence determinants in the murine urinary tract. Mol Microbiol 45:1079-1093. 
3. Barnhart, M. M., F. G. Sauer, J. S. Pinkner, and S. J. Hultgren. 2003. Chaperone-
subunit-usher interactions required for donor strand exchange during bacterial 
pilus assembly. J Bacteriol 185:2723-2730. 
4. Bennett-Lovsey, R. M., A. D. Herbert, M. J. Sternberg, and L. A. Kelley. 2008. 
Exploring the extremes of sequence/structure space with ensemble fold 
recognition in the program Phyre. Proteins 70:611-625. 
5. Bouckaert, J., J. Berglund, M. Schembri, E. De Genst, L. Cools, M. Wuhrer, C. S. 
Hung, J. Pinkner, R. Slattegard, A. Zavialov, D. Choudhury, S. Langermann, S. J. 
Hultgren, L. Wyns, P. Klemm, S. Oscarson, S. D. Knight, and H. De Greve. 2005. 
Receptor binding studies disclose a novel class of high-affinity inhibitors of the 
Escherichia coli FimH adhesin. Mol Microbiol 55:441-455. 
6. Brinton Jr., C. C. 1965. The structure, function, synthesis, and genetic control of 
bacterial pili and a model for DNA and RNA transport in Gram negative bacteria. 
Trans N.Y. Acad. Sci. 27:1003-1165. 
 139
7. Bryan, A., P. Roesch, L. Davis, R. Moritz, S. Pellett, and R. A. Welch. 2006. 
Regulation of type 1 fimbriae by unlinked FimB- and FimE-like recombinases in 
uropathogenic Escherichia coli strain CFT073. Infect Immun 74:1072-1083. 
8. Choudhury, D., A. Thompson, V. Stojanoff, S. Langermann, J. Pinkner, S. J. 
Hultgren, and S. D. Knight. 1999. X-ray structure of the FimC-FimH chaperone-
adhesin complex from uropathogenic Escherichia coli. Science 285:1061-1066. 
9. Darfeuille-Michaud, A., C. Jallat, D. Aubel, D. Sirot, C. Rich, J. Sirot, and B. 
Joly. 1992. R-plasmid-encoded adhesive factor in Klebsiella pneumoniae strains 
responsible for human nosocomial infections. Infect Immun 60:44-55. 
10. Datsenko, K. A., and B. L. Wanner. 2000. One-step inactivation of chromosomal 
genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A 
97:6640-6645. 
11. DeLano, W. L.  2002. The PyMOL molecular graphics system. DeLano 
Scientific, Palo Alto, CA, USA. http://www.pymol.org. 
12. Di Martino, P., V. Livrelli, D. Sirot, B. Joly, and A. Darfeuille-Michaud. 1996. A 
new fimbrial antigen harbored by CAZ-5/SHV-4-producing Klebsiella 
pneumoniae strains involved in nosocomial infections. Infect Immun 64:2266-
2273. 
13. Duguid, J. P. 1959. Fimbriae and adhesive properties in Klebsiella strains. J Gen 
Microbiol 21:271-286. 
 140
14. Duguid, J. P., and D. C. Old. 1980. Adhesive properties of Enterobacteriacae, p. 
186-217. In E. H. Beachy (ed.), Bacterial Adherence Receptors and Recognition. 
Chapman & Hall, London. 
15. Duguid, J. P., I. W. Smith, G. Dempster, and P. N. Edmunds. 1955. Non-flagellar 
filamentous appendages ("fimbriae") and hemagglutinating activity in bacterium 
coli. J. Pathol. Bacteriol. 70:335-348. 
16. Duncan, M. J., E. L. Mann, M. S. Cohen, I. Ofek, N. Sharon, and S. N. Abraham. 
2005. The distinct binding specificities exhibited by enterobacterial type 1 
fimbriae are determined by their fimbrial shafts. J Biol Chem 280:37707-37716. 
17. Eto, D. S., T. A. Jones, J. L. Sundsbak, and M. A. Mulvey. 2007. Integrin-
Mediated Host Cell Invasion by Type 1-Piliated Uropathogenic Escherichia coli. 
PLoS Pathog 3:e100. 
18. Fader, R. C., and C. P. Davis. 1980. Effect of piliation on Klebsiella pneumoniae 
infection in rat bladders. Infect Immun 30:554-561. 
19. Firon, N., S. Ashkenazis, D. Mirelman, I. Ofek, and N. Sharon. 1987. Aromatic a-
glycosides of mannose are powerful inhibitors of the adherence of type 1 
fimbriated Escherichia coli to yeast and intestinal cells. Infect Immun 55:472-476. 
20. Firon, N., I. Ofek, and N. Sharon. 1984. Carbohydrate-binding sites of the 
mannose-specific fimbrial lectins of Enterobacteria. Infect and Immun 43:1088-
1090. 
 141
21. Firon, N., I. Ofek, and N. Sharon. 1983. Carbohydrate specificity of the surface 
lectins of Escherichia coli, Klebsiella pneumoniae and Salmonella typhimurium. 
Carbohydr. Res. 120:235-249. 
22. Garofalo, C. K., T. M. Hooton, S. M. Martin, W. E. Stamm, J. J. Palermo, J. I. 
Gordon, and S. J. Hultgren. 2007. Escherichia coli from Urine of Female Patients 
with Urinary Tract Infections Is Competent for Intracellular Bacterial Community 
Formation. Infect Immun 75:52-60. 
23. Gerlach, G. F., S. Clegg, and B. L. Allen. 1989. Identification and 
characterization of the genes encoding the type 3 and type 1 fimbrial adhesins of 
Klebsiella pneumoniae. J Bacteriol 171:1262-1270. 
24. Guzman, L. M., D. Belin, M. J. Carson, and J. Beckwith. 1995. Tight regulation, 
modulation, and high-level expression by vectors containing the arabinose PBAD 
promoter. J Bacteriol 177:4121-4130. 
25. Hannan, T. J., I. U. Mysorekar, S. L. Chen, J. N. Walker, J. M. Jones, J. S. 
Pinkner, S. J. Hultgren, and P. C. Seed. 2007. LeuX tRNA-dependent and -
independent mechanisms of Escherichia coli pathogenesis in acute cystitis. Mol 
Microbiol 67:116-128. 
26. Hull, R. A., R. E. Gill, P. Hsu, B. H. Minshew, and S. Falkow. 1981. Construction 
and expression of recombinant plasmids encoding type 1 or D-mannose-resistant 
pili from a urinary tract infection Escherichia coli isolate. Infect Immun 33:933-
938. 
 142
27. Hultgren, S. J., T. N. Porter, A. J. Schaeffer, and J. L. Duncan. 1985. Role of type 
1 pili and effects of phase variation on lower urinary tract infections produced by 
Escherichia coli. Infect Immun 50:370-377. 
28. Hultgren, S. J., W. R. Schwan, A. J. Schaeffer, and J. L. Duncan. 1986. 
Regulation of production of type 1 pili among urinary tract isolates of Escherichia 
coli. Infect Immun 54:613-620. 
29. Hung, C.-S., J. Bouckaert, D. Hung, J. Pinkner, C. Widberg, A. De Fusco, C. G. 
Auguste, B. Strouse, S. Langerman, G. Waksman, and S. J. Hultgren. 2002. 
Structure basis of tropism of Escherichia coli to the bladder during urinary tract 
infection. Mol Microbiol 44:903-915. 
30. Hung, D. L., and S. J. Hultgren. 1998. Pilus biogenesis via the chaperone/usher 
pathway:  an integration of structure and function. Journal of Sturctural Biology 
124:201-220. 
31. Jones, C. H., J. S. Pinkner, R. Roth, J. Heuser, A. V. Nicholes, S. N. Abraham, 
and S. J. Hultgren. 1995. FimH adhesin of type 1 pili is assembled into a fibrillar 
tip structure in the Enterobacteriaceae. Proc Natl Acad Sci U S A 92:2081-2085. 
32. Justice, S. S., C. Hung, J. A. Theriot, D. A. Fletcher, G. G. Anderson, M. J. 
Footer, and S. J. Hultgren. 2004. Differentiation and developmental pathways of 
uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci 
U S A 101:1333-1338. 
 143
33. Justice, S. S., S. R. Lauer, S. J. Hultgren, and D. A. Hunstad. 2006. Maturation of 
intracellular Escherichia coli communities requires SurA. Infect Immun 74:4793-
4800. 
34. Klemm, P., and G. Christiansen. 1987. Three fim genes required for the regulation 
of length and mediation of adhesion of Escherichia coli type 1 fimbriae. 
Molecular And General Genetics 208:439-445. 
35. Langermann, S., R. Mollby, J. E. Burlein, S. R. Palaszynski, C. G. Auguste, A. 
DeFusco, R. Strouse, M. A. Schenerman, S. J. Hultgren, J. S. Pinkner, J. Winberg, 
L. Guldevall, M. Soderhall, K. Ishikawa, S. Normark, and S. Koenig. 2000. 
Vaccination with FimH adhesin protects cynomolgus monkeys from colonization 
and infection by uropathogenic Escherichia coli. J Infect Dis 181:774-778. 
36. Langermann, S., S. Palaszynski, M. Barnhart, G. Auguste, J. S. Pinkner, J. 
Burlein, P. Barren, S. Koenig, S. Leath, C. H. Jones, and S. J. Hultgren. 1997. 
Prevention of mucosal Escherichia coli infection by FimH-adhesin-based 
systemic vaccination. Science 276:607-611. 
37. Link, A. J., D. Phillips, and G. M. Church. 1997. Methods for generating precise 
deletions and insertions in the genome of wild-type Escherichia coli: application 
to open reading frame characterization. J Bacteriol 179:6228-6237. 
38. Madison, B., I. Ofek, S. Clegg, and S. N. Abraham. 1994. Type 1 fimbrial shafts 
of Escherichia coli and Klebsiella pneumoniae influence sugar-binding 
specificities of their FimH adhesins. Infect Immun 62:843-848. 
 144
39. Martinez, J. J., M. A. Mulvey, J. D. Schilling, J. S. Pinkner, and S. J. Hultgren. 
2000. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO 
19:2803-2812. 
40. Matatov, R., J. Goldhar, E. Skutelsky, I. Sechter, R. Perry, R. Podschun, H. Sahly, 
K. Thankavel, S. N. Abraham, and I. Ofek. 1999. Inability of encapsulated 
Klebsiella pneumoniae to assemble functional type 1 fimbriae on their surface. 
FEMS Microbiol Lett 179:123-130. 
41. McClelland, M., L. Florea, K. Sanderson, S. W. Clifton, J. Parkhill, C. Churcher, 
G. Dougan, R. K. Wilson, and W. Miller. 2000. Comparison of the Escherichia 
coli K-12 genome with sampled genomes of a Klebsiella pneumoniae and three 
salmonella enterica serovars, Typhimurium, Typhi and Paratyphi. Nucleic Acids 
Res 28:4974-4986. 
42. Mulvey, M. A., Y. S. Lopez-Boado, C. L. Wilson, R. Roth, W. C. Parks, J. 
Heuser, and S. J. Hultgren. 1998. Induction and evasion of host defenses by type 
1-piliated uropathogenic Escherichia coli. Science 282:1494-1497. 
43. Mulvey, M. A., J. D. Schilling, and S. J. Hultgren. 2001. Establishment of a 
Persistent Escherichia coli Reservoir during the Acute Phase of a Bladder 
Infection. Infect Immun 69:4572-4579. 
44. Murphy, K. C., and K. G. Campellone. 2003. Lambda Red-mediated 
recombinogenic engineering of enterohemorrhagic and enteropathogenic E. coli. 
BMC Mol Biol 4:11. 
 145
45. Nilsson, L. M., W. E. Thomas, E. Trintchina, V. Vogel, and E. V. Sokurenko. 
2006. Catch bond-mediated adhesion without a shear threshold: trimannose versus 
monomannose interactions with the FimH adhesin of Escherichia coli. J Biol 
Chem 281:16656-16663. 
46. O'Toole, G. A., and R. Kolter. 1998. Initiation of biofilm formation in 
Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling 
pathways: a genetic analysis. Mol Microbiol 28:449-461. 
47. Ottow, J. C. G. 1975. Ecology, phisiology and genetics of fimbriae and pili. 
Annual Review of Microbiology 29:79. 
48. Ronald, A. R., L. E. Nicolle, E. Stamm, J. Krieger, J. Warren, A. Schaeffer, K. G. 
Naber, T. M. Hooton, J. Johnson, S. Chambers, and V. Andriole. 2001. Urinary 
tract infection in adults: research priorities and strategies. Int J Antimicrob Agents 
17:343-348. 
49. Ronald, A. R., and A. L. Pattullo. 1991. The natural history of urinary infection in 
adults. Medical Clinics Of North America 75:299-312. 
50. Rosen, D. A., J. S. Pinkner, J. M. Jones, J. N. Walker, S. Clegg, and S. J. 
Hultgren. 2008. Utilization of an IBC pathway in Klebsiella pneumoniae urinary 
tract infection and the effects of FimK on type 1 pilus expression, Infect Immun, 
submitted. 
51. Rosen, D. A., T. M. Hooton, W. E. Stamm, P. A. Humphrey, and S. J. Hultgren. 
2007. Detection of intracellular bacterial communities in human urinary tract 
infection. PLoS Med 4:e329. 
 146
52. Salit, I. E., and E. C. Gotschlich. 1977. Hemagglutination by purified Type 1 
Escherichia coli pili. Journal of Experimental Medicine 146:1169-1181. 
53. Saulino, E. T., D. G. Thanassi, J. S. Pinkner, and S. J. Hultgren. 1998. 
Ramifications of kinetic partitioning on usher-mediated pilus biogenesis. EMBO 
17:2177-2185. 
54. Sokurenko, E. V., V. Chesnokova, R. J. Doyle, and D. L. Hasty. 1997. Diversity 
of the Escherichia coli type 1 fimbrial lectin. Differential binding to mannosides 
and uroepithelial cells. J Biol Chem 272:17880-17886. 
55. Sokurenko, E. V., H. S. Courtney, S. N. Abraham, P. Klemm, and D. L. Hasty. 
1992. Functional heterogeneity of type 1 fimbriae of Escherichia coli. Infect 
Immun 60:4709-4719. 
56. Sokurenko, E. V., H. S. Courtney, J. Maslow, A. Siitonen, and D. L. Hasty. 1995. 
Quantitative differences in adhesiveness of type 1 fimbriated Escherichia coli due 
to structural differences in fimH genes. J Bacteriol 177:3680-3686. 
57. Sokurenko, E. V., H. S. Courtney, D. E. Ohman, P. Klemm, and D. L. Hasty. 
1994. FimH family of type 1 fimbrial adhesins: functional heterogeneity due to 
minor sequence variations among fimH genes. J. Bacteriol. 176:748-755. 
58. Struve, C., and K. A. Krogfelt. 1999. In vivo detection of Escherichia coli type 1 
fimbrial expression and phase variation during experimental urinary tract 
infection. Microbiology 145:2683-2690. 
59. Svanborg Eden, C., L. Hagberg, L. A. Hanson, S. Hull, R. Hull, U. Jodal, H. 
Leffler, H. Lomberg, and E. Straube. 1983. Bacterial adherence--a pathogenetic 
 147
mechanism in urinary tract infections caused by Escherichia coli. Prog Allergy 
33:175-188. 
60. Tarkkanen, A. M., B. L. Allen, B. Westerlund, H. Holthofer, P. Kuusela, L. 
Risteli, S. Clegg, and T. K. Korhonen. 1990. Type V collagen as the target for 
type-3 fimbriae, enterobacterial adherence organelles. Mol Microbiol 4:1353-
1361. 
61. Wellens, A., C. Garofalo, H. Nguyen, N. Van Gerven, R. Slättegård, J. P.  
Hernalsteens, L. Wyns, S. Oscarson, H. De Greve, S. J. Hultgren and J. 
Bouckaert. 2008. Intervening with urinary tract infections using anti-adhesives 
based on the crystal structure of the FimH – oligomannose-3 complex. PLoS One, 
submitted. 
62. Wright, K. J., P. C. Seed, and S. J. Hultgren. 2007. Development of intracellular 
bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. 
Cell Microbiol 9:2230-2241. 
63. Wu, X. R., T. T. Sun, and J. J. Medina. 1996. In vitro binding of type 1-fimbriated 
Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. Proc 
Natl Acad Sci U S A 93:9630-9635. 
 
 
 
 
 
 
 148
 
 
 
 
Chapter 5                       
 
 
 
A Streptozocin-Induced Diabetic Mouse Model  
of Urinary Tract Infection  
 
 
 
 
 
 
 
 
 
 
 
 149
Abstract 
 Diabetics have a higher incidence of urinary tract infection (UTI), are infected 
with a broader range of uropathogens, and more commonly develop serious UTI 
sequelae.  To better study UTI in the diabetic host, we created and characterized a murine 
model of diabetic UTI using the pancreatic islet β-cell toxin streptozocin in C3H/HeN, 
C3H/HeJ and C57BL/6 mouse backgrounds.  Intraperitoneal injections of streptozocin 
were used to initiate diabetes in healthy mouse backgrounds as defined by consecutive 
blood glucose levels >250 mg/dl.  UTIs caused by uropathogenic Escherichia coli 
(UTI89), Klebsiella pneumoniae (TOP52 1721), and Enterococcus faecalis (0852) were 
studied and diabetic mice were found to be considerably more susceptible to infection.  
All three uropathogens produced significantly higher bladder and kidney titers than 
buffer-treated controls. Muted effects were seen in the TLR-4 defective C3H/HeJ diabetic 
mouse arguing that the dramatic increase in colonization seen in C3H/HeN diabetic mice 
may be partially due to diabetic-induced defects in innate immunity.  Competition 
experiments demonstrated that E. coli had a significant advantage over K. pneumoniae in 
the bladders of healthy mice and less of an advantage in diabetic bladders.  In the 
kidneys, K. pneumoniae outcompeted E. coli in healthy mice but in diabetic mice E. coli 
outcompeted K. pneumoniae and caused a severe pyelonephritis.  Diabetic kidneys 
contained renal tubules laden with matrix-embedded extracellular E. coli UTI89 bacterial 
communities. Diabetic mice also had glucosuria, which may enhance bacterial replication 
in the urinary tract.  These data support that this murine diabetic UTI model is consistent 
with known characteristics of human diabetic UTI and can provide a powerful tool for 
dissecting this infection in the multi-factorial setting of diabetes. 
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Introduction 
 Urinary tract infection (UTIs), which include infections of the bladder (cystitis) 
and kidney (pyelonephritis), primarily affect women and are responsible for nearly 13 
million annual office visits in the United States (16).  One third of women will experience 
a recurrent infection within 3-6 months of the initial episode (19) and 44% will 
experience a recurrence within one year (21). These infections are most commonly 
caused by the Gram-negative bacterium Escherichia coli, which is responsible for 80-
85% of community acquired UTIs, however there are numerous other pathogens capable 
of infecting the urinary tract (20, 46).  Uropathogenic E. coli (UPEC) employs a wide 
array of virulence factors to successfully colonize and survive within the urinary tract 
including adhesive organelles such as type 1, P, F1C, and S pili (2, 22, 40, 41), iron 
acquisition/transport systems (49), hemolysin (39), and flagella (27, 51). It has recently 
been found that UPEC has the ability to invade bladder urothelial cells and replicate to 
form intracellular bacterial communities (IBCs) largely protected from host innate 
immunity (1, 9, 23, 47).  Bacteria disperse from these IBCs, some in filamentous 
morphology, which subverts elimination by polymorphonuclear leukocytes (PMN) and 
allows for further dissemination throughout the urinary tract (24, 47).  
 Diabetes mellitus is the most common endocrine disease and worldwide incidence 
of this ailment is increasing (38).  Type 1 diabetes is an autoimmune disorder by which 
insulin-producing beta-islet cells are destroyed by one’s own immune system (15).  These 
patients, even with proper management and glycemic control, can develop a variety of 
diabetic sequelae including retinopathy, neuropathy, nephropathy and numerous 
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cardiovascular complications.  Additionally, diabetics are more prone to infection and 
these infections are more severe than in non-diabetics (6, 43).   
 The urinary tract is the most common site of infection in the diabetic host (30).  
Diabetics are more likely to have asymptomatic and symptomatic bacteriuria (14, 42).  
Acute pyelonephritis is approximately ten times more common in the diabetic population 
(37).  In addition to higher risk of developing UTI, diabetic women have increased risk of 
developing complications of UTI such as emphysematous cystitis, abscess formation and 
renal papillary necrosis (42).  Although UPEC remains the predominant etiologic agent 
of UTI in diabetic individuals, infections by Klebsiella species (17, 29), enterococci (5, 
29), Acinetobacter species (36), group B streptococci (35), fungi (26) and other less 
common uropathogens are more prevalent in diabetic women.  Many hypotheses have 
been attributed to the increase of UTI in diabetic women, such as glucosuria, impaired 
immune cell function or functional abnormalities of the urinary tract, however, these 
theories have not been fully tested or confirmed in an animal model of UTI (42).  While 
there are multiple murine models of diabetes, including non-obese diabetic (NOD) mice 
(31), few have been used to effectively investigate diabetic UTI.  This study presents a 
streptozocin-induced murine model of diabetic UTI. This model is consistent with 
epidemiologic observations of diabetic UTI and thus will greatly assist in understanding 
the physiological and molecular mechanisms underlying uropathogenesis in the diabetic 
setting.  Using this model, we discovered that diabetic mice are more prone to UTI and 
differences in virulence observed in the kidney and bladder are dependent on the bacterial 
strain and host background. 
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Materials and Methods 
Bacterial strains and growth conditions.   
Clinical strains used in this study were UTI89, a UPEC cystitis isolate (34), UTI89 
hk::comGFP, a kanamycin resistant and GFP expressing strain of UTI89 (51), TOP52 
1721, a K. pneumoniae cystitis isolate, and 0852, an Enterococcus faecalis UTI isolate 
(25).  Bacteria were cultured at 37°C in Luria-Bertani (LB) broth (UTI89 and TOP52) or 
brain heart infusion (BHI) broth (0852).  UTI89 hk::comGFP growth media also 
contained 50 μg/ml kanamycin. 
 
Induction of diabetes in mice.   
To develop a diabetic mouse model of UTI, we gave 4-5-week-old female C3H/HeN 
(National Cancer Institute), C3H/HeJ (Jackson Laboratories) or C57BL/6 (Jackson 
Laboratories) mice 2-3 intraperitoneal (IP) injections of streptozocin (STZ, Sigma-
Aldrich) to induce pancreatic islet β-cell death.  Mice were weighed prior to injections 
and STZ was freshly dissolved in dilution buffer (0.1M Sodium citrate, pH 4.5 with HCl, 
stored at 4°C) and filter sterilized.  To induce diabetes, mice were given 0.1 ml IP 
injections of 200 mg/kg STZ using Precision Sure Dose ½ CC syringe with 30 x 3/8” 
gauge needle.  Dilution buffer-injected mice were used as healthy controls.  Blood 
glucose levels were measured daily beginning 5 days after the second IP injection.  STZ-
injected mice with glucose levels <250 were given a third STZ IP injection.  This method 
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consistently resulted in 80-85% penetrance of diabetes in STZ-injected mice. Mice were 
considered diabetic after two consecutive readings of >250 mg/dl blood glucose. 
 
Mouse infections, competitions and organ titers.  
Eight-week-old female diabetic or healthy control mice were infected by transurethral 
catheterization as previously described (33).  Static bacterial cultures were started from 
freezer stocks and grown at 37°C for 18 h and then subcultured 1:250 (for UTI89 and 
TOP52) or 1:100 (for 0852) into fresh media.  These subcultures were then grown 
statically at 37°C for 18 h (for UTI89 and TOP52) or 2-3 h (for 0852), pelleted, 
resuspended in PBS and diluted appropriately to yield 50 μl inocula (for UTI89 and 
TOP52) or 200 μl inocula (for 0852) of 1-2 x 107 CFU unless otherwise indicated.  For 
competition experiments, 107 CFU each of K. pneumoniae TOP52 and E. coli UTI89 
hk::comGFP were inoculated together in a total volume of 50 μl.  To quantify bacteria 
present in mouse organs, bladders and kidneys were aseptically harvested at the indicated 
times post infection, homogenized in PBS, serially diluted, and plated onto LB plates, 
BHI plates or LB-kanamycin (50 μg/ml) and BBL CHROMagar Orientation media (BD-
Diagnostics) for competition experiments.  All studies were approved by the Animal 
Studies Committee at Washington University School of Medicine. 
 
Mouse urine collection and analysis.   
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Urine samples were collected from diabetic and healthy mice by bladder massage over a 
sterile 1.5 ml Eppendorf tube prior to bacterial inoculation.  Urine samples were analyzed 
using Multistix Pro 10 LS urine reagent test strips (Bayer) according to manufacturer’s 
instructions. 
 
Histology and electron microscopy.   
Infected mouse bladders and kidneys were aseptically removed, fixed in neutral buffer 
formalin, and paraffin embedded.  Sections were stained with hematoxylin and eosin 
(H&E) and examined using an Olympus BX51 light microscope (Olympus America).  
For transmission electron microscopy (TEM), glutaraldehyde-fixed kidneys were 
harvested and processed as previously described (32).  Sections were viewed on a JEOL 
1200 EX transmission electron microscope (JEOL USA) at 80 kV accelerating voltage. 
 
Urine growth curves.   
Overnight UTI89 and TOP52 shaking LB cultures were subcultured 1:100 into filter-
sterilized urine specimens from healthy volunteers with and without 2% glucose 
supplementation.  Samples were grown shaking at 37°C and OD600 readings were taken 
at various timepoints.  Doubling times were calculated as td = ln 2 (t2 – t1)/(ln OD2 – ln 
OD1).   
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Statistical analysis.  
Competitive indices were calculated as (UTI89 hk::comGFP out/ UTI89 hk::comGFP In)/ 
(TOP52out/TOP52In).  The Wilcoxon signed rank test was used to compare log of 
competitive indices to a theoretical mean of zero.  Continuous variables were compared 
using the Mann-Whitney U test since these variables were not normally distributed.  All 
tests were two-tailed and a P value less than 0.05 was considered significant.  These 
analyses were performed using GraphPad Prism (GraphPad Software, version 4.03).  To 
calculate ID50 values, the Reed and Muench mathematical technique (45) was used and 
infection was defined as organs with bacterial titers above the limit of detection (20 CFU) 
at 72 h post infection. 
 
 
Results 
Diabetic mice have increased susceptibility to UPEC infection and higher bacterial 
burden. 
 It is widely known that diabetics are more susceptible to UTI than non-diabetics.  
To determine if STZ-induced diabetic C3H/HeN mice are more susceptible to UTI 
compared to buffer-treated control mice, various doses of the UPEC cystitis isolate, 
UTI89, were inoculated by transurethral catheterization.  After 72 h of infection, mice 
were sacrificed and bladder and kidney bacterial titers were determined (Fig. 1A).  
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Inocula of 107 (P=0.0006), 106 (P=0.0079), 105 (P=0.0173), 104 (P=0.0080) and 103 
(P=0.0317) CFU of E. coli UTI89 all resulted in significantly higher bladder titers in 
diabetic mice compared to buffer-treated controls.  The majority of healthy buffer-treated 
mice inoculated with 103 or 104 CFU of UTI89 were able to efficiently clear infection 
after 72 h; however, almost all diabetic mice had significant infection even with these 
relatively low inocula.  Defining infection as a titer at 72 h greater than 20 CFU 
(minimum level of detection), the ID50 of E. coli UTI89 was 1.97 x 104 CFU in healthy 
murine bladders and was less than 100 CFU (approximately 68.1) in diabetic bladders.  
Kidney titers were also significantly higher in diabetic mice compared to buffer-treated 
control mice after inoculation with 107 (P=0.0006), 106 (P=0.0079), 105 (P=0.0087), 104 
(P=0.0200) and 103 (P=0.0159) CFU of E. coli UTI89 (Fig. 1B).  By 72 h after 
inoculation with 103 CFU of UTI89, all diabetic mice had significant kidney titers while 
only half of the healthy mice remained infected.  The ID50 of UTI89 was 2.08 x 103 CFU 
in healthy murine kidneys and was less than 100 CFU (approximately 46.4) in diabetic 
kidneys. 
 The kinetics of urinary tract colonization by E. coli UTI89 were compared 
between diabetic mice and healthy controls (Fig. 2A-B). UTI89 efficiently colonized 
mouse bladders as early as 6 h post infection in both healthy and diabetic mice (Fig. 2A). 
The bacterial load in infected bladders of healthy mice decreased to a geometric mean of  
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Figure 1.  Diabetic Mice have Increased Susceptibility to E. coli UTI89 UTI 
compared to Healthy Mice   
Female C3H/HeN diabetic mice (Δ) and buffer-treated control mice (●) were infected 
with varying inocula of UTI89, a UPEC cystitis isolate.  At 72 h post infection, bladders 
(A) and kidneys (B) were harvested, homogenized and CFU were determined.  Titer data 
are combined from 3 independent experiments.  Short bars represent geometric means of 
each group and dotted lines represent limits of detection.  The symbol (**) indicates 
significant P values less than 0.05.   
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Figure 2.  Timecourse of E. coli UTI89 and K. pneumoniae TOP52 Bladder and 
Kidney Infections in Healthy and Diabetic mice   
Female C3H/HeN diabetic mice (Δ) and buffer-treated control mice (●) were inoculated 
with 107 CFU of the UPEC isolate, UTI89 (A-B), or with 107 CFU of the K. pneumoniae 
isolate, TOP52 (C-D) by transurethral catheterization.  For organ titers, bladders (A, C) 
and kidneys (B, D) were harvested at various timepoints post infection and CFU were 
calculated.  Graphs of bacterial burden of E. coli UTI89 in the bladder (A) and kidneys 
(B), and K. pneumoniae TOP52 in the bladder (C) and kidneys (D) are shown.  Titer data 
are combined from 3 independent experiments.  Short bars represent geometric means of 
each group and dotted lines represent limits of detection.  The symbol (**) indicates 
significant P values less than 0.05.  
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9.2 x 103 CFU per bladder by 72 h post infection. Diabetic mouse bladders, on the other 
hand, retained high levels of bacterial colonization at 72 h post infection.  Similar 
patterns of persistent high-level colonization through out the course of infection were 
seen in infected kidneys of diabetic mice (Fig. 2B). 
 These data show that diabetic mice are more susceptible to infection by the UPEC 
isolate, UTI89.  UTI89 had a considerably lower ID50 in the diabetic background than in 
healthy control mice.  UTI89 also had significantly higher bladder titers at 6, 24, and 72 h 
post infection in diabetic mice than in healthy mice.  Additionally, diabetic mice had 
greater UTI89 kidney infections compared to healthy mice, especially at later timepoints 
in infection. 
 
Diabetic mice infected with K. pneumoniae or E. faecalis have higher burdens of 
infection. 
  Urinary tract infections caused by non-UPEC uropathogens are more prevalent in 
diabetic individuals.  To determine how non-UPEC uropathogens perform in the diabetic 
mouse model over time, we inoculated diabetic and buffer-treated control mice with 
either the K. pneumoniae isolate, TOP52 1721 (abbreviated TOP52, Fig. 2C-D), or the E. 
faecalis isolate, 0852 (Fig. 3), in their respective murine models of UTI.  As early as 6 h 
post infection, the bacterial load of K. pneumoniae TOP52 was 100-fold higher in the 
bladders of diabetic C3H/HeN mice than in healthy C3H/HeN mice (Fig. 2C, P=0.0005).  
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This difference between healthy and diabetic bladder TOP52 bacterial burdens was 
further exaggerated to greater than 1000-fold by 24 h post infection (P=0.0007).  K. 
pneumoniae TOP52 showed similar levels of infection in the kidneys of diabetic and 
healthy mice at 6 h but diabetic bacterial burdens were significantly higher by 24 h 
(P=0.0007) and 72 h (P=0.0043) post infection. 
 In the C57BL/6 UTI model, the E. faecalis isolate, 0852, showed no difference in 
bacterial titer at 2 d post infection in the bladders (Fig. 3A) and kidneys (Fig. 3B) of 
diabetic and control mice.  However, diabetic mouse kidneys had significantly higher 
bacterial burdens than buffer-treated control mouse kidneys at both 7 d (P=0.0229) and 
14 d (P=0.0135) post infection.  Significantly higher E. faecalis 0852 titers were also 
observed in diabetic mouse bladders compared to control mouse bladders at 7 d 
(P=0.0119) and 14 d (P=0.0420) post infection. 
 These data demonstrate that diabetic mice have greater burdens of UTI caused by 
the K. pneumoniae isolate, TOP52, or the E. faecalis isolate, 0852, compared to healthy 
mice.  The experiments involving E. faecalis in the C57BL/6 background also illustrate 
the versatility of STZ-induction of diabetes and the ability to adapt this method to 
preexisting models of UTI characterized for specific uropathogens.  Interestingly, the K. 
pneumoniae strain, TOP52, has even larger differences between bladder bacterial loads of 
diabetic and control mice than does the E. coli strain, UTI89, at 6 and 24 h post infection.  
This greater advantage afforded to TOP52 in the diabetic background is consistent with 
the higher rates of K. pneumoniae cystitis observed in diabetic patients. 
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Figure 3.  Timecourse of E. faecalis 0852 Bladder and Kidney Infections in Healthy 
and Diabetic Mice   
Female C57BL/6 diabetic mice (Δ) and buffer-treated control mice (●) were inoculated 
with 107 CFU of the Enterococcus faecalis isolate, 0852, by transurethral catheterization.  
Bladders (A) and kidneys (B) were harvested at various timepoints post infection and 
CFU were calculated.  Graphs of bacterial burden of E. faecalis 0852 in the bladder (A) 
and in the kidneys (B) are shown.  Titer data are combined from 2 independent 
experiments.  Short bars represent geometric means of each group and dotted lines 
represent limits of detection.  The symbol (**) indicates significant P values less than 
0.05. 
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Advantages between UPEC and non-UPEC uropathogens shift in the diabetic host. 
 To directly compare UPEC to Gram negative non-UPEC uropathogens in the 
diabetic model, we conducted competition experiments in which both 107 E. coli UTI89 
hk::comGFP and 107 K. pneumoniae TOP52 were co-inoculated into diabetic and buffer-
treated C3H/HeN mice.  UTI89 hk::comGFP has a kanamycin resistance cassette 
allowing for selection on antibiotic media.  After 24 h, bladders and kidneys were 
harvested, titers of each pathogen were enumerated, and competitive indices were 
calculated.  We then compared the log competitive index of healthy and diabetic mice in 
the bladder (Fig. 4A) and kidney (Fig. 4B).  A value of greater than 0 indicates UTI89 
hk::comGFP outcompetes TOP52 while a value of less than 0 indicates TOP52 
outcompetes UTI89 hk::comGFP.  In the bladders of buffer-treated mice, the log of the 
competitive indices was significantly greater than 0 (P=0.0020), indicating E. coli UTI89 
hk::comGFP has a significant advantage over K. pneumoniae TOP52.  In diabetic 
bladders, the log of competitive indices was also significantly greater than 0 (P=0.0371), 
albeit to a lesser degree than in healthy bladders.  Thus the competitive advantage of 
UTI89 hk::comGFP over TOP52 seems more pronounced in healthy bladders than in 
diabetic bladders.  In the kidney, while K. pneumoniae TOP52 had a significant 
advantage over E. coli UTI89 hk::comGFP in the healthy background (P=0.0137), UTI89 
hk::comGFP substantially outcompeted TOP52 in the diabetic host (P=0.0200).   
 An increased prevalence of non-UPEC strains cause cystitis in diabetic patients.  
In our model, the diabetic condition gave E. coli a lesser advantage over K. pneumoniae  
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Figure 4.  Competition of E. coli UTI89 and K. pneumoniae TOP52 in the Bladder 
and Kidneys of Healthy and Diabetic Mice   
Female C3H/HeN diabetic mice (Δ) and buffer-treated control mice (●) were infected 
with 107 CFU each of E. coli UTI89 hk::comGFP and K. pneumoniae TOP52.  After 24 
h, bladders (A) and kidneys (B) were harvested, CFU of each pathogen were enumerated, 
and competitive indices equal to (UTI89 hk::comGFP out/ UTI89 hk::comGFP In)/ 
(TOP52out/TOP52In) were calculated.  A value greater than zero indicates an E. coli 
UTI89 hk::comGFP advantage, while a value less than zero indicates a K. pneumoniae 
TOP52 advantage.  The log of the competitive indices were significantly different than 
zero in all cases. Data are combined from 2 independent experiments.  Bars represent 
means of each group and dotted lines represents value at which each uropathogen 
competes equally.  
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in the bladder, consistent with the increased prevalence of K. pneumoniae cystitis in 
diabetics.  In the kidney, the situation was different.  We found a dramatic shift in the 
kidney from an environment favoring K. pneumoniae in control mice to an environment 
favoring UPEC colonization in the diabetic setting.   
 
UPEC causes marked interstitial pyelonephritis in diabetic mice. 
 To further investigate the shift favoring an E. coli UTI89 competitive advantage 
in the diabetic kidney, we examined histologic H&E-stained sections of single 72 h 
infections of E. coli UTI89 or K. pneumoniae TOP52.  The renal pelvises (Fig. 5A) of 
buffer-treated control mice inoculated with UTI89 or TOP52 both showed low levels of 
inflammation.  The pelvises of infected diabetic mice infected with UTI89 or TOP52 
were dilated and significantly inflamed, often with large sheets of PMN.  The urothelium 
lining the pelvis was hyperplastic with intraurothelial neutrophilia and collections of 
bacteria were observed within the pelvic space.  The kidney parenchyma (Fig. 5B) of 
healthy control mice infected with TOP52 or UTI89 and of diabetic TOP52-infected mice 
were largely unremarkable with patent tubules and normal-appearing glomeruli.  In 
contrast, the diabetic E. coli UTI89-infected kidney parenchyma displayed a marked 
acute interstitial pyelonephritis with cortical and medullary involvement.  There were 
multiple areas of abcessation with wide-spread destruction of renal architecture.  High 
power views of these regions (Fig. 5C-D) showed marked inflammation that was largely 
neutrophilic in nature with a small component of lymphocytes and plasma cells.  Vast  
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Figure 5.  E. coli UTI89 Causes an Acute Interstitial Pyelonephritis in the Kidneys 
of Diabetic Mice   
Kidney sections from 72 h post infection with E. coli UTI89 or K. pneumoniae TOP52 
were analyzed by light microscopy.  (A)  Renal pelvises from diabetic mice infected with 
either UTI89 or TOP52 revealed increased inflammatory cells, primarily PMN.  (B)  
Kidney parenchyma appeared largely normal in healthy mice and in diabetic mice 
infected with TOP52, however, UTI89-infected kidneys showed marked histopathology 
with loss of tissue architecture and a significant inflammatory infiltrate.  (C-D)  High 
power magnification of UTI89-infected kidneys revealed large collections of bacteria 
filling renal tubule lumen and collections of intratubular and peritubular PMN.  (E-F) 
Electron microscopy of these renal tubules showed tight collection of bacteria embedded 
in an extracellular matrix material.  Scale bars, 100 μm (A, B), 50 μm (C, D), 1 μm (E) 
and 0.2 μm (F). 
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collections of extracellular bacteria filled the lumen of renal tubules.  Intratubular and 
peritubular PMN were also observed.   
 To further characterize the collections of bacteria observed within the kidney 
tubules, TEM was performed (Fig. 5E-F).  Bacteria were tightly packed between simple 
tubular epithelial cells of the kidney.  An extracellular matrix material was observed 
between bacteria. These UPEC collections had similar morphology and spacing to that of 
the intracellular bacterial communities formed in the bladder during cystitis.   
 Bladder histology was similar between E. coli UTI89-infected and K. pneumoniae 
TOP52-infected bladders.  In the healthy mouse bladders at 72 h, moderate acute 
inflammation and epithelial hyperplasia were observed.  Diabetic mouse bladders had 
increased luminal bacteria and PMN compared to buffer-treated controls (data not 
shown). 
 These findings demonstrate a significant pyelonephritic phenotype in the kidneys 
of UPEC-infected diabetic mice.  This phenotype is specific to E. coli UTI89, as it was 
not observed in K. pneumoniae TOP52-infected diabetic kidneys, and is consistent with 
the significant advantage of UTI89 over TOP52 in the diabetic kidney. 
 
Diabetes in TLR-4 deficient mice. 
 Many studies have argued that diabetics have a defect in host inflammatory cell 
function which may contribute to their increased infection rate.  To further investigate 
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whether innate host immunity or other factors irrespective of innate immunity play roles 
in the differences observed between diabetic and healthy infections, we inoculated 
diabetic and healthy C3H/HeJ and C3H/HeN female mice with E. coli UTI89 or K. 
pneumoniae TOP52 (Fig. 6).  C3H/HeJ mice contain a mutation in the Toll-Like 
Receptor 4 (TLR-4) signaling domain and thus fail to transmit signal.   It has been shown 
that UPEC colonize the bladders and kidneys of C3H/HeJ mice to significantly higher 
levels than C3H/HeN mice without inducing a significant neutrophil response early in 
infection (18, 48).  Diabetic C3H/HeJ mice were more prone to infection by E. coli 
UTI89 at 72 h post infection compared to healthy controls (Fig. 6A, P=0.0221).  The 
presence of a diabetic advantage in C3H/HeJ mice suggests that additional TLR-4-
independant factors may be important in diabetic UTI.  However, the difference in UTI89 
titers between healthy and diabetic bladders was greater in C3H/HeN mice (10,000 fold 
increase) than in C3H/HeJ mice (100 fold increase) suggesting that innate immune 
factors related to TLR-4 regulated processes may also be important.  UTI89 had less than 
a ten fold advantage in diabetic kidneys of C3H/HeJ mice (Fig. 6B, P=0.0023) at 72 h 
post infection compared to healthy controls compared to the 10,000 fold advantage seen 
in C3H/HeN kidneys.  Thus, TLR-4 regulated factors may account for much of the 
increase in bacterial burdens in diabetic mouse kidneys compared to healthy controls.   
 K. pneumoniae TOP52 had significantly higher titers in the bladders (Fig. 6C) of 
both diabetic C3H/HeN (P=0.0043) and C3H/HeJ (P=0.0043) mice than in buffer-treated 
controls.  Interestingly, the differences in geometric means of the 72 h titer data were 
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Figure 6.  Differences in Diabetic UTI in C3H/HeN and C3H/HeJ Mice   
Female C3H/HeN and C3H/HeJ diabetic mice (Δ) and buffer-treated control mice (●) 
were inoculated with 107 CFU of E. coli UTI89 (A-B), or with 107 CFU of K. 
pneumoniae TOP52 (C-D).  For organ titers, bladders (A, C) and kidneys (B, D) were 
harvested at 72 h post infection and CFU were calculated.  Graphs of bacterial burden of 
UTI89 in the bladders (A), and kidneys (B) and TOP52 in the bladders (C) and kidneys 
(D) of both mouse backgrounds are shown.  Titer data are combined from 2 independent 
experiments.  Short bars represent geometric means of each group and dotted lines 
represent limits of detection.  The symbol (**) indicates significant P values less than 
0.05.  
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roughly equivalent in the C3H/HeN and C3H/HeJ backgrounds. Similar to UTI89, while 
TOP52 displayed a significant advantage in the kidneys (Fig. 6D) of diabetic C3H/HeN 
mice compared to healthy controls (P=0.0043), TOP52 had no advantage in diabetic 
kidneys of C3H/HeJ mice compared to healthy C3H/HeJ controls (P=0.9307). Thus, 
TLR-4 regulated factors seemingly account for much of the increased advantage of 
TOP52 in the C3H/HeN kidney.  Inducing diabetes in the C3H/HeJ mice produced no 
additional observable effects. Thus, much of the increase in C3H/HeN kidney 
colonization conferred upon inducing diabetes may be due to certain defects in TLR-4 
regulated innate immune factors, although non-TLR-4 related factors may also be 
important.  
 Taken together, these experiments suggest that the diabetic phenotypes observed 
for both UPEC and non-UPEC organisms are likely multi-factorial.  A defect in TLR-4 
regulated factors may be playing a role in diabetic mice.  Nevertheless, other diabetic 
effects, irrespective of TLR-4, are also important in the ability of uropathogens to cause 
high burdens of infection in the urinary tract. 
 
Urine Growth Curves. 
 Poorly regulated diabetic patients often spill glucose into their urine.  To 
determine if STZ-treated diabetic mice have glucosuria, we collected urine samples from 
diabetic and buffer-treated control mice.  Urine test reagent strips were used to determine 
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the glucose status and specific gravity of the mouse urines prior to inoculation with a 
uropathogen.  Diabetic mouse urine consistently had ≥ 200 mg/dl (2%) glucose and a low 
specific gravity of 1.010.  Healthy control mouse urine was negative for glucose and had 
a specific gravity of 1.030.  Only similar trace amounts of protein and ketones were 
found in diabetic and healthy mouse urines. 
 E. coli UTI89 and K. pneumoniae TOP52 grow equally well in LB with doubling 
times of 34 minutes (Fig. 7A).  To determine if the glucosuria of the diabetic mice affects 
uropathogen growth, E. coli UTI89 and K. pneumoniae TOP52 were grown in filter-
sterilized urine from healthy human subjects with and without 2% glucose 
supplementation (Fig. 7B).  Optical density readings of both UTI89 and TOP52 
correlated with CFU during logarithmic growth.  The doubling times of both UTI89 (1.36 
h with glucose, 2.24 without) and TOP52 (1.05 h with glucose and 1.87 without) were 
significantly shorter in glucose supplemented urine.   TOP52 displayed higher yields than 
UTI89 in urine with and without glucose supplementation.   
 These data show that STZ-induced diabetic mice have glucosuria similar to that of 
poorly controlled diabetics.  This urine glucose may contribute to the increased bacterial 
burden within the urinary tract of diabetic mice.   
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Figure 7.  The Addition of Glucose Enhances E. coli UTI89 and K. pneumoniae 
TOP52 Growth in Urine 
Growth of E. coli UTI89 and K. pneumoniae TOP52 over time was measured in LB (A) 
and filter sterilized urine with and without the supplementation of 2% glucose (B).  
Growth curves shown are representative of 3 independent experiments.   
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Discussion 
 Models of STZ-induced diabetes have been used for decades (8, 28, 31), however 
little has been done to study diabetic urinary tract infection.  UTIs are more prevalent and 
more severe in the diabetic population and murine models of infection that accurately 
mirror human infection are required to better understand disease (42).  STZ-induced 
diabetic mice were more susceptible to UPEC UTI and had higher burdens of infection 
than buffer-treated controls.  Remarkably low inocula of the UPEC strain, UTI89, were 
able to effectively infect diabetic mice but were largely cleared from healthy mice.  It is 
also known that diabetic patients are more likely to be infected with non-UPEC 
uropathogens (29).  In STZ-induced diabetic mice, the K. pneumoniae strain, TOP52, and 
the E. faecalis strain, 0852, had significantly higher bacterial titers in the bladders and 
kidneys compared to healthy mice. E. coli UTI89 outcompeted K. pneumoniae TOP52 
1721 in both healthy and diabetic bladders.  However, the advantage of UTI89 over 
TOP52 in the bladders of diabetic mice was reduced.  This result reflects the clinical 
diabetic situation in which UPEC remains the predominant uropathogen with increased 
frequency of K. pneumoniae infection.  In contrast, the advantage of UTI89 in the 
kidneys of diabetic mice over TOP52 was dramatic, since TOP52 outcompeted UTI89 in 
healthy kidneys.  Finally, experiments in C3H/HeJ mice suggested that defects in the 
diabetic urinary tracts to manage and clear bacterial infection are likely multi-factorial, 
possibly involving TLR-4 regulated factors, glucosuria and other unknown factors.  All 
of these findings are consistent with human diabetic UTI epidemiologic data and suggest 
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that this STZ-induced model of diabetic UTI will provide a valuable tool for studying this 
disease.   
 Histologic analysis of mouse kidneys revealed a severe pyelonephritic phenotype 
specific to E. coli UTI89 in the diabetic setting.  Large extracellular bacterial biofilm-like 
communities were observed filling renal tubules.  Bacteria within these communities 
were tightly packed within an extracellular matrix.  Morphologically these bacterial 
collections appeared similar to the UPEC biofilm-like intracellular bacterial communities 
observed within facet cells of the bladder (1, 47).  Further studies are required to 
determine what enables UTI89 to form these communities within the renal tubules of the 
diabetic host. 
 There are numerous hypotheses for the enhanced ability of uropathogens to infect 
the urinary tract of diabetic individuals (12).  Poorly controlled diabetes often results in 
the spilling of glucose into the urine.  Glucosuria increased the growth rates of UTI89 and 
TOP52 and has been shown to increase growth of numerous other uropathogenic isolates 
(10).  Multiple studies have suggested that neutrophil dysfunction and differences in 
cytokine secretion may play important roles in diabetic UTI (11, 42, 50), however, data 
contradicting these claims have also been reported (3).  We discovered that diabetes in 
C3H/HeJ mice resulted in significantly increased colonization of the bladders and 
kidneys by E. coli, albeit the effect was decreased compared to C3H/HeN mice.   
Additionally, induction of diabetes resulted in no advantage for K. pneumoniae in the 
diabetic kidneys of C3H/HeJ mice. These results argue that both TLR-4 related and 
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unrelated factors may be defective in the setting of diabetes.  TLR-4 regulated factors 
affected by diabetes may include the inability of neutrophils to effectively clear bacteria 
as was seemingly the case in the diabetic kidneys infected by E. coli UTI89.  UTI89 was 
able to establish massive extracellular biofilm-like collections even in the presence of a 
robust neutrophilic inflammatory infiltrate. Finally, studies have suggested that bacteria 
have increased adherence abilities in the urinary tract of diabetics, possibly due to lower 
levels of urine Tamm-Horsfall protein in diabetics (4, 7, 44) or potential changes of the 
uroepithelial cells themselves (13).  This murine model of diabetic UTI provides a 
powerful tool for dissecting these and other factors involved in diabetic uropathogenesis. 
 The STZ-induced diabetic UTI mouse model is extremely versatile.  A type 1 
diabetic syndrome can be induced in different murine backgrounds allowing for the 
analysis of specific host factors in knockout or mutant mouse backgrounds.  Additionally, 
uropathogens have been studied in various mouse strains and this method of STZ-
induction can be applied to the mouse strain best characterized for a given uropathogen.  
For example, we were able to induce diabetes and analyze infection using the previously 
established mouse model of E. faecalis UTI in the C57BL/6 murine background (25).  
The STZ method of diabetic induction is extremely practical with high levels of 
penetrance (80-85%) in a relatively short period of time (2-3 weeks) and can be well-
controlled with buffer IP injections in the identical mouse strain.  While STZ produces a 
type 1-like, irreversible insult to pancreatic β-cells leading to a severe diabetic phenotype 
in these mice (8), it may be possible to treat these mice with insulin or other agents to 
contrast UTI in the settings of controlled and uncontrolled diabetes.  It is currently 
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unclear whether the diabetic UTI phenotypes observed will be present in a euglycemic 
diabetic host.  Additionally, this model could be used to test various UTI preventative 
measures, including vaccinations, which may be especially beneficial for this predisposed 
population.  
 This STZ-induced murine model of diabetic UTI is consistent with many known 
characteristics of human diabetic UTI including increased susceptibility to infection and 
more severe infection.  Many of these traits of diabetic UTI are poorly understood and 
require an infection model to test hypotheses of diabetic uropathogenesis.  Using this 
model, we discovered that diabetes affects E. coli, K. pneumoniae and E. faecalis 
pathogenesis in diverse ways.  Defects in TLR-4 dependent and independent pathways 
appear to provide differential advantages to these pathogens.  A dramatic decrease in the 
ID50 may explain the increased susceptibility of diabetics in general and the ability of E. 
coli to establish biofilms in the diabetic kidney provides insights into the increased 
virulence seen in diabetics.  This model of diabetic UTI is versatile, practical and can 
provide a powerful tool for dissecting UTI in the setting of diabetes.   
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Conservation of the IBC Pathogenic Pathway in Human UTI 
 Analysis of human urine specimens suggests an association between intracellular 
bacterial communities (IBCs), filamentous bacteria and acute uncomplicated cystitis in 
young women (27).  Episodes of cystitis caused by uropathogenic Escherichia coli 
(UPEC) in humans likely involve an IBC pathogenic pathway similar to that observed in 
mice.  The ability to utilize an intracellular bladder niche in both murine and human 
infection may represent an imperative virulence determinant.  Intracellular bacteria are 
largely protected from host innate immunity.  While in the intracellular niche, bacteria 
are not subject to the shear forces of urine flow and are not subject to phagocytosis by 
host neutrophils or macrophages.  Additionally, the formation of intracellular biofilms 
may allow bacteria to withstand many antimicrobial therapies, as is the case for bacteria 
in extracellular biofilms (8).  IBC formation may also explain how the relatively few 
bacteria introduced into the bladder with sexual intercourse (4, 5, 16) are able to survive 
and replicate to numbers high enough to elicit symptoms in the host.  The introduction of 
low numbers of bacteria into the bladder is likely a relatively common occurrence, but it 
may be that only in the event of invasion and IBC formation can bacteria replicate and 
persist to sufficiently initiate symptomatic cystitis. 
 The knowledge that the IBC pathway takes place during human cystitis raises 
several more questions that require investigation.  To begin with, it is unclear whether the 
presence of urine IBCs or filamentous bacteria may be prognostic indicators of clinical 
outcome.  Studies with proper follow-up can determine whether these patients are more 
likely to get recurrent cystitis, pyelonephritis or other UTI sequelae.  Also, it is unknown 
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whether IBC formation in human hosts occurs in cycles as has been demonstrated in 
mice; furthermore, it is unknown whether IBC numbers increase with successive cycles.  
To investigate this, patients should be studied in a temporal fashion to analyze the timing 
of this IBC pathway.  It is possible that only a few IBCs are formed upon introduction of 
bacteria to the bladder and bacteria dispersing from these IBCs progress to form greater 
numbers of IBCs with successive cycles.  Filamentation may also show a temporal 
pattern.  Perhaps filaments are less likely to be observed just as a patient becomes 
bacteriuric prior to a strong host inflammatory response or fluxing from IBCs.  Finally, 
the prevalence of this IBC pathway in humans has not been examined in a broad 
population.  Work described here has only analyzed a relatively homogenous population 
of young, healthy, single, well-educated women.  Studies should be extended to 
additional populations including elderly patients, catheterized patients or patients with 
neurogenic bladders.  It is also important to carefully assess the response of patients to 
antibiotic therapy; bacterial strains from patients with urine findings of IBCs and 
filaments may be more likely to develop antibiotic resistance.  Utilizing antibiotics with 
better cell penetration or longer durations of therapy may more efficiently clear the 
bladder of bacteria.   
 Many of the above studies would require verification of IBCs and filaments in 
urine specimens.  This process, which currently requires multiple microscopy modalities, 
can be extremely laborious, especially for large-scale trials.  A urine molecular marker or 
signature of the IBC pathway would be invaluable in further assessing this process in 
human UTI.  For instance, a mass spectrometry profile could be established that would be 
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both sensitive and specific to bacteria in IBCs.  An automated analysis of urine 
specimens could also provide a beneficial lab tool that clinicians may be able to use to 
stratify patients based on likelihood of recurrent infection or efficacy of treatment 
regimen. 
 Further compelling evidence of this pathway occurring in human bladders would 
be biopsy evidence of IBCs.  Biopsy samples from hundreds of surgical pathology cases 
have identified no IBCs in the studied bladder sections.  However, it was not known 
whether sampled patients had a history of UTI and, in the vast majority of cases, bladder 
facet cells could not be found.  This may be due to sampling bias; urologists are more 
likely to biopsy grossly erythematous or inflamed areas of the bladder where an intact 
epithelium is rarely present.  Additionally, it is contraindicated to knowingly take 
biopsies from actively infected patients due to sepsis or other potential complications.  
Still these findings would be valuable and studies of cystectomy specimens or autopsy 
bladder specimens are warranted.   
 While the herein described urine studies revealed the presence of IBCs in 
exfoliated facet cells, they have not assessed the presence of a quiescent intracellular 
reservoir (QIR) in human bladders.  In the murine model, small numbers of UPEC have 
been shown to persist within endocytic vesicles of the urothelium.  QIRs consist of small 
foci of bacteria dormant within LAMP1-positive endocytic vesicles that can ultimately 
emerge to seed recurrent bacteriuria (25, 29).  QIRs were discovered and have been 
characterized primarily in C57BL/6 mice, but have also been found in C3H/HeN mice.  
Upon epithelial maturation and differentiation, these foci of bacteria can escape their 
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vesicular compartment and form IBCs in the host urothelium seeding recurrent UTI.  
Chemical compounds such as protamine sulfate, or the introduction of bacteria, can 
induce epithelial turnover resulting in a recurrent UTI caused by the dormant reservoir 
strain.  It is imperative to determine whether QIRs are formed in bladders of human hosts 
because they could have considerable implications on UTI recurrence.  This could be 
done through biopsy studies of female patients with a known recent history of UPEC 
cystitis.  Given the small size of QIRs, identification may prove challenging, thus a 
human study should include a large number of patients with several biopsies per patient 
to provide the power necessary to detect these small bacterial foci.   
 If QIRs are found in humans, perhaps many recurrent UTIs can be prevented by 
promoting urotheial turnover, as they can be in mice.  The drug protamine sulfate, 
commonly known to counteract heparin, could potentially be used to induce the turnover 
of the bladder urothelium and clear the organ of QIRs.  A trial could be performed in 
which patients with a history of frequent, recurrent UTI could receive bladder lavages of 
protamine sulfate or phosphate buffered saline (placebo) with an adjuvant antibiotic.  If 
protamine sulfate can successfully induce the emergence of intracellular bacteria, the 
presence of antimicrobials will eliminate the uropathogen.  The main outcome measure 
would be recurrent cystitis rates among patients in one year of follow-up following 
treatment.  Ideally oral drugs could be developed that are excreted in the urine to induce 
urothelial turnover to be taken as an adjuvant to antibiotic therapy.   
 Studies are currently being conducted in which women with a history of UTI are 
followed temporally with urine and periurethral cultures taken daily.  These studies are 
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providing new data regarding the periurethral ascension and the bladder reservoir models 
of recurrence.  Many patients have periurethral colonization with the recurrent 
uropathogen for days or weeks prior to bacteriuria, possibly supporting an ascension 
model of recurrence.  Other patients display periurethral cultures devoid of uropathogens 
prior to bacteriuria, supporting a bladder reservoir model.  However, one thing apparent 
from these studies is that there is constant seeding of faecal, periurethral and bladder sites 
with bacteria from the other sites.  The development of treatment modalities for UTI and 
UTI prevention in addition to antibiotics is necessary.  Vaccines or probiotic therapies 
have shown promise in the past (23, 24, 33) and may help reduce uropathogen 
colonization and seeding of these anatomic sites, especially in extremely susceptible 
populations. 
 The IBC pathogenic pathway is conserved in human UTI.  The extent of this 
conservation and the prevalence of this pathway in patients with cystitis remains obscure, 
however, the presence of IBCs in humans is a remarkable discovery.  This finding 
changes the historical paradigm that UTI is an extracellular infection and validates the 
already established murine cystitis model.  UTI pathogenesis is clearly more complex 
than once considered and these newly elucidated steps in the infectious process raise 
several novel questions and may provide additional therapeutic targets for this common 
disease.   
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Conservation of the IBC Pathogenic Pathway Among Uropathogens 
 The IBC pathogenic pathway was discovered and characterized with the UPEC 
strain, UTI89 (2, 19).  Recently, work by Garofalo and colleagues has demonstrated that 
the majority of UPEC isolates from various clinical syndromes of UTI are capable of 
forming IBCs within the murine bladder (11).  However, the ability of non-UPEC 
uropathogens to progress through an intracellular niche had not been assessed until now.  
The ability to form intracellular biofilms during infection that are largely protected from 
host innate immunity is likely a valuable virulence property for bacteria.  Perhaps this 
ability is what sets UPEC apart from other pathogens; IBC formation may be the reason 
UPEC is by far the most predominant uropathogen.  Alternatively, other uropathogens 
may have also evolved the ability to progress through an intracellular niche during 
infection of the bladder.  If this is the case, one must also investigate mechanistic 
conservation of the pathway.  Are there differences between the IBC pathways of UPEC 
and other uropathogens?  Do non-UPEC uropathogens utilize the same set of virulence 
factors as UPEC in causing infection and just how similar are these factors?  These are 
some of the questions that should be addressed in analyzing the conservation of the IBC 
pathogenic pathway among uropathogens.    
 
Several non-UPEC uropathogens form IBCs 
 Cystitis isolates were tested in the C3H/HeN murine model of UTI for the ability 
to form IBCs.  IBCs were observed in several of the clinical isolate infections including 
Citrobacter diversus, Enterobacter aerogenes, and two strains of Klebsiella pneumoniae 
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(Figure 1).  A summary of the findings for each species of uropathogen tested can be 
found in Table 1.  It is important to note that in this study, only two timepoints were 
assessed, 6 hours and 24 hours, previously shown to be ideal for UPEC IBC detection; it 
is possible that some of these strains may produce IBCs at timepoints not analyzed.  
Moreover, the method utilized here for IBC detection was histological bladder section 
analysis.  Although this is sufficient for IBC detection with robust IBC formers such as 
UPEC, it may not be sensitive enough for locating IBCs formed by strains producing few 
IBCs.  For infections with isolates in which IBCs could not be found, further testing is 
warranted.  Gentamicin protection assays could be used at various timepoints to 
determine whether populations of intracellular bacteria exist in these infections.   
 Despite these limitations, it is clear that the ability to form IBCs is conserved 
among some, but not all, non-UPEC uropathogens.  All strains that were found to form 
IBCs were Gram-negative uropathogens that are thought to encode type 1 pili.  All of 
these strains, with the exception of the K. pneumoniae isolates, had mannose-sensitive 
hemagglutination (MSHA) of guinea pig erythrocytes indicative of type 1 piliation.  This 
suggests that uropathogens that progress through an IBC pathway likely all utilize type 1 
pili or other adhesins during pathogenesis, however, further testing is required to confirm 
this hypothesis.   
 For those uropathogens that do form IBCs, their respective pathogenic pathways 
in the urinary tract should be characterized and dissected with respect to UPEC.  Small 
differences in the progression of the IBC pathway may have profound differences on the 
virulence of that organism or the ability to persist.  These comparisons may also further  
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Figure 1.  Intracellular Bacterial Communities are Formed by Several Non-UPEC 
Uropathogens. 
Intracellular bacterial communities were found in histologic sections (hematoxylin and 
eosin) of mouse bladders after infection with A) K. pneumoniae TOP67 2444, B) 
Enterobacter aerogenes FOSF6600 26-1445, and C) Citrobacter diversus TOP68 2384.  
Scale bars, 50 μm. 
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Table 1.  Ability of Uropathogens to Form IBCs in Murine Model 
Uropathogen 6 h IBCs* 24 h IBCs* 
Escherichia coli Yes Yes 
Klebsiella pneumoniae Yes Yes 
Enterobacter aerogenes Yes Yes 
Citrobacter diversus Yes ND 
Pseudomonas aeruginosa No No 
Staphylococcus saprophyticus No No 
Enterococcus faecalis No No 
    *“ND” means not determined.  “No” means IBCs were not observed in multiple experiments,  
       however they cannot be entirely ruled out. 
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elucidate virulence properties of UPEC that are important in pathogenesis and provide 
explanations for its predominance as a uropathogen.  However, differences in host 
response to bacterial pathogens likely have significant effects on UTI outcome.  
Therefore, the host response to these uropathogens should also be assessed.  The level of 
host urothelial exfoliation, influx of inflammatory cells, and cytokine release could all be 
important elements in clearing the uropathogen.     
 Extensive experiments investigating the ability of a Proteus mirabilis isolate to 
form IBCs were not done, however, a small trial was performed with two mice.  No IBCs 
were observed in histologic sections, although this is clearly not a sufficiently large 
population to draw any conclusions.  Given that Proteus mirabilis is the third leading 
cause of Gram-negative UTI, more detailed studies are warranted.  Also, P. mirabilis has 
the ability to swarm, a property that may be interesting to further study in the setting of 
UTI (1).  Finally, another intriguing pathogen to study in the murine cystitis model is 
Salmonella, the close relative of E. coli.  Salmonellae are not commonly isolated from the 
urinary tract, however, recent studies have shown that Salmonella serotype Tennessee is 
an emerging uropathogen (14).  
 Not all Gram-negative strains tested in this study formed IBCs.  Pseudomonas 
aeruginosa did not form detectable IBCs and had extremely low bladder titers at both 6 
and 24 hours post infection.  This result was not surprising considering P. aeruginosa 
does not encode type 1 pili.  It would be interesting to see if expression of type 1 pili 
rendered P. aeruginosa competent for IBC formation in the murine bladder.  This could 
be done by cloning the fim operon in a vector that can replicate in P. aeruginosa.  This 
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has been successively done previously in the Enterohemorrhagic E. coli (EHEC) strain 
O157:H7, which gained the ability to form IBCs with expression of type 1 pili (11). 
 There is no evidence of Gram-positive uropathogens utilizing an intracellular 
niche during infection.  Staphylococcus saprophyticus and Enterococcus isolates did not 
form detectable IBCs and may have greater kidney tropism in the murine model of UTI 
(21).   In C3H/HeN mice, these Gram-positive uropathogens had extremely low bladder 
titers compared to the other uropathogens tested.  The C3H/HeN murine cystitis model 
may not be a useful model for studying Gram-positive infections.  Further efforts should 
be made to better understand the pathogenesis of Gram-positive uropathogens, especially 
S. saprophyticus, the second leading cause of UTI among sexually-active young women. 
 
Quiescent intracellular reservoir formation 
 While various uropathogens were tested for their ability to form IBCs, their 
ability to form QIRs was not evaluated.  Gentamicin protection assays on bladders of 
abacteriuric mice 2 weeks post infection would be helpful in determining which 
uropathogens maintain an intracellular niche.  Follow-up immunohistochemistry studies 
could validate the ability of a uropathogen to form QIRs.  Whether a bacterium is able to 
form a QIR may be important in that pathogen’s ability to cause non-reascension 
recurrent infection.  One may expect higher same-strain recurrence rates for uropathogens 
with the ability to form QIRs.  An assessment of same-strain recurrence rates for women 
in the SCOR study at the University of Washington are shown based on index strain in 
Table 2.  This study, like many in the literature, can provide accurate estimates of E. coli  
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Table 2.  SCOR Study Recurrence Rates with 3 Months Follow-Up 
Index Uropathogen Enrollment 
UTIs 
No. (%) 
Same Strain* 
Recurrent UTIs 
No. (%) 
Same Strain* 
Recurrent UTIs x 2# 
No. (%) 
Escherichia coli 85 19 (22.4) 5 (5.9) 
Staph. saprophyticus 7 0 (0.0) 0 (0.0) 
Klebsiella pneumoniae 2 1 (50.0) 0 (0.0) 
Coag.-negative Staph. 2 1 (50.0) 0 (0.0) 
Group B Streptococci 2 0 (0.0) 0 (0.0) 
Proteus mirabilis 1 0 (0.0) 0 (0.0) 
Enterococcus 1 0 (0.0) 0 (0.0) 
Enterobacter aerogenes 1 0 (0.0) 0 (0.0) 
    *Determination of “same strain” was done by PFGE typing for Gram-negative strains and  
     antibiotic profiling for Gram-positive strains. 
     #This group of patients had multiple recurrent UTIs in the 3 month follow-up period. 
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cystitis recurrence rates in the three month follow-up period, however, the population 
tested is not sufficiently large enough for estimating recurrence rates of non-UPEC 
uropathogens.  Interestingly, the second most predominant uropathogen, S. 
saprophyticus, did not cause recurrences in the seven cases followed in this study.  
Further work needs to be done following women with non-UPEC UTIs, in order to assess 
outcome and recurrence rates specific to each non-UPEC uropathogen.   
 
Enterobacter aerogenes uropathogenesis 
 The Enterobacter aerogenes cystitis isolate FOSF6600 was also assessed for its 
ability to progress through an IBC cycle.  Enterobacter aerogenes is a member of the 
Enterobacteriaceae and is part of the normal flora of the large intestine.  Enterobacter 
species cause 1% of community-acquired, 2.4% of pediatric, 7% of nosocomial UTI (18).  
The incidence of Enterobacter UTI is increasing and drug resistance is an escalating 
problem in these strains (15, 28).  FOSF6600 produced an MSHA titer similar to that of 
UTI89 after static growth.  This isolate was then inoculated into the C3H/HeN murine 
cystitis model and was monitored for IBC formation.  Although many IBCs were found 
at both 6 and 24 hour timepoints, interestingly, no filamentous bacteria were observed in 
these bladder sections.  Notably, bladder bacterial titers were similar to UTI89 at early 
timepoints of infection, yet FOSF6600, in contrast to UTI89, was cleared from the 
bladder by two weeks post infection. 
 To further investigate the lack of filamentation by FOSF6600 in vivo, mitomycin 
C studies were performed.  Mitomycin C induces the SOS response ultimately leading to 
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inhibition of cell division and the onset of filamentation.  The pathway has been well 
characterized: the LexA protein binds to conserved SOS boxes in the promoter region of 
genes such as SulA, an FtsZ inhibitor.  Upon induction of stress, RecA stimulates the 
autoproteolysis of LexA leading to transcription of SulA and other SOS response genes.  
SulA inhibits FtsZ ring formation preventing septum formation and leading to bacterial 
filamentation (7).  In our investigation, while UTI89 formed long filaments in response to 
mitomycin C SOS induction, FOSF6600 did not (Figure 2).  To further investigate this 
finding, an in vitro timecourse of mitomycin C SOS-induction was performed on UTI89, 
UTI89ΔsulA, Enterobacter aerogones FOSF6600, and the Klebsiella pneumoniae strains 
TOP52 and TOP67 and percent filamentation was measured on a semi-quantitative scale 
(Figure 3).  UTI89ΔsulA and FOSF6600 had severely delayed and deficient filamentation 
compared to UTI89, TOP52 and TOP67. 
 The phenotypes observed with FOSF6600 are extremely similar to those observed 
with UTI89ΔsulA.  UTI89ΔsulA does not filament in the murine cystitis model and is 
unable to persist in the bladder (20).  These findings suggest the importance of bacterial 
filamentation for persistence in vivo.  Additionally, it was found that UTI89ΔsulA was 
able to persist in the C3H/HeJ murine background with deficient TLR-4 signaling.  Thus, 
filamentation may be less important in infections of murine bladders lacking a robust 
innate immune response.  To investigate this further, C3H/HeJ mice were infected with 
Enterobacter aerogenes FOSF6600.  FOSF6600 was able to persist and produced higher 
bladder and kidney titers in C3H/HeJ mice than in C3H/HeN mice (Figure 4).  In 
C3H/HeJ mice, FOSF6600 had bladder and kidney titers similar to those of UTI89. 
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Figure 2.  Mitomycin C Induces Filamentation of UTI89 But Not FOSF6600. 
Cultures of A) E. coli UTI89 and B) E. aerogenes FOSF6600 were induced with 150 
ng/ml mitomycin C in early log phase.  Bacteria were cytocentrifuged onto poly-lysine 
coated slides and stained with Hema 3.  Bacteria were observed by light microscopy 
using a 40X objective.  Many long filamentous organisms were found in the UTI89 
cultures but not the FOSF6600 cultures. 
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Figure 3.  Semi-quantitative Timecourse of Bacterial Filamentation after Mitomycin 
C Induction. 
Cultures of E. coli UTI89, UTI89ΔsulA, E. aerogenes FOSF6600, and K. pneumoniae 
strains TOP52 and TOP67 were induced with 150 ng/ml mitomycin C in early log phase 
and analyzed at given timepoints post induction.  Filamentation was measured on a semi-
quantitative scale based on percent of all bacteria in filamentous morphology.  FOSF6600 
displayed poor filamentation similar to UTI89ΔsulA. 
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Figure 4.  E. aerogenes FOSF6600 Bladder and Kidney Titers in C3H/HeN and 
C3H/HeJ Murine Backgrounds. 
Female C3H/HeN mice (▲) and C3H/HeJ mice (●) were inoculated with 107 CFU of the 
E. aerogenes isolate, FOSF6600, by transurethral catheterization.  For organ titers, 
bladders (A) and kidneys (B) were harvested at various timepoints post infection and 
CFU were calculated.  Short bars represent geometric means of each group.  All 
significant P values, as calculated by Mann-Whitney U tests, are displayed. 
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 To determine if E. aerogenes encoded sulA, polymerase chain reactions were 
performed and verified the presence of a sulA locus in FOSF6600 and two other E. 
aerogenes isolates.  The genes had a high percent identical to each other and the SOS box 
was highly conserved with that of E. coli.  There may be differences in SulA, LexA, or 
even RecA that could affect the SOS response of E. aerogenes compared to E. coli.  E. 
aerogenes may have a higher SOS threshold than E. coli, thus not filamenting in vivo at 
early timepoints and making it susceptible to early clearance in the murine cystitis model. 
 To further investigate these possibilities, LexA production and cleavage can be 
monitored by western blot analysis, after SOS induction with varying levels of 
mitomycin C.  Additionally, qRT-PCR can be performed on sulA and other SOS response 
genes in FOSF6600 to determine relative levels of upregulation with SOS induction.  
Finally, SOS response genes including sulA can be swapped between UTI89 and 
FOSF6600 to see if FOSF6600 will gain the ability to filament or UTI89 will lose its 
ability to filament.  To this point, in vivo and in vitro studies have been done with the E. 
aerogenes strain FOSF6600.  It is important to see if these lack of filamentation and 
inability to persist phenotypes occur with other E. aerogenes strains.  If they do, this may 
be a more general phenomenon that helps explain why E. aerogenes is not a more 
prevalent uropathogen. 
 
Klebsiella pneumoniae Uropathogenesis 
 K. pneumoniae is the second leading cause of Gram-negative UTI and thus 
represents an ideal pathogen to study in comparison to the predominant uropathogen, E. 
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coli.  Only a single K. pneumoniae isolate has been fully sequenced and this ATCC 
700721 strain is a pneumonia isolate.  One 26 year old woman in the SCOR study at the 
University of Washington was enrolled with an index K. pneumoniae UTI.  This patient 
was treated with trimethoprim-sulfamethoxazole and subsequently reported back to the 
clinic with recurrent UTI nine days later (Figure 5).  This recurrent infection was caused 
by the same K. pneumoniae strain as the index UTI.  Periurethral and urine cultures 
demonstrated that in the days leading up to recurrent UTI, this patient developed K. 
pneumoniae bacteriuria prior to detectable periurethral cultures.  These findings may 
suggest a bladder reservoir model of UTI recurrence, as opposed to the common 
paradigm of re-ascension.  This patient’s index strain, TOP52 1721, was used for 
subsequent studies on K. pneumoniae uropathogenesis. 
 Infections in the murine cystitis model have demonstrated that K. pneumoniae is 
able to form bacterial filaments and IBCs which are morphologically identical to those 
formed by UPEC.  While TOP52 had lower bacterial titers early in urinary tract infection, 
it had similar titers to UPEC at later timepoints.  At 2 weeks post infection, TOP52 
displayed similar bimodal bladder titers as those observed for UTI89.  In UPEC, some 
mice have high titers at 2 weeks representing chronic active infection that has not been 
cleared by the host or, in a few cases, recurrent bacterial infection following an 
abacteriuric period.  Other mice have lower titers at 2 weeks, likely represent bacteria in 
QIRs.  In TOP52-infected mice, the nature of this bimodal titer distribution has not been 
assessed, but may represent syndromes similar to those in UTI89-infected mice.  To 
determine whether TOP52 is able to form QIRs, gentamicin protection assays and  
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Figure 5.  Patient with Klebsiella pneumoniae Recurrent UTI. 
Selected 14-day window patterns prior to K. pneumoniae recurrent UTI. Days with 
positive periurethral (P) cultures for K. pneumoniae are shaded and urine culture (U) 
results are graphed.  In this case, urine cultures were positive prior to periurethral 
colonization possibly suggesting a potential bladder reservoir model of recurrence. 
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subsequent immunofluorescent microscopy need to be performed on bladders 2 weeks 
post inoculation.  For these studies, the C57BL/6 murine background may be more 
appropriate since UPEC QIRs are more prevalent after 2 week infection in this mouse 
strain. 
 Differences in UPEC and K. pneumoniae acute cystitis are likely related to type 1 
pilus expression and function.  The K. pneumoniae fim operon contains an additional 
gene, fimK, which has an effect on the K. pneumoniae phase switch, primarily keeping it 
in the OFF orientation.  The stop codon of fimH overlaps the start codon for fimK.  RT-
PCR analysis verified that fimK is co-transcribed as part of the fim operon.  RNA purified 
from TOP52 and TOP52/pfimX cultures was DNAse treated twice and was verified to be 
DNA free by PCR using generic 16S RNA primers.  cDNA was then synthesized and 
used as a template for PCR reactions using primers to amplify fimA, fimH, and a region of 
DNA spanning fimH and fimK.  RT-PCR showed bands for TOP52 and TOP52/pfimX 
with all three primers sets confirming that fimK is co-transcribed with the fim operon 
(Figure 6).  As expected, induction of the TOP52 type 1 operon with the recombinase 
fimX resulted in greater PCR product compared to TOP52 alone. 
 While it is clear that the presence of FimK inhibits type 1 piliation in K. 
pneumoniae, the mechanism of this inhibition requires further study.  Also, FimK may be 
exclusively acting on expression of type 1 pili or it may affect the expression of other 
adhesins or virulence factors in K. pneumoniae.  The C-terminal domain of FimK 
contains an EAL domain.  EAL domains have been implicated in the cleavage of the 
ubiquitous second messenger molecule, cyclic di-GMP (6, 30, 31).  Loss of FimK may  
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Figure 6.  RT-PCR Confirmation that fimK is Co-transcribed with the K. 
pneumoniae TOP52 1721 fim Operon. 
RNA was isolated from TOP52 and TOP52/pfimX cultures and DNAse treated twice.  
cDNA was synthesized from the RNA and PCR reactions were run using cDNA as a 
template with primers to fimA, fimH and primers spanning fimH-fimK.  The presence of a 
PCR product with the primers spanning fimH-fimK indicates that these are polycistronic 
in mRNA.  Complementation with fimX increases expression of the fim operon and thus 
the intensity of these bands.   
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lead to elevated levels of cyclic di-GMP which have been implicated in biofilm 
formation, production of adhesive surface structures, and inhibition of motility (10, 22, 
32).  To determine if FimK is an active phosphodiesterase with the ability to cleave cyclic 
di-GMP, in vitro experiments can be performed.  FimK can be purified, used to react with 
synthetic cyclic di-GMP and products can be analyzed by mass spectrometry.   
 In addition to the expression differences between UPEC and K. pneumoniae type 
1 pili, sequence variation of their FimH adhesins leads to significant functional 
differences both in vitro and in vivo.  In the murine cystitis model, FimH of TOP52 
(FimH52) was not essential for early colonization, but was required for invasion and IBC 
formation in the murine bladder.  In vitro, the adhesin domain of FimH52 lacks the 
mannose-sensitive hemagglutination (MSHA) phenotype typically characteristic of type 1 
pili.  TOP52 FimH-dependent biofilms were inhibited by heptyl mannose, but not methyl 
mannose, suggesting the need for additional contacts outside of the mannose binding 
pocket.   
 FimH residues of TOP52 and UTI89 known to interact with mannose or form the 
hydrophobic ridge are fully conserved.  There are only 17 amino acid changes between 
the adhesin domains of the FimH proteins.  Two of these changes are located adjacent to 
important mannose-binding residues Gln133 and Asp140 (17).  Arg132 and Asp141 of E. 
coli FimH form a salt bridge helping stabilize and orienting important mannose-binding 
residues.  These amino acids are changed to His132 and Ser140 in FimH52 and may affect 
mannose binding (Figure 7).  These two residues were mutated, FimH52 residues to 
FimH89 residues, and vice versa, and were expressed in UTI89ΔfimH.  Hemagglutination  
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Figure 7.  Model of the Mannose Binding Pocket of K. pneumoniae FimH. 
The TOP52 FimH sequence was threaded onto the crystal structure of FimH from the E. 
coli strain J96 (17).  This view shows the tip of the adhesin domain binding to mannose 
(yellow).  Arg132 and Asp141 of E. coli FimH (green) are changed to His and Ser, 
respectively, in FimH of TOP52 (pink).   These residues form a salt bridge in E. coli 
FimH which helps to stabilize the FG loop and mannose binding residues Gln133 and 
Asp140.  These changes in K. pneumoniae FimH may affect mannose binding. 
 
 
 
 
 
 
 
 
 209
assays (HAs) with guinea pig red blood cells were performed with these site-directed 
mutants (Table 3).  FimH52 did not display a gain of function with mutations in these 
residues.  However, FimH89 did exhibit lower HA titers.  Single changes, either R132H or 
D141S, resulted in loss of HA titer.  The double mutant R132H-D141S resulted in a 
FimH89 with an HA titer of 1:4 compared to the 1:16 titer of wildtype FimH89.  It should 
be noted that the stability and expression of all of these mutants are being confirmed.  
These amino acids may be playing a role in the altered function of FimH52 but they alone 
likely do not account for the entire phenotype.   
 A number of approaches can be taken to further investigate the structural 
differences in the E. coli and K. pneumoniae FimH proteins.  While expression of fimH 
on a plasmid in trans to the fim operon is poor, fimH site-directed mutants can be inserted 
into the native fim operon site in UTI89ΔfimH by homologous recombination.  This will 
allow for wildtype levels of pilus expression utilizing the native promoter dynamics.  
With relatively little variation in the FimH adhesin domains of TOP52 and UTI89, these 
methods are feasible to test many of these changes and their effects on FimH function.  
Additionally, while structural modeling provides insight into FimH52, a crystal structure 
of FimH52, possibly bound to heptyl mannose, would greatly aid in our understanding 
these structural considerations.   
 While many questions remain, much has been discovered regarding K. 
pneumoniae pathogenesis in the urinary tract in this work.  Despite being able to progress 
through an IBC pathway, K. pneumoniae forms fewer IBCs and has lower bladder titers 
than UPEC early in infection.  These differences are related, in part, to its extra gene,  
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Table 3.  Hemagglutination Assays with FimH Mutants 
Strain Guinea Pig RBC 
 
HA Titer (1:2x) 
Guinea Pig RBC 
+ Mann. 
HA Titer (1:2x) 
UTI89 9 3 
UTI89ΔfimH 3 3 
UTI89ΔfimH/pBAD 0 0 
UTI89ΔfimH/pfimH89 4 0 
UTI89ΔfimH/pfimH89R132H 0 0 
UTI89ΔfimH/pfimH89D141S 0 0 
UTI89ΔfimH/pfimH89RHDS 2 0 
UTI89ΔfimH/pfimH52 0 0 
UTI89ΔfimH/pfimH52H132R 0 0 
UTI89ΔfimH/pfimH52S141D 0 0 
UTI89ΔfimH/pfimH52HRDS 0 0 
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fimK, and its effects on type 1 pilus expression.  Additionally, small sequence variations 
between the FimH of E. coli and K. pneumoniae result in differences in function and 
ability to colonize the urinary tract.  Despite its poor adhesive properties in the urinary 
tract, K. pneumoniae FimH remains an important virulence factor allowing K. 
pneumoniae to progress through an IBC pathway during UTI and ultimately persist in the 
host.  It remains unclear why K. pneumoniae has evolved altered FimH and and active 
suppression of type 1 pili.  K. pneumoniae’s primary niche may be outside of the urinary 
tract and expression of type 1 pili may be disadvantageous in this setting.  This work 
begins to explain the difference in prevalence of E. coli and K. pneumoniae UTI and 
emphasizes the importance of type 1 pili in the ability of uropathogens to infect the 
urinary tract. 
 
Uropathogenesis in the Diabetic Setting 
 Diabetics have a higher incidence of urinary tract infection (UTI), are infected 
with a broader range of uropathogens, and more commonly develop serious UTI 
sequelae.  Very low inocula, less than 100 CFU, of UTI89 can lead to robust infection in 
diabetic mice.  Also, non-UPEC uropathogens are more capable of causing robust 
infection in the diabetic urinary tract.  The development of a diabetic mouse model 
provides a powerful and versatile tool for dissecting this infection in the multi-factorial 
setting of diabetes.   
 IBCs were observed in bladders of diabetic mice infected with UTI89 or TOP52, 
however, it is not clear how important the IBC pathway is to pathogenesis in these 
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compromised hosts.  Are uropathogens not capable of causing robust acute infection (i.e. 
UTI89ΔfimH) or persisting in healthy hosts (i.e. UTI89ΔsulA) able to do so in diabetic 
mice?  Do uropathogens filament in diabetic bladders and, if so, is this filamentation 
required for persistence?  One may expect that an impaired inflammatory response in 
diabetic mice may not induce the filamentation of uropathogens during infection.  Trial 
studies with a UTI89 mutant deficient in capsule formation have shown successful 
infection in diabetic mice but poor infection in the healthy host.  The diabetic setting may 
be compromised enough to allow persistence of uropathogens that lack virulence factors 
otherwise important in the healthy host. 
 Numerous hypotheses can be raised to explain the enhanced ability of 
uropathogens to infect the urinary tract of diabetic individuals including glucosuria, 
neutrophil dysfunction, decreased cytokine secretion and enhanced adherence properties 
of urothelial cells (12).  These hypotheses can be tested in the murine model.  Neutrophil 
dysfunction can be assayed via neutrophil killing assays assessing the potency of 
neutrophils isolated from diabetic and non-diabetic mice against various uropathogens.  
Cytokine secretion can be compared by carrying out bladder, kidney and urine bioplex 
assays.  Studies have suggested that bacteria have increased adherence abilities in the 
urinary tract of diabetics, possibly due to lower levels of urine Tamm-Horsfall protein (3, 
9, 26) or potential changes of the uroepithelial cells themselves (13).  Levels of Tamm-
Horsfall protein can be assayed in the urine using immunoblot or antigenic titration 
analyses.  To probe for changes in the urothelium, overlay binding studies can be 
performed in which bacteria are placed onto diabetic and healthy bladder sections and 
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bound bacteria are quantified after several washes.  It would be interesting to find that 
diabetic bladders have higher levels of integrins, uroplakins or a yet undiscovered 
bacterial receptor expressed on their surface. 
 We do not yet know how the effects of insulin therapy affect diabetic UTI.  
Presumably, euglycemic diabetic mice will not be as susceptible to UTI as uncontrolled, 
hyperglycemic diabetic mice.  However, it is also possible that after a given amount of 
time in an uncontrolled diabetic state, elicited damages will render mice particularly 
susceptible to UTI despite glycemic control.  Further understanding of UTI in controlled 
diabetic mice is especially applicable to the millions of individuals receiving treatment 
for diabetes.  Additionally, this predisposed population may gain the most benefit from 
prophylactic UTI vaccinations.  The streptozocin-induced diabetic model of UTI is the 
ideal setting for testing the efficacies of these treatments.   
  
 
Overall Conclusions 
 In summary, this thesis work set out to better understand the pathogenesis of 
uropathogens in the urinary tract.  Prior studies have revealed that UPEC employs a 
complex developmental process in mice, initiated by the intimate contacts between the 
pathogen adhesive organelles and the host epithelium, to successfully colonize and persist 
within the harsh environment of the urinary tract.  The IBC pathogenic pathway is critical 
in the ability of a uropathogen to cause UTI and interferences at any step in this 
pathogenic cycle could alter the infection course.  This thesis extends our knowledge of 
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the IBC pathogenic pathway in two important ways.  First, this study has demonstrated 
the presence of IBCs and bacterial filaments in human samples suggesting an IBC 
pathogenic pathway in human cystitis.  Second, this work has confirmed the ability of a 
number of non-UPEC uropathogens to progress through an IBC pathogenic pathway in a 
murine model of cystitis.  These findings indicate the importance of thoroughly 
understanding the mechanisms that underlie this process and how these differ among 
uropathogens.  These discoveries alter the current paradigm of bacterial pathogenesis in 
the urinary tract and could ultimately lead to better treatment modalities for patients 
suffering UTIs.   
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